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1 Introduction 
1.1 Characterization of specific tumor types 
The main focus of this work is the epigenetic characterization of two specific tumor forms, in 
particular acute myeloid leukemia (AML) and colorectal carcinoma. The following sections 
provide an overview of cancer development as well as genetic and epigenetic features that 
are associated with the respective tumor form. 
1.1.1 Leukemia 
1.1.1.1 Normal hematopoiesis and leukemia development 
The term hematopoiesis describes the formation of all blood cellular components as 
represented in Figure 1-1. The cell system is tightly controlled and characterized by a 
remarkable cellular turnover that constantly regenerates from very few hematopoietic stem 
cells (HSC) (Steffen et al., 2005).  
 
 
Figure 1-1 Schematic representation of the hematopoiesis 
All blood cells develop from pluripotent stem cells. Pluripotent stem cells have a self-renewal capacity and can 
also differentiate towards either the myeloid or the lymphoid pathway (Wikipedia contributors, 2010). 
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HSCs reside in the bone marrow and have the capability to give rise to any one of the 
separate blood cell types. In addition, they are self-renewing and have the potential for 
asymmetric division. While proliferating, one daughter cell remains as HSC, whereas the 
other daughter cell develops towards either the myeloid or the lymphoid pathway. Common 
myeloid progenitors (myeloblasts) differentiate into granulocytes, macrophages, 
megakaryocytes and erythrocytes whereas T-cells, B-cells and natural killer cells are derived 
from common lymphoid progenitors (Orkin, 2000). Blood cell precursors progress through a 
series of stages in the bone marrow before entering the circulating blood stream. While the 
process of cell division is driven by early and lineage-specific growth factors and their 
receptors, the decision of differentiation is determined by specific transcription factors that 
activate lineage-specific genes (Larsson and Karlsson, 2005; Steffen et al., 2005). Because 
of the high cell division rates of the progenitor cells there is an obviously high probability for 
mutations which accumulate in stem cells if not recognized by the cellular repair system. 
Consequently, progenitor cells may lose their ability to differentiate and escape the regulation 
of proliferation which can lead to the formation of hematopoietic tumors such as leukemia 
(Steffen et al., 2005). Leukemias can be clinically subdivided into two groups: (A) Acute 
leukemia which is characterized by the rapid progression and accumulation of malignant 
cells and is therefore lethal without therapy within several weeks or months. (B) Chronic 
leukemia typically shows a much slower progression of disease, even if untreated, patients 
can survive for months or even years. White blood cells for this kind of malignancy are 
relatively mature but still abnormal. Both groups of leukemia can be further subdivided into 
lymphocytic and myeloid leukemia depending on their hematopoietic origin. In the present 
work, acute myeloid leukemia (AML) cell lines or primary AML samples were analyzed.  
 
1.1.1.2 Acute myeloid leukemia (AML) 
AML represents a clonal myeloid stem cell disorder that results from genetic and epigenetic 
alterations. Both, differentiation arrest and excessive proliferation in the immature progenitor 
pool result in the accumulation of non-functional progenitor cells, termed myeloblasts in the 
bone marrow and the peripheral blood, where they interfere with the production or the 
functions of normal blood cells (Jabbour et al., 2006; Shipley and Butera, 2009; Stone et al., 
2004). The development of AML has been associated with several risk factors such as age, 
exposure to viruses, radiation, chemical hazards and previous hematologic diseases or 
chemotherapy as well as genetic disorders (Deschler and Lubbert, 2006).  
Genetic events that are crucial for leukemic transformation comprise alterations in myeloid 
transcription factors as well as mutations of signal transduction intermediates (Steffen et al., 
2005). Specific cytogenetic abnormalities are described in many patients with AML. 
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Cytogenetic events involve inversions, deletions and balanced translocations that often result 
in the fusion of two genes at the chromosomal breakpoints (Steffen et al., 2005). Abnormal 
fusion proteins such as AML1-ETO, PLZF-RARa and MLL fusion proteins are expressed and 
can cause a block of differentiation. Most, if not all of those fusion proteins can recruit 
corepressors and histone deacetylases, which in turn induce conformational changes of the 
DNA structure. Consequently, the DNA accessibility for the transcription machinery is 
impaired leading to the repression of target genes. Another example is the t(15;17) 
translocation. The encoded PML-RARα fusion protein disrupts the normal response of RARα 
(retinoic acid receptor α) to retinoic acid. It binds to the retinoic receptor element in the 
promoter of several myeloid specific genes and inhibits differentiation of the cells (Steffen et 
al., 2005). Cytogenetic aberrations often have prognostic significance. Translocations such 
as t(8;21)(q22/q22) and t(15;17)(q22/q12) or inversion inv16(p13;q22), creating the fusion 
proteins AML1-ETO, PML-RARa and PEBP2βMYH11, respectively, are associated with good 
outcomes after treatment. In contrast, AML patients with a complex karyotype, partial 
chromosomal deletions (e.g. 5q) or deletion of whole chromosomes (5 and/or 7) are known 
to respond poorly to treatment (Table 1-1). However, recent studies revealed many genetic 
abnormalities that escape classical cytogenetic detection (Lowenberg, 2008). Changes in 
expression levels may be due to small amplifications or deletions as well as point and/or 
frameshift mutations in the coding region of critical genes. Constitutive activation of signal 
transduction molecules was observed in tyrosine kinase receptors Flt3, Ras, and Kit 
(Lowenberg, 2008). For example, thorough sequencing of many mutant alleles from patient 
samples revealed internal tandem duplications (ITD) of varying lengths in the juxtamembrane 
region of the Flt3 receptor (Flt3-ITD). In cell line models constitutive autophosphorylation of 
Flt3-ITD has been shown to facilitate cellular proliferation independently of external growth 
factors (Steffen et al., 2005). Other somatic mutations have been observed which affect 
transcription factors playing an important role in lineage-specific differentiation. Examples 
include PU.1, C/EBPα and GATA-1.  
 
Table 1-1 Cytogenetic-based risk stratification 
(adapted from Appelbaum et al., 2001; Jabbour et al., 2006; Shipley and Butera, 2009) 
Risk category Abnormality 
Favorable t(8;21), t(15;17), inv(16), t(16/16) 
Intermediate 
Normal karyotype, t(9;11), del(7q), del(9q), del(11q), del(20q),       
+8, +11, +13, +21, -Y 
Unfavorable 
Complex karyotype, -5, -7, inv(3)/t(3;3), t(6;9), t(6;11), t(11;19), 
del(5q) 
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Recently, considerable progress has been made in our understanding of the genetic 
processes involved in transforming hematological cells. The increasing numbers of 
cytogenetic and genetic abnormalities (markers) detected in AML allow for further dissection 
of AML into molecular subtypes with distinct prognosis. To date, there are two commonly 
used classification schemata for AML, the French-American-British (FAB) system and the 
newer World Health Organization (WHO) classification. According to the FAB classification 
AMLs are categorized into subtypes, M0 through M7, based on the type of cell from which 
leukemia developed and the degree of maturity of the leukemic cells. The WHO classification 
is an advancement of the FAB classification and includes more meaningful prognostic 
information such as morphological, immunophenotypic, genetic and clinical criteria (Bennett 
et al., 1976; Vardiman et al., 2002). The distinction of specific subtypes of disease with 
different prognosis enables risk-guided and targeted treatment strategies optimized for each 
patient (Lowenberg, 2008; Shipley and Butera, 2009; Stone et al., 2004).  
However, despite aggressive therapy, only 20-30% of patients enjoy long-term disease-free 
survival (Shipley and Butera, 2009).  
 
1.1.2 Colorectal cancer 
Colorectal cancer describes cancerous growth in the colon, rectum and appendix that 
represents about 95% of all colon tumors. It constitutes the third most common form of 
cancer and the third leading cause of cancer-related deaths in the Western world. Colorectal 
cancer became one of the most frequent malignant diseases in Europe and affects about 
one million people world-wide each year. The development of this neoplastic disease 
represents a multistep process in which genetic and epigenetic alterations accumulate and 
consequently lead to the transformation of normal colonic epithelial cells to colon 
adenocarcinoma cells (Grady and Carethers, 2008). Genetic abnormalities include hereditary 
as well as somatic mutations in specific DNA sequences, affecting in particular DNA 
replication or DNA repair genes (Ionov et al., 1993). APC, K-Ras, BRAF and p53 genes 
(Ades, 2009) are also often mutated leading to uncontrolled cell division. APC mutations, for 
example, play a critical role in the inherited familial adenomatous polyposis (FAP) which 
represents a predisposition to cancer (Grady and Carethers, 2008). 
A key molecular step in the early tumorigenesis process of colon cancer formation is the loss 
of genomic stability. In colon cancer three forms of genomic instability have been described: 
microsatellite instability (MSI), chromosome instability (CIN) (gains and losses of 
chromosomal regions), and chromosomal translocations (Grady and Carethers, 2008).  
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Colorectal cancer staging describes the depth of penetration, whether it has invaded 
adjacent organs and whether it has spread to lymph nodes or distant organs and is important 
for choosing the best method of treatment. The most used staging system is the TNM system 
of the American Joint Commitee on Cancer (AJCC). ”T” describes the degree of invasion of 
the intestinal wall, ”N” the degree of lymphatic node involvement and ”M” the degree of 
metastasis (Greene, 2007). Additionally, the numbers I, II, III, IV describe the tumor 
progression with higher numbers indicating worse prognosis. Staging of cancer is an 
important and powerful predictor of survival and treatment methods. 
When colorectal cancer is detected at early stages with little spread, it is curable in up to 
80% of the cases. The primary treatment is surgical while chemotherapy and/or radiotherapy 
may be recommended depending on the individual patient's staging and other medical 
factors.  
 
1.2 The concept of epigenetics  
The identity and the developmental potential of a cell are not only defined by its genetic 
component. The primary DNA sequence is only a foundation for understanding how the 
genetic program is read. Superimposed upon the DNA sequence (the genetic code) is a 
second layer of information, called the epigenetic code (Bernstein et al., 2007). The term 
“epigenetics” was first used by Conrad Waddington to describe “the causal interactions 
between genes and their products which bring the phenotype into being” (Waddington, 
1942). At present “epigenetics” refers to heritable changes in gene expression without a 
change in DNA sequence (Goldberg et al., 2007). The key modifications conferring 
epigenetic control are DNA methylation, histone modifications, which interplay with each 
other, with regulatory proteins and with non-coding RNAs and thus define the chromatin 
structure of a gene and its transcriptional activity (Delcuve et al., 2009). The present work 
particularly focuses on DNA methylation, which provides a stable, heritable and critical 
component of the epigenetic code.  
 
1.3 DNA methylation 
The four bases adenine, guanine, cytosine and thymine spell out the primary sequence of 
DNA. In addition there exists a “fifth base” which is produced by covalent modification of 
postreplicative DNA. DNA methyltransferases (DNMTs) transfer the methyl group that is 
provided by S-adenosylmethionine (SAM) to the carbon 5 position of a cytosine residue to 
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form 5’-methylcytosine (5mC) (Figure 1-2) (Herman and Baylin, 2003; Singal and Ginder, 
1999). In mammals, this modification is mainly found on cytosines followed by a guanine, the 
so-called CpG dinucleotides (CpGs). CpG dinucleotides are not equally distributed 
throughout the mammalian genome and are also vastly underrepresented (Fazzari and 
Greally, 2004; Ng and Bird, 1999; Razin, 1998). The human genome contains only 5-10% of 
the CpG dinucleotides compared to what would be statistically predicted, which is probably 
due to a process of natural selection (Singal and Ginder, 1999). One possible explanation for 
this distribution is the tendency of methylated cytosines to deaminate. Deamination of 
cytosine gives rise to uracil which is recognized as foreign by uracil-DNA glycosylases and 
correctly repaired. In contrast, deamination of mC gives rise to thymine, which is also a 
naturally occurring genomic base, not be recognized as “misplaced” and therefore prone to 
mutation and depletion in the genome over time (Fazzari and Greally, 2004). Despite their 
relative underrepresentation, CpG dinucleotides can be accumulated in small stretches of 
DNA. GC-rich sequences are present in satellite repeat sequences, middle repetitive rDNA 
sequences, centromeric repeat sequences and CpG islands (CGI) (Herman and Baylin, 
2003; Plass, 2002). CGIs are often defined as regions longer than 500 bp with a GC content 
of 55% or higher and a ratio of observed versus expected CpG frequency of 0.6 or greater 
(Gardinergarden and Frommer, 1987; Plass, 2002; Plass and Soloway, 2002; Takai and 
Jones, 2002), and frequently associate with promoter regions of housekeeping genes as well 
as up to 40% of tissue-specific genes and are usually unmethylated (Antequera and Bird, 
1993).  
 
Figure 1-2 Schematic representation of the biochemical pathways for cytosine methylation, demethylation 
and mutagenesis of cytosine and 5mC  
Cytosine can be methylated to form 5-methylcytosine. Deamination of 5-methylcytosine gives rise to thymine, 
whereas deamination of cytosine gives rise to uracil, which is normally recognized by the uracil-DNA glycosylase 
(Singal and Ginder, 1999). 
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1.4 Biological functions and consequences of DNA 
methylation 
About 1% of total DNA bases in human somatic cells constitute 5mC (Ehrlich and Wang, 
1981). Nearly 80% of the CpG dinucleotides that are not associated with CpG islands are 
methylated (Bird, 2002; Herman and Baylin, 2003). Methylation of CpG sites is generally 
correlated with transcriptional silencing which is thought to prevent the transcription of large 
and potentially harmful parts of the genome that consist of repeat elements, inserted viral 
sequences and transposons (Herman and Baylin, 2003). In contrast, the majority of the 
dinucleotides in CpG islands, especially those associated with gene promoters, are usually 
unmethylated, whether or not the gene is being transcribed (Herman and Baylin, 2003). An 
exception to this rule are those islands of genes involved in imprinting and X chromosome 
inactivation as well as embryonic development and tissue-specific differentiation (Mohn and 
Schubeler, 2009). 
Genomic imprinting is a process of establishing gene expression patterns in a 
parent-of-origin specific manner (Li et al., 1992). While the vast majority of genes are 
expressed equally from both parental alleles, some genes are only expressed from one of 
either alleles due to epigenetic silencing of a specific allele.  
The inactivation of all but one X chromosome is a mechanism of dosage compensation and 
is achieved by synergistic expression of Xist (X-inactive specific transcript) RNA from the 
inactivated chromosome, histone deacetylation and methylation (Avner and Heard, 2001). 
Controlled DNA methylation is also crucial for gene regulation during embryonic development 
(Okano et al., 1999). During gametogenesis and embryogenesis dramatic changes in 
genome-wide patterns of methylation are observed (Kafri et al., 1992; Monk et al., 1987; Reik 
et al., 2001). Global demethylation after fertilization is followed by waves of de novo 
methylation at the time of implantation. Not all sequences in the genome, however, are 
demethylated upon fertilization and not all sequences become de novo methylated after 
implantation. These exceptions further emphasize the regional specifity of genomic DNA 
methylation (Reik et al., 2001; Robertson, 2002). 
In mammals, there are at least 200 differentiated cell types, each of them containing the 
same genome, but using only a small proportion of available genes. Tissue-specific 
differentiation occurs without changes in DNA sequence (Ohgane et al., 2008). 
Genome-wide DNA methylation profiles store the “cellular memory” of gene-set activity that 
governs tissue/cell type feature and is heritable to the next cell generation (Ohgane et al., 
2008). However, the extent of tissue-specific methylation profiles throughout the genome is 
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largely unknown and has been the subject of much debate (Walsh and Bestor, 1999; 
Warnecke and Clark, 1999). 
 
1.5 Regulation of DNA methylation 
The establishment of DNA methylation patterns during embryonic development as well as 
the maintenance and regulation of CpG methylation are not yet fully understood (Ng and 
Bird, 1999; Razin, 1998; Suzuki et al., 2002). In mammalian cells, three DNA 
methyltransferases (DNMT) have been identified. DNMT3a and DNMT3b are de novo 
methyltransferases, which are strongly expressed during germ-cell development and early 
embryogenesis, but at low levels in somatic cells (Klose and Bird, 2006). On the other hand, 
DNMT1 has a preference for hemimethylated DNA and was therefore assigned to function in 
maintenance methylation during DNA (Costello and Plass, 2001; Plass and Soloway, 2002). 
DNMT1 is ubiquitously expressed in somatic tissue and was identified in an enzyme complex 
together with proliferating cellular antigen (PCNA) located at the replication fork (Costello and 
Plass, 2001; Plass, 2002). Other components of this protein complex are histone 
deacetylase 2 (HDAC2) and a DNMT1-associated protein (DMAP1) both mediating 
transcriptional repression (Plass, 2002). All three enzymes are essential for embryonic 
development (Costello and Plass, 2001). Mouse embryos lacking both copies of DNMT1 or 
DNMT3a die before birth, while DNMT3b deletion leads to death a few weeks after birth 
(Plass, 2002).  
DNA methylation is a dynamic but tightly regulated process. Since certain developmental 
events also involve erasure of the methylation pattern, an enzyme with demethylating activity 
has been suggested and debated (Plass, 2002). Three main biochemical mechanisms have 
been proposed that may result in active demethylation: removal of the methyl group, excision 
of the methylated base or excision of the methylated nucleotide (Bhattacharya et al., 1999; 
Gehring et al., 2009; Zhu et al., 2000). As opposed to plants, in mammals no specific 
demethylase has been identified so far, but enzymes involved in DNA repair are potential 
factors in the DNA demethylation process. It was assumed that glycosylases and 
endonucleases could cleave and relieve 5mC from DNA followed by repair of the affected 
site (Jost et al., 1995). Furthermore, base excision repair enzymes, glycosylases and 
DNMT3a/b have been found within the pS2 gene promoter. In this model system dynamic 
CpG demethylation and CpG remethylation processes are inherent to transcriptional cycling 
of the pS2 gene, implying a role of DNMTs in demethylation events beside DNA repair 
enzymes (Metivier et al., 2008). Another, alternative explanation for DNA demethylation 
 Introduction 
 - 9 -    
could include DNA replication in the absence of maintenance methylation, resulting in 
passive demethylation (Costello and Plass, 2001). 
 
1.6 Epigenetics and gene regulation 
1.6.1 Mechanisms of methylation-mediated gene silencing 
CpG methylation, the most abundant epigenetic modification in vertebrate genomes, plays 
an essential part in the control of gene expression. DNA methylation is normally linked with 
stable transcriptional silencing of associated genes and much effort has been invested into 
studying the mechanisms that underpin this relationship. Two main models have been 
proposed to explain how transcriptional repression may be achieved. (A) The methyl group 
points into the major groove of the DNA and the space occupied can directly block the 
binding of transcription factors. Several transcription factors, including c-Myc/Myn, 
CREB/ATF, E2F and NFκB as well as the regulatory protein CTCF, recognize sequences 
that contain CpG residues and binding to each has been shown to be inhibited by 
methylation (Allis et al., 2007) (Bell et al., 1999; Singal and Ginder, 1999). (B) The second 
mechanism involves proteins that detect methylated DNA through methyl-CpG binding 
domains (MBDs) (Plass, 2002). MeCP1 and MeCP2 were the first two methyl-CpG binding 
activities to be described (Esteller, 2005). While MeCP1 was originally identified as a large 
multi-protein complex, MeCP2 is a single polypeptide with an affinity for single methylated 
CpGs (Esteller, 2005). Characterization of MeCP2 led to to the identification of two domains, 
a methyl-CpG binding domain (MBD) and a transcriptional repression domain (TRD) 
(Esteller, 2005). Database searches identified additional proteins with DNA binding motifs 
related to that of MeCP2 and designated the MBD family comprising MeCP2, MBD1, MBD2, 
MBD3 and MBD4 (Figure 1-3) (Allis et al., 2007; Wolffe et al., 1999), with MBD2 being the 
DNA binding component of MeCP1 complex. Three of the MBD proteins, namely MBD1, 
MBD2 and MeCP2, have been implicated in methylation–dependent repression of 
transcription (Bird and Wolffe, 1999) (Allis et al., 2007). Another methyl-DNA binding 
repressor called Kaiso exists, which lacks the MBD, but recognizes methylated DNA through 
zinc-finger domains (Klose and Bird, 2006). The proteins have different affinities towards 
5mC from MBD3 showing very little affinity to MBD2 that can bind to a single CpG residue 
(Ballestar and Wolffe, 2001; Fraga et al., 2003). Recently, it has been shown that the MBD of 
MeCP2 recognizes the hydration of methylated DNA rather than 5mC itself (Ho et al., 2008). 
Knowledge of the target site of the MBD domains is a prerequisite for understanding its 
biological role. Klose et al. could show that, despite of their overlapping DNA sequence 
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specifity, each methyl-CpG binding protein is targeted independently in the genome (Klose et 
al., 2005). MeCP2 strongly prefers mCpG sites flanked by a run of AT-rich DNA, whereas 
MBD1 has an additional DNA-binding domain specific for non-methylated CpG (Klose et al., 
2005). Kaiso is a bifunctional DNA-binding protein which can recognize DNA sequences 
containing two methylated CpG dinucleotides (Klose et al., 2005). Only MBD2 so far appears 
to have an exclusive affinity for mCpG (Allis et al., 2007). DNA methylation and the binding of 
MBD proteins strongly impact on the modification and structure of chromatin discussed in the 
next paragraph. 
 
 
Figure 1-3 Characteristic domains of methyl-CpG binding proteins 
Five members of the MBD protein family are aligned at their MBD domains (red). Other domains are labeled and 
include transcriptional repression domains (TRD), CXXC domains (zinc fingers some of which are implicated in 
binding to non-methylated CpG), an E-repeat (E), GR repeats of unknown functions or a T:G mismatch 
glycosylase domain which is involved in repair of 5-methylcytosine deamination. Kaiso lacks the MBD domain but 
binds methylated DNA via zinc fingers (ZF) and possesses a POZ/BTB domain to repress transcription (adapted 
from Klose and Bird, 2006).  
 
1.6.2 Cooperation between DNA methylation and chromatin 
modifications 
In general, the eukaryotic genome is divided into transcriptionally competent euchromatin 
and transcriptionally incompetent heterochromatin. The nucleosome represents the basic 
and repeating subunit of chromatin and is composed of a hetero-octamer of histone proteins 
and 147 bp DNA wrapped around this core 1.7 times in a left-handed helix (Figure 1-4). The 
histone octamer consists of two H2A-H2B dimers and one H32-H42 tetramer and is almost 
perfectly symmetrical in its tertiary structure (Kornberg, 1974; Kornberg and Lorch, 1999). A 
single copy of H1 can bind to the 50 bp linker DNA between nucleosomes and plays a 
significant role in the higher-order packaging of chromatin through stabilizing the chromatin 
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fibre. The position and stability of nucleosomes is a reversible ATP-dependent process. 
Hence, chromatin is in spite of its strong compaction, a highly dynamic and variable 
structure. Core histones are highly conserved in eukaryotes and have two subunits: the 
carboxy-terminal part featuring their common motif, the histone fold, mediates interactions 
with the DNA. The amino-terminal tails of all eight core histones protrude through the DNA 
and are exposed on the nucleosomal surface where they are subject to an enormous range 
of post-translational modifications including acetylation of lysines, methylation of lysines and 
arginines as well as phosphorylation of serines and threonines (Reid et al., 2009; Turner, 
2007). These modifications either allow for improved access for the transcription machinery 
or the reverse, whereby transcription is prevented in this region due to the conformation of 
the protein-DNA structure (Bernstein and Allis, 2005; Ducasse and Brown, 2006). 
 
 
Figure 1-4 DNA compaction into chromatin 
In eukaryotes, DNA is packed into chromatin. The basic repeat element of chromatin is the nucleosome, 
composed of a histone octamer around which 147 bp of DNA are coiled (adapted from Figueiredo et al., 2009).  
 
Recent studies have highlighted the role of DNA methylation in controlling gene expression 
and have confirmed its links with histone modification and chromatin remodeling (Klose and 
Bird, 2006). Methyl-binding proteins (MBPs) (see section 1.6.1) act as important “translators” 
between DNA methylation and histone-modifier proteins since on the one hand they are able 
to read the epigenetic methyl-CpG code and on the other hand each of the four MBPs has 
been shown to associate with a different corepressor complex (Lund and van Lohuizen, 
2004). For example, MeCP2 interacts with the mSin3a corepressor complex and a histone 
deacetylase (HDAC). Besides, it is also able to recruit DNMT1 to promoters (Ballestar and 
Wolffe, 2001; Jones et al., 1998; Kimura and Shiota, 2003; Nan et al., 1998). Of particular 
interest is MBD1, which can associate with the histone H3 lysine 9 (H3K9) methyltransferase 
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SETDB1 only during DNA replication (Sarraf and Stancheva, 2004). MBD2 is the 
DNA-binding component of MeCP1, which additionally includes the NuRD (nucleosome 
remodeling and histone deacetylation) (or Mi-2) corepressor complex (Wade et al., 1999). 
NuRD comprises MTA2 (metastasis-associated protein), MBD3, the histone deacetylases 
HDAC1 and HDAC2, a large chromatin-remodeling protein (Mi-2) and RbAp46/48, a 
component of several chromatin-related processes (Feng and Zhang, 2001; Loyola and 
Almouzni, 2004) (Allis et al., 2007). 
Histone modifications and chromatin remodeling can block transcription factors whereby a 
transcriptionally inactive chromatin environment is established (Esteller, 2007b). The most 
important processes concerning histone modifications will be focused in more detail in the 
following sections. Additionally, an example of the cooperation between DNA methylation 
and chromatin modification is summarized in Figure 1-5. 
 
 
Figure 1-5 DNA methylation, chromatin structure and recruitment of multiple repressors in a 
hypermethylated CpG island 
The open chromatin structure of a transcriptionally active gene with loosely spaced nucleosomes (grey cylinders) 
marked by DNA demethylation, histone acetylation and histone H3K4 methylation is shown at the top. The 
transcriptionally silenced state with more tightly packed nucleosomes is shown at the bottom. In formation of 
heterochromatic structures MBDs, HDACs, DNMTs and H1 are involved. MeCP2 is believed to recruit the Sin3A 
HDAC complex and HMT activity to the methylated site. Histone acetylation is indicated by yellow circles, H3K4 
and H3K9 methylation is indicated by red and orange hexagons, respectively and methylated CpG dinucleotides 
are indicated by blue circles. Proteins involved in transcriptional activation: Pol II=DNA polymerase II; 
TF=transcription factor; CoA=coactivator, HAT=histone acetyltransferase; TBF=TATA-binding factor; 
TAF=TBP-associated factor; Histone H3 lysine 4 methyltransferase (K4 HMT) is indicated in red. Proteins 
involved in transcriptional silencing: DNMT=DNA methyltransferase; MBD and MeCP2=methyl binding domains; 
HP1=heterochromatin protein 1 is indicated in dark red; Histone H3 lysine 9 methyltransferase (K9 HMT) is 
indicated in light red (adapted from Allis et al., 2007; Laird, 2005). 
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1.6.3 The histone code 
The so-called histone code as part of the epigenetic code, comprises multiple histone 
modifications which act sequentially or in a combination either on one or on multiple histone 
tails and thereby specify unique downstream functions (de, X et al., 2005; Strahl and Allis, 
2000). Recent discoveries showed that the functional epigenetic landscape is much more 
complex than previously thought which led to a refining of the histone code hypothesis. One 
aspect is that specific histone marks can have either repressive or activating consequences 
depending on the influence of adjacent modifications (de, X et al., 2005). For example, 
methylation of histone 3 lysine 9 (H3K9me) can initiate gene silencing but, in the context of 
methylated H3K4 and H4K20 it helps maintaining active marks (de, X et al., 2005). Likewise, 
H3K36 has a positive effect on transcription when it is found on the coding region and a 
negative effect when it is located inside the promoter sequence. Furthermore the data 
revealed that modifications on the same or different histones may be interdependent (de, X 
et al., 2005). That means that modification in one residue can determine that of another one 
either in cis or also in trans (de, X et al., 2005). An example for cis effects is represented by 
the activating mark H3K4me, which has two consequences: disrupting the binding of the 
repressive NuRD complex as well as blocking the methylation of H3K9. The best studied 
example for a trans effect is the ubiquitination of H2B being required for methylation of 
H3K4me3 (de, X et al., 2005; Kouzarides, 2007).  
Consequently, a specific histone mark alone does not describe a specific transcriptional state 
(active or passive), which turns transcription on or off, respectively. Actually, the marks have 
to be read in the context and in combination within the landscape of all the other marks 
decorating the chromatin platform and can thus represent a mechanism for differential 
regulation of chromatin activity in several distinct biological settings (Berger, 2007; Strahl and 
Allis, 2000; Weissmann and Lyko, 2003).  
Within the last few years there has been considerable progress in the development of 
high-throughput methods for analyzing histone modifications. Systematic and extensive 
studies of chromatin modifications performed either by mass spectrometry, ChIP-on-chip 
experiments or sequencing methods revealed a complex landscape including clusters of 
modified histones at transcription start sites, distal regulatory elements and conserved 
sequences, and broad domains at gene clusters and developmental loci (Bernstein et al., 
2007). Altogether at least eight distinct types of modifications on over 60 different histone 
residues were identified (Kouzarides, 2007). The most prominent ones are illustrated in 
Figure 1-6. 
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Figure 1-6 Post-translational histone modifications 
The modifications include acetylation (ac), methylation (me) and phosphorylation (ph) on lysine (K), arginine (R), 
serine (S) and threonine (T) residues. Histone modifications occur mainly on the N-terminal tails of histones H2A, 
H2B, H3 and H4 (adapted from Bhaumik et al., 2007). 
 
While the combination of all different histone modifications is an important aspect of 
epigenetic gene regulation, the remainder of this chapter will focus on histone acetylation 
and methylation, and how they relate to DNA methylation and gene expression. 
 
1.6.3.1 Histone acetylation 
Histone acetylation promotes transcriptionally active chromatin states by neutralizing the 
basic charge of the lysine residues, which weakens the interaction between the DNA and 
histone proteins, as well as between neighboring nucleosomes (Kouzarides, 2007). 
Acetylation occurs by the action of histone acetyltransferases (HAT). HATs are divided into 
three main families, GNAT, MYST and CBP/p300 that do not show much preference for a 
specific lysine residue generally (Kouzarides, 2007). Most of the acetylation sites are located 
on the histone tails, with the exception of lysine K56 located within the core domain of 
histone H3. K56 is facing towards the major groove of the DNA and can therefore strongly 
affect histone-DNA interactions when acetylated (Kouzarides, 2007). 
The antagonists to histone acetylases represent the histone deacetylases (HDAC) which 
remove the acetylation marks from the lysine residues. Thereby the positive charge of the 
histones is restored and therefore interacts with the negative charges on the DNA-phosphate 
backbone resulting in a more condensed chromatin structure. There are three distinct 
families of HDACs described: class I and class II HDACs and class III NAD-dependent 
enzymes of the Sir family (Kouzarides, 2007). HDACs have been found to be associated with 
transcriptional repressor complexes (see section 1.6.2). In addition, HDACs are able to 
interact directly with transcription factors like YY1 or the nuclear corepressor NCoR, as well 
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as with other HDACs (Dobrovic and Kristensen, 2009). Therefore, in addition to inducing a 
closed chromatin structure, HDACs are co-recruited with other proteins which block 
transcription. 
 
1.6.3.2 Histone methylation 
While histone acetylation to date has only been found associated with gene activation, 
histone methylation may have either activating or repressive effects on transcription 
depending on the specific residue modified and the context of other modifications. Additional 
complexity comes from the fact that lysine but also arginine residues can be methylated to 
different extents by histone methyltransferases (HMTs): lysine can be mono-, di- and 
trimethylated and arginine can be mono- or dimethylated, both, symmetrically and 
unsymmetrically (Kouzarides, 2007). All three states of H3K4 methylation are characteristic 
features of gene expression. Trimethylation of histone H3 lysine 36 (H3K36me3) and 
monomethylation of H3 lysine 27 (H3K27me1), H3 lysine 9 (H3K9me1), H3 lysine 20 
(H3K20me1), H3 lysine 79 (H3K79me1) and H2B lysine 5 (H2BK5me1) are also associated 
with transcribed chromatin. In contrast, trimethylation of H3 lysine 9 (H3K9me3), H3 lysine 27 
(H3K27me3) and H3 lysine 79 (H3K79me3) is generally linked to repression (Barski et al., 
2007; Bernstein et al., 2007).  
It was long believed that histone methylation was irreversible and thus the only stable histone 
modification. However, the recent discovery of histone demethylases has shown that histone 
methylation is as dynamic as the other histone modifications. Currently, there are two known 
types of histone demethylase domains: the LSD1 domain and the JmjC domain. Contrary to 
histone acetyltransferases, the histone methyltransferases as well as the histone 
demethylases show a high degree of substrate specifity, which is possibly the reason why 
methylation is currently the best characterized modification (Kouzarides, 2007). 
 
1.6.3.3 Recognition of chromatin modifications and the translation of the 
histone code 
The functional consequences of histone modifications can be either direct, causing structural 
changes to chromatin, or indirect, acting through the recruitment of effector proteins (Berger, 
2007). There are two main classes of proteins that can interact with specific chromatin 
modifications and bind via specific domains (Kouzarides, 2007). While methylation is 
recognized by so-called chromodomains, acetylation is recognized by bromodomains 
(Kouzarides, 2007). 
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Bromodomains are cysteine-rich motifs which facilitate protein-protein interactions and were 
found to be widely distributed among the different enzymes that acetylate (e.g.GCN5/PCAF, 
PCAF (CBP/300), TAFII250, TAF1l), methylate (e.g. MLL, a member of the TRX proteins) or 
remodel (SWI/SNF complex) chromatin (Daniel et al., 2005; de, X et al., 2005; Kouzarides, 
2007; Taverna et al., 2007). Remodeling factors may promote transcription by moving away 
blocking nucleosomes from transcription factor binding sites, as has been described for the 
Mi-2/NuRD and SWI/SNF complexes discovered in yeast (Hassan et al., 2002; Jacobson et 
al., 2000). 
The chromodomain was first identified as a common domain in HP1 
(chromodomain-containing heterochromatin protein 1) and the Polycomb protein of 
Drosophila (de, X et al., 2005). Later, chromodomains have also been detected in many 
other chromatin regulators like in ATP-dependent chromatin-remodeling enzymes (BPTF, 
CHD1, RAD54, Mi-2), HATs (ING2, MORF4L1) and HMTs (SUV39H1 and H2). Recently, it 
was shown that the HP1 chromodomain can recognize methylation of H3K9 (Bernstein et al., 
2007) which induces transcriptional repression and heterochromatinization (Bartova et al., 
2008). HP1 is associated with deacetylase and methyltransferase activity. Another example 
are the Polycomb (PcG) and trithorax (TrxG) group proteins that function as antagonistic 
chromatin-modifying complexes. They operate through binding to cis-acting PcG responsive 
elements (PREs) and form the molecular basis of the cellular memory. TrxG is required for 
the active state, whereas PcG proteins mediate the repressed state of gene expression. PcG 
proteins play pivotal roles in development and in the epigenetic silencing of lineage-specific 
gene repression. They are required for embryonic stem (ES) cell pluripotency and are 
markedly downregulated upon differentiation. PcG proteins are divided into two families 
based on distinct Polycomb repressor complexes, namely PRC1 and PRC2. PRC proteins 
are recruited to their response elements. PCR2 modifies the chromatin by catalyzing H3K27 
and H3K9 methylation, while PCR1 complexes create stably repressed chromatin structure 
through recognition of H3K27me3 via its chromodomain protein PC, in analogy to the 
formation of constitutive heterochromatin (Muller et al., 2002; Peters and Schubeler, 2005; 
Ringrose and Paro, 2007). 
However, effector proteins and complexes often contain multiple modification binding 
domains, with the potential to bind adjacent marks either within one histone or among 
multiple nucleosomes. HP1, for example, may function as a dimer that binds two methylated 
sites (Rice and Allis, 2001). Figure 1-7 illustrates the function of conserved motifs with certain 
chromatin-modifying proteins (Rice and Allis, 2001). 
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Figure 1-7 Schematic representation of the function of bromo- and chromodomains 
(A) PCAF and TAFII250 contain a HAT catalytic domain that may acetylate lysine residues on the histone tails (not 
shown for TAFII250). Additionally, each protein contains a bromodomain or double bromodomain, respectively, 
that binds to the acetylated lysines on the histone tails to promote transcription. (B) SUV39H1 contains a catalytic 
SET domain flanked by two cysteine-rich domains (Cys) which are necessary for methyltransferase activity. The 
chromodomain of HP1 binds to specific methylated histone tails such as H3K9 and induces the assembly of 
heterochromatin. The exact functions of the HMT chromodomain and HP1 chromo shadow domain are not known 
(adapted from Rice and Allis, 2001). 
 
In summary, chromatin provides a platform that becomes regulated by structural marks 
which can be read by nuclear factors. In order to act as marks which can influence the 
chromatin structure and thereby the transcriptional state of a gene, modifications have to be 
directed to the specific loci. There are several ways of targeting modifying enzymes to their 
sites of action (Imhof, 2006). One possibility is the targeting through interaction with specific 
transcription factors. Moreover, histone modifying enzymes have also been shown to interact 
with RNA polymerases or the replication clamp proliferating cell nuclear antigen (PCNA) 
(Imhof, 2006). Another targeting mechanism is the recruitment of histone deacetylases by 
methyl binding proteins (MBPs) to methylated cytosines. Recently, another mechanism of 
targeting histone modifying activities has been proposed involving the transcription of 
non-coding RNAs (Imhof, 2006). The non-coding Xist RNA, for example, coats the entire 
inactive X chromosome, causing chromosome-wide gene silencing. This process is 
accompanied by the deposition of histone modifications like H3K27me3 and H4K20me1 
(Bartova et al., 2008). 
The ability of the histone code to dictate the chromatin environment allows not only the 
regulation of transcriptional activity but also the regulation of other nuclear processes such 
as replication, DNA repair, and chromosome condensation (Kouzarides, 2007). 
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1.6.4 Non-coding RNA 
Recent studies have demonstrated that non-coding RNAs (ncRNAs) such as miRNAs act as 
diverse players in gene regulation, especially in the epigenetic control of chromatin. ncRNAs 
are able to direct methylation of CpGs as well as histone modifications that are correlated to 
long-term gene silencing (Costa, 2008). In a yeast model, Moazed et al. demonstrated that 
components of the RNAi (RNA interference) participate directly in heterochromatin formation 
(Moazed et al., 2005; Moazed, 2007). Therefore, it was proposed that the nascent RNA 
transcripts from centromeric repeats may act as a platform for heterochromatin assembly. Liu 
et al. could show by knockout experiments with Tetrahymena that H3K27me1 (a mark for 
repressive heterochromatin) is dependent on the RNAi machinery (Liu et al., 2007). This 
provides an indication that ncRNAs may mediate the heritability of histone modifications and 
heterochromatin formation (Flanagan, 2007).  
One of the best studied examples of ncRNAs involvement is the dosage compensation 
through silencing of the second X chromosome by the ncRNA Xist as described above 
(Bernstein and Allis, 2005).  
Although, the knowledge about the influence of non-coding RNA on transcriptional changes 
is far from being complete, those molecules are considered to be important epigenetic 
regulators.  
 
1.7 Epigenetic alterations during tumorigenesis 
Cancerogenesis constitutes a multistep process in which defects in various tumor genes 
accumulate (Plass, 2002). The initiation and progression of cancer is due to genetic changes 
such as point mutations, missense or frameshift mutations, deletions and translocations, but 
also to epigenetic changes (Herman and Baylin, 2003). Epigenetic tumor-specific alterations 
comprise most importantly DNA methylation as well as histone modifications which can 
influence gene regulation of oncogenes or tumor suppressor genes and contribute to 
uncontrolled cell growth (Costello and Plass, 2001; Plass, 2002). DNA methylation changes 
in cancer cells include both loss of methylation in CpG depleted regions where most CpGs 
should be methylated (hypomethylation) or gains of methylated CpGs in CpG islands 
(hypermethylation) (Herman and Baylin, 2003; Plass, 2002). Figure 1-8 summarizes the 
different mechanisms through which DNA methylation can promote oncogenesis. 
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Figure 1-8 Models for the different mechanisms through which cytosine methylation can promote 
oncogenesis  
(1) A consequence of hydrolytic deamination of 5mC are cytosine to thymine transitions. Those point mutations 
within promoters of tumor suppressor genes (if both alleles are affected) may contribute to tumorigenesis. 
(2) Specific oncogenes have been observed to be hypomethylated and maybe therefore activated in human 
tumors. (3) Tumor suppressor genes can be inactivated through promoter hypermethylation. (4) Loss of 
methylation may contribute to chromosome instability which possibly leads to gene deletions during mitotic 
recombination (adapted from Singal and Ginder, 1999). 
 
1.7.1 Global hypomethylation 
A major hallmark in cancer is the occurrence of genome-wide hypomethylation (Plass, 2002; 
Singal and Ginder, 1999). The extent of global hypomethylation is correlated to the tumor´s 
malignancy grade. Therefore, decreased levels of overall genomic methylation may serve as 
biological marker with prognostic value (Costello and Plass, 2001). The majority of 
hypomethylation events occur in repetitive elements localized in satellite sequences or 
centromeric regions (Plass, 2002). Furthermore, hypomethylation contributes to the 
activation of latent retrotransposons and to the potentially harmful expression of inserted viral 
genes, imprinted genes and genes on the inactive X chromosome (Costello and Plass, 2001; 
Herman and Baylin, 2003). In addition, the global loss of DNA methylation affects the 
functional stability of chromosomes in cancer. Pericentromeric regions of the chromosomes 
depend on high levels of cytosine methylation for stability and for proper replication of the 
DNA (Herman and Baylin, 2003). Aside from the genome-wide hypomethylation, the 
demethylation and consequently the activation of specific proto-oncogenes have been 
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reported (Singal and Ginder, 1999). Proto-oncogenes are normal genes that can become 
oncogenes due to mutations or increased expression. They usually code for proteins that are 
either involved in regulation of cell growth and differentiation or in signal transduction. As 
oncogenic mutations are dominant, only one mutated allele is necessary to confer the 
cancerous behavior. Some well described examples of proto-oncogenes include Ras, bcl-2 
or c-myc (Costello and Plass, 2001). 
 
1.7.2 Regional hypermethylation 
CpG islands located in the promoter region of certain genes fulfill gene regulatory functions 
and are generally unmethylated in healthy cells. Exceptions are imprinted genes and genes 
on the inactive X chromosome. There is also evidence that selected genes show progressive 
age-related increases in promoter methylation (Issa, 2003). Particularly, in cancer cells, 
prevalently CpG islands (CGIs) of tumor suppressor genes can be hypermethylated despite 
genome-wide hypomethylation (Hirst and Marra, 2009). Aberrant de novo CGI promoter 
methylation leads to gene silencing affecting genes involved in cell cycle, DNA repair, 
metabolism, cell adherence, apoptosis, premature aging and miRNA expression (Esteller, 
2007b; Hirst and Marra, 2009). The Retinoblastoma (Rb) gene was the first tumor 
suppressor gene targeted by CGI hypermethylation. Another tumor suppressor gene 
frequently found hypermethylated in cancer is p16, an important cell cycle regulatory protein. 
P16 (also known als INK4a or CDKN2A) is responsible for blocking cell cycle progression at 
the G1/S boundary. Loss of p16 function through methylation may lead to cancer progression 
by allowing deregulated cellular proliferation (Singal and Ginder, 1999). The number of 
genes that are known to be affected by epigenetic inactivation exceeds the number of 
cancer-related genes inactivated by mutation (Herman and Baylin, 2003). Mutations in tumor 
suppressor genes are mostly recessive which explains why the complete disruption of a 
tumor suppressor gene’s function requires inactivation of both alleles for malignant 
transformation of a cell (Costello and Plass, 2001; Herman and Baylin, 2003).  
So far, the mechanism for tumor-specific hypermethylation is not yet fully explored. The 
profiles of CpG island hypermethylation of tumor suppressor genes vary according to the 
tumor type (Esteller, 2005; Esteller, 2007b). Different mechanisms for aberrant de novo 
methylation in cancer may have evolved. One possibility is that methylation changes arise in 
a random fashion and may lead to progressive proliferation through a selective advantage 
(Jones and Baylin, 2007). The second possibility constitutes a dysregulation of histone and 
DNA modifying enzymes such as DNMTs. The third possibility for abnormal de novo 
methylation in tumor cells includes the absence of “protective” transcription factors or a loss 
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of chromatin boundaries leading to the spreading of DNA methylation into affected CpG 
islands (Turker, 2002). The fourth possibility comprises the targeted recruitment of DNMTs to 
methylation targets by interaction with transcription factors such as the Ets family 
transcription factor PU.1 (Metivier et al., 2008; Suzuki et al., 2006) or the SET-containing 
histone methyltransferases like G9a (Feldman et al., 2006) or EZH2. The histone 
methyltransferase EZH2 specifically methylates both H3K9 and H3K27. EZH2 is associated 
with the Polycomb group (PcG) complexes (see section 1.6.3.3 and 1.7.4), and is recruited to 
PcG-specific sites through SUZ12 (Vire et al., 2006). EZH2 has emerged as a key histone 
methyltransferase involved in methylation of H3K27 within promoters of developmental 
genes that become methylated and therefore reversibly repressed to maintain pluripotency in 
ES cells. It was shown that stem cell PcG targets are more likely affected by cancer-specific 
de novo methylation than non-PcG targets during malignant transformation (Schlesinger et 
al., 2007). This finding supports the hypothesis that reversible gene expression in a stem cell 
is replaced by permanent silencing in a cancer cell with perpetual state of self-renewal 
(Widschwendter et al., 2007). This is possibly due to the upregulation of EZH2 observed in 
many tumors. Recent studies have described a direct connection between EZH2 and the 
DNMTs (Vire et al., 2006), thus providing a link between histone methylation and DNA 
methylation during cancer development.  
 
1.7.3 Differential DNA methylation patterns in AML and colorectal 
cancer 
In addition to the large amount of well defined genetic aberrations as described previously, 
DNA methylation changes at crucial genes are able to contribute to the multistep 
transformation process of normal to cancerous cells (Farrell, 2005; Galm et al., 2006; Pfeifer 
and Besaratinia, 2009; Plass et al., 2008). Although some genes are affected in multiple 
tumor types, such as the cell cycle regulator p16, methylation profiling studies have shown 
that each tumor type has a characteristic methylation pattern indicating the involvement of 
cell type- or lineage-specific transcription factors. Interestingly, the methylation profile in 
hematopoietic malignancies differs from solid tumors regarding the affected genes. Table 1-2 
gives a summary of those genes that have frequently reported to be hypermethylated in AML 
and in colorectal carcinoma, respectively. 
There is growing evidence for the diagnostic and prognostic potential of methylation changes 
in different tumor types. Methylation profiles may act as potential new biomarkers of risk 
prediction in tumor patients, complementing standard immunophenotyping, cytogenetic and 
molecular analyses (Galm et al., 2006; Plass et al., 2008). 
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Table 1-2 Genes frequently methylated in acute myeloid leukemia (AML) and colorectal carcinoma  
(adapted from Galm et al., 2006; Toyota et al., 2001; Wong et al., 2007) 
AML Colorectal carcinoma 
Gene Function Gene Function 
p15 Cyclin-dependent kinase inhibitor APC Signal transduction, β-catenin regulation 
E-cadherin Cell adhesion CDH13 Cell signaling 
SOCS-1 Cell signaling CDKN2A Cell cycle regulation 
p73 p53 similar protein CHFR Mitotic stress checkpoint 
DAPK1 Programmed cell death induced by IFNγ HIC1 Regulation of DNA damage responses 
HIC1 Transcriptional regulation HPP1 TGF-β antagonist 
RARβ2 Retinoic acid receptor-β2 MGMT Repair of DNA guanosine methyl adduct 
CRBP1 Carrier protein involved in retinol transport  MLH1 Mismatch repair 
MYOD1 Myogenic differentiation RASSF1A DNA repair, cell cycle regulation 
SDC4 Receptor in intracellular signaling TIMP3 Matrix remodeling, tissue invasion 
 
1.7.4 Differential histone modifications in tumors 
Global changes in the pattern of CpG methylation eventually lead to genome-wide changes 
in histone modification patterns in human tumor cells (Fraga et al., 2005). These alterations 
of histone marks occur early in tumorigenesis and accumulate during its process (Esteller, 
2007a). Promoter hypermethylation in cancer cells is generally linked to changes in the 
histone modification pattern including hypoacetylation at histones H3 and H4 (Esteller, 2006). 
Furthermore, in some cases H3K9 methylation has been shown to occur in hypermethylated 
DNA sequences. Usually, aberrant DNA hypermethylation is also accompagnied by loss of 
H3K4 trimethylation (Esteller, 2006).  
In cancer cells, altered patterns of histone modifications occur not only in promoter regions of 
tumor suppressor genes but also within constitutive heterochromatin. Studies of 
genome-wide posttranslational modifications of histone H4 have shown that cancer cells 
exhibit decreased levels of H4K16 acetylation and H4K20 trimethylation compared to normal 
tissues (Esteller, 2007a; Fraga et al., 2005; Fraga and Esteller, 2005). Those alterations 
occur mainly within the context of repetitive DNA sequences that become hypomethylated in 
tumor cells. It was thus suggested that the global loss of monoacetylation and trimethylation 
of H4 is a common hallmark of cancer cells (Fraga et al., 2005; Fraga and Esteller, 2005). A 
summary of altered histone modifications and DNA methylation patterns is shown in Figure 
1-9.  
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Figure 1-9 Histone modification maps and DNA methylation patterns for a typical chromosome in normal 
and cancer cells 
Nucleosomes (grey cylinders) are shown in the context of chromosomal location and transcriptional activity. 
Histone acetylation and methylation (di- and tri-) are indicated. In normal cells, genomic regions that include the 
promoters of tumor suppressor genes are enriched for histone modification marks associated with active 
transcription, such as acetylation of H3 and H4 lysine residues and H3K4me3. In the same cells, DNA repeats 
and other heterochromatic regions are characterized by H3K27me3, H3K9me2 and H4K20me3 which are 
repressive marks. In cancer cells, both, the active histone marks on tumor suppressor genes and repressive 
marks at DNA repeat regions are lost. Above and below the nucleosomal arrays, respectively, the respective DNA 
methylation pattern is represented. CpG islands of tumor suppressor genes become hypermethylated in cancer 
cells which leads to transcriptional inactivation of these genes. At the same time, the genome of a cancer cell 
undergoes global hypomethylation at repetitive sequences and some tissue-specific and imprinted genes. This 
hypomethylation might contribute to tumorigenesis, causing chromosomal instability or changes such as loss of 
imprinting. E, exon (adapted from Esteller, 2007a). 
 
Recent analyses have shown that a number of different histone modifying enzymes are 
altered in various types of cancer contributing to changes in histone patterns. The observed 
loss of H4K20me3 could be due to altered expression levels of histone methyltransferases 
(like EZH2, SUV39H or SUV4-20H) (Esteller, 2007a). The proper balance between 
acetylation and deacetylation of H4K16 is mediated by specific HATs. Inactivating mutations 
in the HAT p300, for example, have been described in many tumor forms. Recently, HDAC2 
Normal cell
Cancer cell
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has been identified as another component of the epigenetic machinery that is mutated and 
therefore inactivated in human cancer (Esteller, 2007a).  
 
One of the most interesting phenomena currently emerging in the field of histone 
modifications and cancer is the discovery of bivalent domains on histone tails. Bivalent 
domains comprise both, transcriptionally repressive and active marks at the same time, 
which facilitates a switch between transcriptional activation and repression. Those domains 
were first described in ES cells (Bernstein et al., 2006). Upon differentiation, tissue-specific 
genes which become highly expressed display only the activating H3K4 methylation, while 
genes which become silenced display only the repressive H3K27 methylation (Bernstein et 
al., 2006; Pietersen and van Lohuizen, 2008). Bivalent domains serve to silence 
developmental genes in ES cells, while preserving the potential for activating them during 
differentiation (Bernstein et al., 2006; Pietersen and van Lohuizen, 2008) (see sections 
1.6.3.3 and 1.7.2). 
It is believed that genes with bivalent marks are especially sensitive to silencing by DNA 
methylation during tumorigenesis (Ohm et al., 2007). Notably, embryonal carcinoma cells 
(EC) also display increased levels of other repressive marks (H3K9 di-and tri-methylation) on 
the histones associated with the respective genes, implicating that these bivalent histone 
marks represent a transition state between genes in ES cells and fully silenced genes in 
adult cancer cells (Ohm et al., 2007).  
 
1.7.5 Therapeutic strategies targeting epigenetic aberrations 
In contrast to genetic alterations, epigenetic changes which contribute to tumorigenesis are 
potentially reversible. This offers the possibility of novel therapies for cancer treatment, 
particularly with regard to acute myeloid leukemia (AML) and myelodysplastic syndrome 
(MDS) (Galm et al., 2006; Herman and Baylin, 2003). Many studies in multiple tumors 
demonstrated an increased activity of DNMTs as well HDACs. Therefore, the development of 
strategies will be required which inhibit and antagonize (reverse) the activity of those 
enzymes in order to prevent and treat neoplastic diseases (Herman and Baylin, 2003; Singal 
and Ginder, 1999). 
Currently, there are two demethylating agents approved for clinical use by the United States 
FDA: 5-azacytidine (Vidaza, AZA; Pharmion Corp) and 5-aza-2´-deoxycytidine (decitabine, 
Dacogen; MGI Pharma/SuperGen) (Herman and Baylin, 2003; Plass et al., 2008). These 
agents are cytosine analogues and exert their hypomethylating activity by competing with the 
endogenous pool of deoxynucleosides for incorporation into newly synthesized DNA during 
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replication. Once incorporated into DNA, azanucleosides covalently bind and trap the 
DNMTs resulting in inactivation. This may lead to loss of promoter hypermethylation and 
re-expression of silenced tumor suppressor genes (Plass et al., 2008). 
Previous studies demonstrated the dominance of the DNA methylation over histone 
deacetylation in the process of gene silencing. Thus, treatment of cells with one of the HDAC 
inhibitors such as Trichostatin A, valproic acid, the hydroxamid acid or SAHA (Vorinostat), 
alone, rarely results in reactivation of cancer genes (Plass et al., 2008). However, these 
agents exert additive or synergistic effects if some demethylation is first achieved by low 
doses of 5-aza-2´-deoxycytidine (Galm et al., 2006; Herman and Baylin, 2003). In vivo, the 
sequential treatment with low doses of demethylating agents followed by HDAC inhibitors is 
the basis for new therapeutic strategies.  
Recent studies have shown that epigenetic mutations may be more harmful than genetic 
mutations. Thus, patients might benefit from the new emerging anti-cancer treatments which 
target the epigenome. Additionally, because many of the hypermethylation events occur very 
early in tumor development, inhibiting or reversing these changes could be of high potential 
for cancer prevention in the future.  
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2 Research objectives 
Besides genetic alterations, epigenetic changes are now recognized as an additional 
mechanism contributing to tumorigenesis (Plass, 2002). Because DNA methylation is stable 
in genomic DNA preparations, it is the most suitable of all known epigenetic modifications for 
diagnostic applications and may provide useful molecular markers to complement clinical 
diagnostics and prognostics. To date, most of the studies are based on single gene 
approaches to identify candidate genes. However, for the systematical identification of 
relevant epigenetic biomarkers global analyses of DNA methylation are of major clinical 
interest.  
The main focus of this thesis was to establish and adapt the previously developed 
methyl-CpG immunoprecipitation (MCIp) technique for comparative methylation analyses. 
Based on this approach, genome-wide methylation profiles of tumor cell lines and tumor 
patients should be generated, to detect potential marker genes which are hypermethylated in 
tumors and could be associated with cancer development and therefore have diagnostic or 
therapeutic relevance. Analyses should be performed with two specific tumor types, namely 
acute myeloid leukemia (AML) and colon cancer carcinoma. 
The molecular mechanisms controlling the methylation status of CpG islands in normal and 
malignant cells are poorly understood. Therefore, to get insights into this process, factors 
should be identified which are mainly responsible on the one hand for maintaining the 
unmethylated state of CpG islands in health and disease and on the other hand for de novo 
methylation in cancer. Computational methods should be applied to identify candidate 
sequence motifs associated with unmethylated and methylated CpG islands, respectively. 
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3 Material and equipment 
3.1 Equipment 
8-Channel PipettorImpact2 Equalizer 384 Thermo Fisher Scientific, Hudson, US 
Autoclave      Technomara, Fernwald, Germany 
Bioanalyzer 2100    Agilent Technologies, Böblingen, Germany 
BioPhotometer     Eppendorf, Hamburg, Germany 
Centrifuges      Heraeus, Hanau; Eppendorf, Hamburg, Germany 
Densitometer     Molecular Dynamics, Krefeld, Germany 
Electrophoresis equipment    Biometra, Göttingen; BioRad, Munich, Germany 
Fast-Blot machine    Agfa, Köln 
FACS Calibur     BD, Heidelberg, Germany 
Heat sealer (Fermant 400)    Josten & Kettenbaum, Pensberg, Germany 
Heat sealer     Eppendorf, Hamburg, Germany 
Heatblock     Stuart Scientific, Staffordshire, UK 
Incubators      Heraeus, Hanau, Germany 
J6M-E centrifuge    Beckmann, Munich, Germany 
Laminar air flow cabinet    Heraeus, Hanau, Germany 
Lightcycler     Roche, Mannheim 
Luminometer (Sirius)     Berthold Detect. Systems, Pforzheim, Germany 
MassARRAY Compact System   Sequenom, Hamburg, Germany 
MassARRAY MATRIX Liquid Handler  Sequenom, Hamburg, Germany 
MassARRAY Phusio chip module  Sequenom, Hamburg, Germany 
Megafuge 3,0 R    Heraeus, Osterode, Germany 
Microarray hybridization chambers SureHyb Agilent Technologies, Böblingen, Germany 
Microarray scanner; 5 micron resolution  Agilent Technologies, Böblingen, Germany 
Microarray slide holder    Agilent Technologies, Böblingen, Germany 
Microscopes     Zeiss, Jena, Germany 
Multifuge 3S-R     Heraeus, Osterode, Germany 
Multipipettor Multipette plus   Eppendorf, Hamburg, Germany  
NanoDrop     PeqLab, Erlangen, Germany 
PCR-Thermocycler PTC-200   MJ-Research/Biometra, Oldendorf, Germany 
PCR-Thermocycler Veriti 384 well  Applied Biosystems, Foster City, USA 
pH-Meter      Knick, Berlin, Germany 
Picofuge     Heraeus, Osterode, Germany 
Power supplies     Biometra, Göttingen; Germany 
Realplex Mastercycler epGradient S  Eppendorf, Hamburg, Germany 
Sigma 2 – Sartorius    Sartorius, Göttingen, Germany 
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Sonifier 250     Branson, Danbury, USA 
Sorvall RC 6 plus    Thermo Fisher Scientific, Hudson, USA 
Speed Vac     Christ, Osterode, Germany 
Thermomixer     Eppendorf, Hamburg, Germany 
Typhoon™      Amersham Biosciences, Germany 
Ultracentrifuge Optima L-70    Beckman, Munich, Germany 
Waterbath     Julabo, Seelstadt, Germany 
Water purification system    Millipore, Eschborn, Germany 
 
3.2  Consumables 
384-well PCR plates    Thermo Fisher Scientific, Hudson, USA 
96 well optical bottom plates (black)  Nunc Brand Products, Roskilde, Denmark 
8-channel pipettor tips Impact 384  Thermo Fisher Scientific, Hudson, USA 
Adhesive PCR sealing film   Thermo Fisher Scientific, Hudson, USA 
Cell culture flasks and pipettes   Costar, Cambridge, USA 
CLEAN resin     Sequenom, Hamburg, Germany 
Cryo tubes     Nunc, Wiesbaden, Germany 
Filter tubes: Millipore Ultrafree-MC  Millipore, Eschborn, Germany 
Heat sealing film    Eppendorf, Hamburg, Germany 
Luminometer vials    Falcon, Heidelberg, Germany 
MATRIX Liquid Handler D.A.R.Ts tips  Thermo Fisher Scientific, Hudson, USA 
Micro test tubes (0.5, 1.5, 2 ml)   Eppendorf, Hamburg, Germany 
Microarray gasket slides   Agilent Technologies, Santa Clara, USA 
Multiwell cell culture plates and tubes  Falcon, Heidelberg, Germany 
nProteinA Sepharose 4 FastFlow  GE Healthcare, Munich, Germany 
Nylon Transfer membrane   MSI, Westboro, USA 
PCR plate Twin.tec 96 well   Eppendorf, Hamburg, Germany 
rProteinA Sepharose 4 FastFlow  GE Healthcare, Munich, Germany 
Sepharose Cl-4 beads    Sigma-Aldrich, Munich, Germany 
SpectroCHIP bead array   Sequenom, Hamburg, Germany 
Sterile combitips for Eppendorf multipette Eppendorf, Hamburg, Germany 
Sterile micropore filters    Millipore, Eschborn, Germany 
Sterile plastic pipettes    Costar, Cambridge, USA 
Syringes and needles    Becton Dickinson, Heidelberg, Germany 
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3.3  Chemicals 
All reagents used were purchased from Sigma-Aldrich (Taufkirchen, Germany) or Merck 
(Darmstadt, Germany) unless otherwise noted. Oligonucleotides for real-time PCR were 
synthesized and high-pressure liquid chromatography purified by Metabion 
(Planegg-Martinsried, Germany). Oligonucleotides adapted to methylation analysis with the 
MassARRAY system (see section 4.4.6) were purchased from Sigma-Aldrich (Taufkirchen, 
Germany). 
 
3.4  Enzymes and kits 
aCGH Hybridization Kit    Agilent Technologies, Waldbronn, Germany 
Alkaline phosphatase    Roche, Mannheim, Germany 
Aprotinin     Roche, Mannheim, Germany 
BioPrime Purification Module   Invitrogen, Karlsruhe, Germany 
BioPrime Total Genomic Labelling System Invitrogen, Karlsruhe, Germany 
Blood & Cell Culture DNA Midi Kit  Qiagen, Hilden, Germany 
BSA      Sigma, Deisenhofen, Germany 
Blood and Tissue Culture Kit   Qiagen, Hilden, Germany 
DNA Ladder 1 kb plus    Invitrogen, Karlsruhe, Germany 
DNA molecular weight standard   Invitrogen, Karlsruhe, Germany 
dNTPs      NEB, Frankfurt, Germany 
Dual-Luciferase Reporter Assay System Promega, Madison, USA 
EpiTect Bisulfite Kit    Qiagen, Hilden, Germany 
Exo-Klenow-Fragment    Invitrogen, Karlsruhe 
EZ DNA methylation kit    Zymo Research, Orange, USA 
FastStart TaqDNA polymerase   Roche, Mannheim, germany 
Gene expression hybridization Kit  Agilent, Waldbronn, Germany 
HhaI Methylase     NEB, Frankfurt, Germany 
Hpa II Methylase    NEB, Frankfurt, Germany 
Human Cot-1 DNA    Invitrogen, Karlsruhe, Germany 
Klenow Enzyme    NEB, Frankfurt, Germany 
Klenow exo- (3’-5’ exo minus)   NEB, Frankfurt, Germany 
Lipofectamin transfection reagent  Invitrogen, Karlsruhe, Germany 
Linear Amp. Kit plus, one colour  Agilent Technologies, Waldbronn, Germany 
NucleoSpin Plasmid Quick Pure  Macherey-Nagel, Düren, Germany 
NucleoSpin® Extract II    Macherey-Nagel, Düren, Germany 
Pepstatin     Roche, Mannheim, Germany 
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PicoGreen ds DNA Quantitation Reagent MoBiTec, Göttingen 
Plasmid Midi Kit    Qiagen, Hilden, Germany 
PMSF (Phenylmethanesulfonylfluoride)  Sigma, Deisenhofen, Germany 
Proteinase K     Roche, Mannheim 
QIAquick PCR Purification Kit   Qiagen, Hilden, Germany 
QuantiFast SYBR green   Qiagen, Hilden, Germany 
Repli-G Midi Kit     Qiagen, Hilden, Germany 
Restriction endonucleases   NEB, Frankfurt; Roche, Mannheim; Germany 
Reverse Transkriptase SuperSkript II  Promega, Madison, USA 
RNA 6000 Nano Kit    Agilent Technologies, Waldbronn, Germany 
RNA Spike-in Kit    Agilent Technologies, Waldbronn, Germany 
RNeasy Midi and Mini Kit   Qiagen, Hilden, Germany 
S-adenosylmethionine (SAM)   NEB, Frankfurt, Germany 
Shrimp Alkaline Phosphatase (SAP)  Sequenom, Hamburg, Germany 
Sss I CpG methylases    NEB, Frankfurt, Germany 
T-Cleavage MassCleave Reagent kit  Sequenom, Hamburg, Germany 
TaqDNA Polymerase    Roche, Mannheim, Germany 
T4 DNA Ligase     Promega, Madison, USA 
T4 DNA Ligase buffer    NEB, Frankfurt, Germany 
TOPO TA Cloning Kit    Invitrogen, Karlsruhe 
Wizard DNA Clean-Up System   Promega, Madison, USA 
 
3.5 Molecular weight standards 
DNA ladder 1 kB Plus was purchased from Invitrogen (Karlsruhe, Germany). The 
Kaleidoscope Prestained standard protein marker was purchased from BioRad (Munich, 
Germany). 
 
3.6 Oligonucleotides 
3.6.1 Sequencing primers 
Gene Primer sequence (sense & antisense) 
M13 reverse 5'-GGA AAC AGC TAT GAC CAT GAT-3' 
T7 5’-TAA TAC GAC TCA CTA TA-3’ 
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3.6.2 Real-time PCR primers for MCIp 
Gene Primer sequence (sense & antisense) 
CBX6 
5’-AAGCTTCCGCCATTGCTCTG-3’ 
5’-TCCGTTCCTGGACAGCCC-3’ 
CDKN2B 
5’-GGCTCAGCTTCATTACCCTCC-3’ 
5’-AAAGCCCGGAGCTAACGAC-3’ 
CHI3L1 
5’-ATCACCCTAGTGGCTCTTCTGC-3’ 
5’-CTTTTATGGGAACTGAGCTATGTGTC-3’ 
COL14A1 
5’-AGACGCAATGCAGTTCCATGG-3’ 
5’-ATCTCCCTACACCGTGAACCC-3’ 
CYP1B1 
5’-TGTTGAATCCGTGCTTAGTAGAGACC-3’ 
5’-CAGAGTAGCATTCAGAAAGGCAGATGG-3’ 
CYP27B1 
5’-CATCCGTTCTCTCTGGCTGTCC-3’ 
5’-CTGTCGAGGCTACACGAGCTGC-3’ 
Empty6.2 
5'-GAAACCCTCACCCAGGAGATACAC-3’ 
5'-TGCAGTGGGACTTTATTCCATAGAAGAG-3' 
DMRT2 
5’-CACGTTTTTGCTAGAGGTGAGGG-3’ 
5’-TCCTCCATCCGTACTGACATAGGG-3’ 
ESR1 
5’-GACTGCACTTGCTCCCGTC-3’ 
5’-AAGAGCACAGCCCGAGGTTAG-3’ 
FARP1 
5’-GCTCCGTAGAGTTCCCGAAACC-3’ 
5’-AGCGAATCCCATGACAGTTCCC-3’ 
FNBP1 
5’-ATCCAAAGGTCTGCACAAATGTTCCTG-3’ 
5’-CGAGGGAGAAAGATAAGCTGTGGG-3’ 
HOXD10 
5’-TCTATAGTGACGCTACCTTTCCCG-3’ 
5’-CTTGAGAGGACAACGACATTTAGGG-3’ 
JUN 
5’-AGGAGTTAGTGTGACAGGGTCGC-3’ 
5’-CCAAATCGCACTCTTATATCCTGGC-3’ 
JUN (p) 
5’-ATTGGCTCGCGTCGCTCTC-3’ 
5’-GGAGCATTACCTCATCCCGTG-3’ 
KLF5 
5’-AGACACTTCATTTAGTAGCTCTTTGGCG-3’ 
5’-GCCCTCTCACAGCAAGACCC-3’ 
KLF11 
5’-GACAGCGGGCTAGATGTCTCC-3’ 
5’-GTCAGGGGAAGCCGAAACG-3’ 
KLF11 (p) 
5’-GTTGAGGCCTCTAGGTGGGTCTC-3’ 
5’-CCACGCTTATAGGAACCTCCTGC-3’ 
LDLR 
5’-GGGTACAAATAATCACTCCATCCCTG-3’ 
5’-TAAATCCCTCAGACTCCTCCCG-3’ 
MAFB 
5’-TGTGCAGACTATGTATGGCTCCG-3’ 
5’-AAACACTCTGGGAGCCACAGG-3’ 
MAFB (p) 
5’-TCGAGGTGTGTCTTCTGTTCGG-3’ 
5’-GACCTGCTCAAGTTCGACGTG-3’ 
MLF1 
5’-AAATCTGATAGGCTTCATCCCATTTCC-3’ 
5’-GTCCTGTATCCGAAACATTCTCTGG-3’ 
PAX9 
5’-CTCTGCTTGTCATAACTGCAACTCGG-3’ 
5’-TGATGACTGTGGATGGGAGGATAGG-3’ 
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Gene Primer sequence (sense & antisense) 
PDE4B 
5’-CAGGAGGTCTGTGAGGTAGGTG-3’ 
5’-TGTGTAGTAGGTTGTAACTGCTGAGG-3’ 
PFC 
5’-CGTTACGGGTTTCCTGATTGGC-3’ 
5’-GGAATCTAGGGAGGTCCAGGAG-3’ 
PLA2G7 
5’-GTGCTGGTGTCATTTCTCCCTG-3’ 
5’-TCTAGCTCCATTTCTCCTCAGACC-3’ 
RAB3C 
5’-TGAGGGATCGGGCTATTCGC-3’ 
5’-GCCAAGAGAGGAGATCAATGCC-3’ 
RAX 
5’-CATGGACACCCGTGAATTCCGAG-3’ 
5’-AGGTAAAGCGCCCAGGTTGAG-3’ 
RGMA 
5’-AAAGACCGTATCGCACTCCCTC-3’ 
5’-CGCAGAGACTGGAAAGAACCG-3’ 
RPIB9 
5’-AAAGACTCTACACTGGCACCACG-3’ 
5’-TAGTGCCGACATTTCTTGCCC-3’ 
RPP30 
5’-AGCTTCTAAGTTACTATCAGCCCTTCC-3’ 
5’-GTATTGTTCCAACACTCCCACGTCC-3’ 
SETBP1 
5’-TGTGCGTTTCTAGAGGAGCCG-3’ 
5’-AAATCGATACCGAAGGGTTCCC-3’ 
SLITRK3 
5’-TACCTCTTACAACACCAGCGAGC-3’ 
5’-GGATCAGTTAGGTGTAAGGACGTTGG-3’ 
SNRPN 
5’-TACATCAGGGTGATTGCAGTTCC-3’ 
5’-TACCGATCACTTCACGTACCTTCG-3’ 
SSIAH2 
5’-CTGAGACACTCCGCTCCAGC-3’ 
5’-TGTTATTGGCTGTCTCTGCACCTC-3’ 
TGIF 
5’-GTCCGGGAAGGAACTGTGCTC-3’ 
5’-CTGCTCGGGACAGAAGAGAACAC-3’ 
TLR2 
5’-TGTGTTTCAGGTGATGTGAGGTC-3’ 
5’-CGAATCGAGACGCTAGAGGC-3’ 
ZFP36L1 
5’-AAACATTGTCCCGAGACTCACTTCC-3’ 
5’-GTCTGTCCAGCGGCATTACC-3’ 
ZNF516 
5’-CAGGTGATGATGGAACCCACTC-3’ 
5’-TGCTGCCCTTCACTTTTCTACG-3’ 
ZNF516 (p) 
5’-CCCTCAGTGTGGCAGAACTTTG-3’  
5’-CCCAGCCTGGAAATGGTC-3’ 
  
3.6.3 Real-time PCR primers for ChIP-on-chip 
Gene Primer sequence (sense & antisense) 
HDAC3 
5’-TCAGCTCTCCCGGTATCTGG-3’ 
5’-GACAAATGGCCCTCGCATCC-3’ 
LDHB 
5’-GTCGTGCGGAGAAGACAAAGTCAG-3’ 
5’-CTAAGAGGCTGCGGTGGTTGTG-3’ 
CTCF 
5’-GTCCCTTCCCTTATCAGCACCC-3’ 
5’-GCACGGTTTAATCGCTCCACAG -3’ 
RAN 
5’-CGTCTCCGGCGTTTGAATTGC-3’ 
5’-GCGATACCTTCCAGAAGCGTC-3’ 
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Gene Primer sequence (sense & antisense) 
CAPNS1_1 
5’-AGACCTGGATCCAGCTAGCC-3’ 
5’-AACTCTCGGGTCGGACACTG-3’ 
CAPNS1_2 
5’-CAATGTCCGCTTCGGCTCTAGG-3’ 
5’-TGACTCAGGCCGCAACTCTC-3’ 
CXCR4 
5’-AGATGCGGTGGCTACTGGAG-3’ 
5’-CAGAAACTTCAGTTTGTTGGCTGCG-3’ 
MED8 
5’-CTAGTACGCCCAACGCAACTC-3’ 
5’-CTGATTGGTGGACGAAGCCTTCTC-3’ 
LOC116349 
5’-TAGCCGTAGAGGGTGAGTCG-3’ 
5’-ACAGGGAGAGCAAGGATGAAAGAC-3’ 
AIP 
5’-CGCAGAGAACCAATCACCATCC-3’ 
5’-CTTCGGCAACTCCTAGCACC-3’ 
KLF15 
5’-ACCTCCTTGCTTCCCACCTC-3´ 
5´-CAGGCCAGTCTCACGTTCTCAC-3´ 
 
3.6.4 Real-time RT-PCR primer 
Gene Primer sequence (sense & antisense) 
MAFB 
5’-GAGCCGGAGAGAGAGACG-3’ 
5’-AGGAGTCTCCAGATGGCCTTG-3’ 
JUN 
5’-CGGCGGTAAAGACCAGAAGG-3’ 
5’-CGCCCAAGTTCAACAACCG-3’ 
KLF11 
5’-ACCTACTTCAAAAGTTCCCACC-3’ 
5’-CATGAAACGTCGGTCACACAC-3’ 
SSIAH2 
5’-GTTTCAGCACTACAAGGCTAAACGG-3’ 
5’-AAGCTGCCTTGCTCTGGAGC-3’ 
ZNF516 
5’-GTTCTGAAGTTCATACCACCTCCG-3’ 
5’-TCAGAGGCACTGTCTGGACGG-3’ 
 
3.6.5 LM-PCR oligonucleotides 
Gene Primer sequence (sense & antisense) 
LM_JW102_sticky 5’-GCGGTGACCCGGGAGATCTGAATTCT-3’ 
LM_JW103_sticky 5’-GAATTCAGATC-3’ 
 
3.6.6 Bisulfite amplicon generation (Nested PCR) 
Gene 
 
Primer sequence (sense & antisense) 
RAB3C outer 
5’-ATTGGGAGAGGTAATTTAGGAG-3’ 
5’-ATTTTAAACAAACACTCTTATCCTC-3’ 
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Gene 
 
Primer sequence (sense & antisense) 
 
inner 
5’-TTTGGAAAGGAGTAGGGAGG-3’ 
5’-ATCCCTCATCAAAACAACCC-3’ 
MAFB outer 
5’-GGGTAYGGYGTGGTATTGGG-3’ 
5’-TAAAATAAATCACAACTTAACCTATCCATC-3’ 
 
inner 
5’-TTTAATTTAATTTTGTGGGGTGGT-3’ 
5’-CTCTAAAAACCACAAATCTCTTAAAACC-3’ 
JUN outer 
5’-TTTAGATGGGAATAAGYGTGTAGG-3’ 
5’-TACTACAAATCCAACTTCAAACC-3’ 
 
inner 
5’-TYGGGAAAATAAGTTTAGAAGG-3’ 
5’-ACTCTTATATCCTAACATCCTATCC-3’ 
SSIAH2 outer 
5’-TTTAATATATGGGATAGAGAGAATTTGG-3’ 
5’-TTCTATCCTTTTAATTAACCRCCTCAC-3’ 
 
inner 
5’-AAATAGTAGGGGGAGTGATGGG-3’ 
5’-AAACCCAAAAACTCACAACTTCC-3’ 
KLF11 outer 
5’-TGTTTATGTGAGTGGTGGGG-3’ 
5’-ACCCACCTAAAAACCTCAACC-3’ 
 
inner 
5’-TTGTTTTYGTTTTTTGGATGGAG-3’ 
5’-TATTTTTAACTTCTATCATTCTCCC-3’ 
ZNF516 outer 
5’-CACCCAATTCTACCCCTCC-3’ 
5’-ATTTTTTTATTGGGAGTTGATG-3’ 
 
inner 
5’-ACCTCTCCATTACATCATCCC-3’ 
5’-GTTTTTGGTAAATTTTAGAAGGTG-3’ 
CPM outer 
5’-TTGGTTAGTTAGTTGGGTTTTGG-3’ 
5’-AAACAATTATACTAACCTTCTTCTCTTTCC-3’ 
 
inner 
5’-TTGGTATTTAGATTTGGAGTGGG-3’ 
5’-TAATATACAATAACTTCCACCATAACCA-3’ 
 
3.6.7 MassARRAY QGE  
3.6.7.1 Oligonucleotides 
Gene Primer sequence (sense & antisense) 
MGMT_MBD-Fc_1_TAG 5’- ACG TTG GAT GCG CCC CTA GAA CGC TTT G -3’ 
 
5’- ACG TTG GAT GAG ACA CTC ACC AAG TCG CAA AC -3’ 
 
3.6.7.2 Competitors 
Gene Primer sequence (sense & antisense) 
Comp_MGMT-1 
5’- CGC CCC TAG AAC GCT TTG CGT CCC GAC GCC CGC AGG TCC CCG 
CGG TGC GCA CCG TTT GCG ACT TGG TGA GTG TCT -3’ 
 
5’- AGA CAC TCA CCA AGT CGC AAA CGG TGC GCA CCG CGG GGA CCT 
GCG GGC GTC GGG ACG CAA AGC GTT CTA GGG GCG -3’ 
 
 Material and equipment 
 - 35 -    
3.6.8 Bisulfite amplicon generation (MassARRAY) 
All primers designed for methylation analysis using the MassCLEAVE assay are or will be 
available within the supplementary information of the corresponding publications. 
 
3.7 Antibodies 
Chromatin immunoprecipitation (ChIP) 
Anti-YY1     Santa Cruz, sc-1703 
Anti-NRF1     Abcam, ab34682 
Anti-Sp1     Upstate, 07645 
Anti-rabbit IgG     Upstate 
Western Blot 
Goat anti-IgG F(c), HRP conjugated  Rockland, Gilbertsville, USA 
 
3.8  Antibiotics 
Ampicillin     Ratiopharm, Ulm, Germany 
Hygromycin     Clontech, Mountain View, USA 
Zeozin      Invitrogen, Karlsruhe, Germany 
 
3.9 Plasmids 
pCpG-mcs     Invivogen, San Diego, USA 
pGL3-Basic     Promega, Mannheim, Germany 
pCR®2.1-TOPO    Invitrogen, Karlsruhe, Germany 
 
3.10 E.coli strains 
PIR1  F-∆lac169 rpoS(Am) robA1 creC510 hsdR514 endA recA1 uidA(∆MluI)::pir-116 
TOP10  F-mcrA ∆(mrr-hsdRMS-mcrBC) Ф80lacZ∆M15 ∆lacΧ74 recA1 deoR araD139  
∆(ara-leu)7697 galU galK rpsL (StrR) endA1 nupG 
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DH10ß  F-mcrA ∆(mrr-hsdRMS-mcrBC) Ф80lacZ∆M15 ∆lacΧ74 recA1 deoR araD139  
∆(ara-leu)7697 galU galK rpsL endA1 nupG 
 
3.11 Cell lines 
Human cell lines  
THP-1      Human acute monocytic leukemia (DSMZ no ACC 16) 
U937      Human histiocytic lymphoma (DSZM no ACC 5) 
KG-1      Human acute myeloid leukemia (DSZM no ACC 14) 
 
Insect cell lines 
Drosophila Schneider 2 (S2) cells  
 
3.12 Databases and software 
Agilent feature extraction 9.5.1   Agilent Technologies, Waldbronn, Germany  
BLAT      http://genome.brc.mcw.edu 
EpiTYPER 1.0.5    Sequenom, Hamburg, Germany 
Generunner version 3.05   Agilent Technologies, Waldbronn, Germany 
Genespring 10.0.2     
Perlprimer version 1.1.14   
PubMed      www.ncbi.nlm.nih.gov/entrez 
Spotfire decision site 7.0 
UCSC Genome. Browser    www.genome.ucsc.edu 
 
Reference sequence: Genomic locations are based on the March 2006 human reference sequence 
(NCBI Build 36.1) that was produced by the International Human Genome Sequencing Consortium. 
 
The following databases were used to annotate genes associated with CpG islands that were either 
bound by general transcription factors (Sp1, NRF1 or YY1) or associated with a particular methylation 
status: 
Biological Process:  Functional groupings of proteins (Gene Ontology, 
http://www.geneontology.org/) 
Molecular Function: Mechanistic actions of proteins (Gene Ontology) 
Cellular Component:  Protein localization (Gene Ontology) 
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KEGG Pathways:  Groups of proteins in the same pathways 
(From KEGG, http://www.genome.jp/kegg/pathway.html) 
Interactions:  Groups of proteins interacting with the same protein (From NCBI Gene, 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene) 
Interpro:  Proteins with similar domains and features  
(Interpro, http://www.ebi.ac.uk/interpro/) 
Pfam:   Proteins with similar domains and features (Pfam, http://pfam.sanger.ac.uk/) 
SMART:  Proteins with similar domains and features 
(SMART, http://smart.embl-heidelberg.de/) 
Gene3D:  Proteins with similar domains and features 
(Gene3D Database, http://gene3d.biochem.ucl.ac.uk/Gene3D/) 
Prosite:  Proteins with similar domains and features 
(Prosite Database, http://ca.expasy.org/prosite/) 
PRINTS:  Proteins with similar domains and features (PRINTS Database, 
http://www.bioinf.manchester.ac.uk/dbbrowser/PRINTS/index.php) 
Chromosome Location: Genes with similar chromosome localization 
miRNA Targets:  Genes targeted by similar miRNAs 
(miRBase target database http://microrna.sanger.ac.uk/) 
 
3.13 Statistical testing 
All statistical analysis of enrichment data (motifs or attributes) was performed using a 
cumulative hypergeometric distribution (or Fisher Exact test, referred to as the 
hypergeometric test). Statistical testing of differences in mRNA level distributions was done 
using the two-sided Mann–Whitney U test.
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4 Methods 
4.1  General cell culture methods 
For washing and harvesting, mammalian cells were centrifuged using the general cell 
program: 8 min, 300×g, 4°C. 
 
4.1.1 Cell line culture conditions and passaging 
Cells were cultured in RPMI 1640 (HyClone) or DMEM (Gibco) routinely supplemented with 
10% inactivated FCS, L-glutamine (2 mM), sodium pyruvate (1 mM), antibiotics (50 U/ml 
penicillin and 50 µg/ml streptomycin), 2 ml vitamins, non essential amino acids and 50 µM 
ß-mercaptoethanol. Media supplements were purchased from Gibco and Biochrome 
(L-glutamine), respectively. 
FCS was heat inactivated for 30 min at 56°C before use. Exceeding incubation times and 
higher temperatures should be avoided because heat sensitive growth factors could be 
damaged. Each batch of FCS as well as each RPMI batch was tested before use. 
Culturing of cells was performed at 37°C, with 5% CO2 and 95% relative humidity in an 
incubator. U937, THP-1 and KG-1 cells grow in suspension and were split 1:4 to 1:8 in fresh 
medium every 2-4 days.  
 
4.1.2 Culturing of stably transfected Drosophila S2 cells and 
expression of the methyl binding polypeptide MBD-Fc 
MBD-Fc stands for a fusion protein consisting of the methyl-CpG binding domain (MBD) of 
human MBD2 (methyl-CpG binding domain protein 2) and the Fc-tail of human IgG1. The 
MBD-Fc vector was stably transfected into Drosophila S2 cells using the Effectene 
transfection reagent (Qiagen) and hygromycin selection. A detailed description of design and 
generation of the fusion protein can be found in Gebhard, 2005 and Gebhard et al., 2006b. 
 
Expansion in cell culture bottles 
MBD-Fc S2 cells were seeded at a density of 1-2×106 cells/ml in Insect-Xpress medium 
(Lonza) including 50 U/ml penicillin and 50 µg/ml streptomycin but without FCS at 21-23°C. 
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400 µg hygromycin was added for selection of plasmid containing cells. Cells were splitted 
once a week, without exceeding 10×106 cells/ml. 
 
Protein production 
Cells were transferred into 2,000 ml roller bottles and cultured at a density of 4×106 cells/ml 
in up to 400 ml Insect-Xpress medium supplemented with penicillin, streptomycin and 
hygromycin as described above. Cells should not exceed a density of 10×106 cells/ml. For 
large-scale protein production, after 3-5 days the culture media was exchanged and 
5×106 cells/ml were seeded in 400 ml Insect-Xpress medium. Instead of hygromycin, 0.5 mM 
CuSO4 was added to stimulate the metal inducible promoter of the used vector. The MBD-Fc 
containing culture medium was harvested after 4 days like described in section 4.2.1. For 
recovery, cells were cultured again in Insect-Xpress medium containing standard antibiotics 
and selection antibiotic for 3-5 days. The cycle of production was repeated until protein 
quality and amount clearly decreased. 
 
4.1.3 Assessing cell number and vitality 
The number of viable and dead cells was determined by Trypan blue exclusion. Cell 
suspensions were diluted with Trypan blue solution and then counted in a Neubauer 
haemocytometer. Dead cells appear blue since the blue stain is able to enter the cytoplasm. 
The concentration of viable cells was then calculated using the following equation: 
Number of viable cells/ml  C=N×D×10
4 
 
 N:  average of unstained cells per corner square (1 mm containing 16 sub-squares) 
 
 D: dilution factor 
 
Required solutions and materials:  
 Trypan blue solution:  0.2% (w/v)  Trypan blue in 0.9% NaCl solution 
 
 Neubauer haemocytometer slide with coverslip  
 
4.1.4 Freezing and thawing cells 
Cells were harvested and resuspended at 5-10×106 cells/ml in 800 µl ice cold medium, 
including 10% FCS. After inverting the mix and transferring it into cryo-vials, 160 µl DMSO 
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(10% final) and 640 µl FCS (40% final) were added and the tubes were rapidly inverted to 
mix cells properly. To allow gradual freezing at a rate of 1°C/min, the cryo-vials were placed 
in isopropanol-filled cryo-containers (Nalgene) for two hours, then transferred to -80°C for 
48 h. For long-term storage, samples were transferred in liquid nitrogen (-196°C).  
 
4.1.5 Mycoplasma assay 
Cell lines were routinely checked for mycoplasma contamination by the MycoAlert® 
Mycoplasma detection assay (Cambre, Rockland, USA) according to the manufacturer’s 
instructions. 
4.1.6 Isolation of human monocytes 
Peripheral blood mononuclear cells (PB-MNCs) were separated by leukapheresis of healthy 
donors (Graw et al., 1971), followed by density gradient centrifugation over Ficoll/Hypaque 
(Johnson et al., 1977). Monocytes were then isolated from MNCs by counter current 
centrifugal elutriation (Sanderson et al., 1977). 
Elutriation was performed in a J6M-E centrifuge equipped with a JE 5.0 elutriation rotor and a 
50 ml flow chamber (Beckman, Munich, Germany). After sterilizing the system with 6% H2O2 
for 20 min, the system was washed with PBS. Following calibration at 2,500 rpm and 4°C 
with Hanks BSS, MNCs were loaded at a flow rate of 52 ml/min. Fractions were collected 
and the flow-through rate was sequentially increased according to Table 4-1. 
 
Table 4-1 Elutriation parameter and cell types 
Fraction Volume (ml) Flow rate (ml/min) Main cell type contained 
Ia 1000 52 platelets 
Ib 1000 57 
B- and T- lymphocytes, NK cells 
IIa 1000 64 
IIb 500 74 
IIc 400 82 
IId 400 92 
III 800 130 monocytes 
 
Monocytes represent the largest cells within the MNCs and are therefore mainly obtained in 
the last fraction. Monocytes were >85% pure as determined by morphology and CD14 
antigen expression. Low amounts of monocytes may be also detected in the IId fraction. 
Monocytes (fraction III) were centrifuged (8 min, 300×g, 4°C), resuspended in RPMI culture 
medium and counted. Monocyte yields were donor-dependent, typically between 10-20% of 
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total MNCs. Supernatants of monocyte cultures were routinely collected and analyzed for the 
presence of interleukin-6 (IL-6), which was usually low, indicating that monocytes were not 
activated before or during elutriation. 
 
4.2 General protein biochemical methods 
4.2.1 Purification of the recombinant protein MBD-Fc 
4.2.1.1 Dialysis 
The MBD-Fc containing culture supernatant (see section 4.1.2) was harvested by 
centrifugation of the cells at 320×g for 10 min at 4°C. To remove (dead) cells and debris the 
supernatant was centrifuged at 2,000×g for 20 min at 4°C before the final centrifugation step 
of 15,000×g for 1 hour at 4°C to get rid of smaller debris. Afterwards the supernatant was 
dialyzed against 1×TBS (pH 7.4) for 3-4 days whereas the buffer was exchanged twice a 
day. 
 
Required buffers: 
 10×TBS pH 7.4   151.4 g  (500 mM) Tris 
     219.2 g  (1.5 M)  NaCl 
     9.3 g  (10 mM) EDTA 
     125 mg  (0.05%) NaN3 
     Add ddH2O to 2500 ml 
 
4.2.1.2 Affinity chromatography 
After dialysis the protein containing supernatant was purified and enriched using a ProteinA 
sepharose column (Amersham): 
The column (Pharmacia) was filled with 3 ml rProteinA sepharose beads (GE Healthcare, 
Uppsala, Sweden) in 1×TBS. After washing the column with 1×TBS, the dialyzed protein 
supernatant was loaded, followed by another washing step with 1×TBS. Constant flow rate of 
dialyzed cell culture supernatant was achieved using a peristaltic pump (Heidolph, 
Schwabach, Germany). Elution was performed in 1 ml fractions with elution buffer into 1.5 ml 
tubes each containing 50 µl neutralization buffer. The different fractions were measured 
using a Biophotometer (Eppendorf, Hamburg, Germany). The protein containing fractions 
(determined by a photometer) were combined and dialyzed against 1×TBS (as described 
above) using Slide-A-Lyzer Dialysis Cassettes (Pierce, Rockford, USA). 
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Regeneration was performed by washing the column with 3 M KCl and finally with 1×TBS, 
now prepared for another purification cycle or for storage at 4°C. 
 
Required buffers and solutions: 
 Elution buffer pH 3.0  2.9 g  (0.1 M)   Citric acid 
     Add ddH2O to 100 ml 
 
 Neutralization buffer pH 8.8 18 g  (1.5 M)  Tris 
     Add ddH2O to 100 ml 
 
 Recovering solution   22.4 g  (3.0 M)  KCl 
     Add ddH2O to 100 ml 
 
4.2.1.3 Conservation of the purified MBD-Fc 
To stabilize and preserve the protein, 0.2% gelatine and 0.05% NaN3 were added. The 
MBD-Fc fusion protein was now ready for further experiments or for long-term storage at 
4°C. 
 
4.2.1.4 Quantification and quality control of MBD-Fc 
Quality of each protein batch was assessed by SDS-PAGE (see section 4.2.2) followed by 
Coomassie staining (or Western Blot analysis as described in section 4.2.3) as well as by 
control-MCIp (see section 4.4.4). 
Protein concentration was determined relative to a BSA standard curve using a densitometer 
after SDS-PAGE. 
 
4.2.2 Discontinuous SDS-PAGE 
Protein samples were separated by using a discontinuous gel system. This technique 
separates proteins according to their electrophoretic mobility, which is besides other 
characteristics a function of the polypeptide chain length. A polyacrylamide gel is composed 
of stacking and separating gel layers that differ in salt and acrylamide (AA) concentration. 
For a sodium dodecyl sulfate (SDS) polyacrylamide (AA) gel electrophoresis (SDS-PAGE) 
the protein preparation was diluted 1:5 with H2O in a volume of 10 µl and supplemented with 
10 µl SDS sample buffer. Accordingly, a bovine serum albumin (BSA) standard curve was 
prepared containing four different dilutions comprising 1, 0.5, 0.25 and 0.125 mg/ml. All 
samples were incubated to 95°C for 5 minutes and subsequently loaded into a SDS-PAGE 
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assembly together with a pre-stained protein size standard (Bio-Rad Laboratories, Munich, 
Germany). 
 
Table 4-2 SDS-PAGE stock solutions 
Stock solution Separating gel Stacking gel 
Final AA concentration 13.5% 5% 
Stacking gel buffer - 25 ml 
Separating gel buffer 25 ml  
SDS 1 ml 1 ml 
Rotiphorese Gel 30 (30%) 45 ml 16.65 ml 
H2O adjust to 100 ml 
 
Table 4-3 SDS-PAGE gel mixture 
Stock solution Separating gel Stacking gel 
Separating gel stock solution 10 ml - 
Stacking gel stock solution - 5 ml 
TEMED 10 µl 5 µl 
Ammoniumpersulfate 10% freshly 
prepared 
50 µl 40 µl 
 
The separating gel was prepared the day before electrophoresis and overlaid with 
water-saturated isobutanol until it was polymerized. Isobutanol was exchanged for separating 
gel buffer diluted 1:3 with water and the gel was stored overnight at 4°C. The following day, 
the stacking gel was poured on top of the separating gel, and the comb was inserted 
immediately. After polymerization, the gel was mounted in the electrophoresis tank, which 
was filled with 1×Laemmli buffer. Protein samples were loaded and the gel was run with 
25 mA/110 volts until the sample buffer bands reached the surface of the stacking gel. Then 
the voltage was increased to 200 V and the gel was run for 2-4 h. Proteins were then 
resolved through the separating gel according to their size. 
 
Required buffers and solutions: 
 Separating gel buffer 90.83 g  (1.5 M)  Tris/HCl, pH 8.8 
    Add ddH2O to 500 ml 
  
 Stacking gel buffer 30 g  (0.5 M)  Tris/HCl, pH 8.8 
    Add ddH2O to 500 ml 
 
 SDS (10%)  10 g   (10%)  SDS 
    Add ddH2O to 500 ml 
  
 Ammonium persulfate 100 mg  (10%)  Ammonium persulfate 
 (APS)   Add ddH2O to 1 ml 
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 Laemmli buffer (5×) 15 g  (40 mM) Tris 
    21 g  (0.95 M) Glycine 
    15 g  (0.5%)  SDS 
    Add ddH2O to 3000 ml 
 
4.2.3 Western Blot analysis and immunostaining 
After separation by SDS-PAGE, proteins were blotted electrophoretically onto a PVDF 
membrane (Immobilon-P, Millipore) using a three-buffer semi-dry system and visualized by 
immunostaining using specific antibodies and the ECL detection kit. 
The membrane was cut to gel size, moistened first with methanol followed with buffer B and 
placed on top of three Whatman 3MM filter paper soaked with buffer A (bottom, on the 
anode) followed by three Whatman 3MM filter paper soaked with buffer B. The SDS-PAGE 
gel was then removed from the glass plates, immersed in buffer B and placed on top of the 
membrane. Another three Whatman 3MM filter papers soaked with buffer C were placed on 
top of the gel followed by the cathode. Air bubbles in between the layers had to be avoided. 
Protein transfer was conducted for 30 – 45 min at 0.8 mA/cm2 gel surface area. 
 
Required buffers: 
 Buffer A  36.3 g  (0.3 M)  Tris, pH 10.4 
    200 ml  (20%)  Methanol 
    Add ddH2O to 1000 ml 
 
 Buffer B  3.03 g  (25 mM) Tris, pH 10.4 
    200 ml  (20%)  Methanol 
    Add ddH2O to 1000 ml 
 
 Buffer C  5.2 g  (4 mM)  ε-amino-n-caproic acid, pH 7.6 
    200 ml  (20%)  Methanol 
    Add ddH2O to 1000 ml 
 
Blotted membranes were then blocked either with 5% milk in PBST for 1 h at RT then 
washed once for 5 min with PBST or TBST before incubation at RT for 1 h with the primary 
antibody. After washing three times 10 min with the appropriate washing buffer, the 
membrane was incubated for 1 h at RT with a horseradish-peroxidase (HRP)-coupled 
secondary antibody, detecting the isotype of the first antibody. Three washing steps of 
3×10 min preceded the visualization of bound antibody using the ECL kit. Blots were 
exposed to an autoradiography film (HyperfilmTM ECL, Amersham) for 5 seconds to 30 min 
depending on the signal intensity. 
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Required buffers and materials: 
 TBS (2×)  9.16 g  (20 mM) Tris /HCl, pH 7.4 
    35.1 g  (150 mM) NaCl 
    Add ddH2O to 2000 ml 
 
 TBST (1×)  500 ml  (1×)  TBS (2×) 
    1 ml  (0.1%)  Tween 20  
    Add ddH2O to 1000 ml 
 
4.2.4 Coomassie staining of SDS gels 
SDS-gels were tossed in ddH2O (three times, 5 min each) and subsequently incubated in the 
Coomassie solution for about 20 – 60 min. After washing overnight in ddH2O, proteins 
appear as blue bands on a transparent background. For documentation purposes the ready 
stained gel was scanned using a personal Densitometer SI (Molecular Dynamics). The gel 
image was loaded into the ImageQuant 5.0 software and protein bands were quantified using 
the BSA-standard curve as a reference. 
 
Required solution: 
 Coomassie Bio Safe Bio Rad, Munich, Germany 
 
4.3 General molecular biological methods 
4.3.1 Bacterial culture 
4.3.1.1 Bacterial growth medium 
E.coli strains were streaked out on solid LB-agar with specific antibiotics and grown overnight 
(O/N) at 37°C. Single colonies were then picked into liquid LB-medium and then incubated 
O/N with shaking at 200 rpm. 
 LB-medium: 10 g  NaCl 
   10 g  Bacto Tryptone (Difco) 
   5 g  Yeast extract 
   Add ddH2O to 1000 ml, autoclave 
 
 LB-agar plates: 15 g  Agar 
   10 g  NaCl 
   10 g  Bacto Tryptone (Difco) 
   5 g  Yeast extract 
   Add ddH2O to 1 l, autoclave, cool to 50°C and add the appropiate antibiotic. 
   Pour the agar solution into 10 cm Petri dishes, and store inverted at 4°C. 
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4.3.1.2 Transformation of chemically competent E.coli 
Chemically competent E.coli (50 µl) were thawed on ice, 1-25 ng plasmid DNA in 2-5 µl 
volume (e.g. 2 µl from TOPO-cloning) was added and the suspension was mixed gently and 
incubated on ice for 30 min. Cells were then heat-shocked in a water bath at 42°C for 30 s, 
immediately cooled on ice for 2 min and 250 µl SOC medium was added. To express the 
resistance, bacteria were incubated for 1 h at 37°C with shaking. For blue/white screening of 
insert-containing clones after transformation (in case of TOP10 cells), 40 µl of X-gal was 
dispersed on a prewarmed LB-plate prior to use and incubated at 37°C for additional 30 min. 
Afterwards 50-150 µl of the transformation reaction were plated and incubated at 37°C on 
LB-agar containing the antibiotic necessary for selection of transformed cells overnight. 
 
 SOC medium 20 g (2%)  BactoTrypton (Difco) 
   5 g (0.5%)  BactoYeastExtract (Difco) 
   0.6 g (10 mM) NaCl 
   0.2 g (3 mM)  KCl 
   Add ddH2O to 1000 ml, autoclave and add to the cooled solution: 
 
   10 ml (10 mM) MgCl2 (1 M), sterile filtered 
   10 ml (10 mM) MgSO4 (1 M), sterile filtered 
   10 ml (20 mM) Glucose (2 M), sterile filtered 
 
 X-gal  40 mg   X-gal (5-bromo-4-chloro-3-indolyl-ß-D-galactoside)
      In 1 ml DMF, store at -20°C protected from light 
 
4.3.1.3 Glycerol stock 
For long-term storage, bacteria were stored in 20% glycerol by adding 500 µl liquid culture to 
200 µl of 80% glycerol, mixing and freezing at -80°C. 
 
4.3.1.4 Plasmid isolation from E.coli 
To check if the isolated single E.coli colonies contained the correct plasmid, a DNA mini-prep 
was carried out using NucleoSpin® Plasmid Quick Pure Kit from Macherey-Nagel following 
the supplied instructions. Afterwards the plasmid constructs were sequenced. To isolate 
larger amounts of ultra pure DNA (100 µg) for transfection experiments, plasmids were 
isolated using the QIAGEN Plasmid Midi Kit for endotoxin-free midi-preps according to the 
manufacturer’s instructions. 
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4.3.2 Molecular cloning 
Direct cloning of PCR products was done using the TOPO-TA Cloning kit (Invitrogen) 
according to the manufacturer’s instructions. Alternatively, DNA fragments were 
PEG-precipitated and the precipitates as well as the cloning vector were digested with the 
appropriate restriction endonucleases (New England Biolabs or Roche). For directional 
cloning, restriction sites were introduced by adding the appropriate recognition sequences to 
the primer sequences. The cut fragments and the vector were gel-purified and combined in a 
10 µl ligation reaction with a 3- to 5-fold molar excess of insert to vector, using 25-50 ng of 
vector. Ligation was carried out overnight at 16°C with 1 U T4 DNA Ligase or alternatively 
5 min using a rapid ligation system. 2 µl of the reaction was then used to transform 
chemically competent E.coli (see section 4.3.1.2). 
Successful insertion of the fragment into the vector was controlled by preparing plasmid DNA 
from liquid cultures (see section 4.3.1.4). To control correct insertion and sequence integrity, 
plasmid constructs were sequenced using vector-specific primers. 
 
4.3.2.1 PEG precipitation 
To precipitate DNA from small volumes, e.g. PCR reactions or endonuclease digestion, one 
volume of PEG-mix was added to the DNA-containing solution, vortexed and incubated for 
10 min at RT. After centrifugation (10 min, 13,000 rpm, RT), the supernatant was discarded 
and the precipitated DNA was washed by carefully adding 200 µl 100% EtOH to the tube wall 
opposite of the pellet, followed by a centrifugation step (10 min, 13000 rpm, RT) and careful 
removal of the supernatant. The pellet was dried and resuspended in H2O at half to 
three-quarters of the initial volume. 
 PEG-mi x  26.2 g  (26.2%) PEG 8000 
   20 ml  (0.67 M) NaOAc (3 M) pH 5.2 
   660 µl  (0.67 mM) MgCl2 (1 M) 
   Add ddH2O to 250 ml 
 
4.3.2.2 Restriction endonuclease digestion 
To verify the presence and orientation of plasmid insert, or to clone insert DNA into a 
plasmid, DNA was digested with appropriate restriction enzymes. Enzymes and their buffers 
were purchased from Roche or New England Biolabs (Germany). The digestion of plasmid 
DNA or PCR products was carried out using 10 U enzyme/1 µg DNA in 20 µl at 37°C for 
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2 hours. Digestion of genomic DNA was performed overnight with 1.5 U/µg DNA in 30 µl 
reaction volume (see section 4.3.3.4). 
 
4.3.2.3 CIAP treatment 
To prevent re-ligation of digested vectors, vector-ends were treated with CIAP (calf intestinal 
alkaline phosphatase, Roche) at 37°C for 30 min before gel extraction. 
 
4.3.2.4 Gel purification 
To purify DNA from analytical agarose gels, desired bands were excised under UV 
illumination and purified with the QIAEX II gel extraction kit (Qiagen) or NucleoSpin Extract II 
following the manufacturer’s instructions. 
 
4.3.2.5 Ligation reaction 
Restriction enzyme treated vectors and PCR products were ligated in a 10 µl reaction at a 
3- to 5-fold molar excess of insert to vector, using 25-50 ng of vector. Ligation was carried 
out overnight at 16°C with 1U T4 DNA ligase and 1 µl T4 DNA ligase buffer. 
 
4.3.2.6 Sequencing 
DNA sequencing was done by Geneart (Regensburg, Germany) with ABI sequencing 
technology based on the Sanger didesoxy method. Sequence files were analyzed and 
aligned with Generunner, Bioedit or with the Blat function of the UCSC genome browser. 
 
4.3.3 Preparation and analysis of DNA 
4.3.3.1 DNA preparation from normal cells 
Genomic DNA (gDNA) was isolated using the Qiagen Blood & Cell Culture DNA Midi Kit or, 
for smaller cell numbers, the Blood and Tissue Culture Kit (Qiagen). gDNA concentration 
was then determined with the NanoDrop spectrophotometer and quality was assessed by 
agarose gel electrophoresis. 
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4.3.3.2 DNA preparation from clinical samples 
Colorectal cancer samples were collected from 20 patients who underwent colon resection 
for biopsy-proven invasive colorectal adenocarcinoma at the University of Regensburg. The 
study was performed in agreement with the Institutional ethical review board of the University 
of Regensburg (05/003). The tissue was snap frozen and stored at –80°C (in cooperation 
with PD. Dr. W. Dietmeier, Department of Pathology). Each resection specimen was staged 
and graded by routine pathology analysis according to the TNM classification by the 
American Joint Committee on Cancer. DNA from frozen colon tissues was isolated using the 
PUREGENE™ DNA Purification Kit (Gentra, Minneapolis, USA) according to the supplier’s 
recommendation.  
Leukemic blasts and bone marrow cells from AML patients were collected during routine 
diagnostic bone marrow aspirations (in cooperation with Prof. Dr. G. Ehninger, TU Dresden). 
Patients had given informed consent to additional sample collection and analyses according 
to a protocol approved by the local ethical committee.  
 
4.3.3.3 Agarose gel electrophoresis 
The required amount of agarose as determined according to Table 4-4 was added to the 
corresponding amount of 1×TAE. The slurry was heated in a microwave oven until the 
agarose was completely dissolved. The ethidium bromide was added after cooling the 
solution to 50-60°C. The gel was cast and mounted in the electrophoresis tank and covered 
with 1×TAE. DNA-containing samples were diluted 4:1 with DNA loading dye (5×), mixed and 
loaded into the slots of the submerged gel. Depending on the size and the desired resolution, 
gels were run at 40-100 volts for 30 min to 3 h. 
 
Table 4-4 Agarose concentration for different separation ranges 
Efficient range of separation (kb) % agarose in gel 
0.1 – 2 2.0 
0.2 – 3 1.5 
0.4 – 6 1.2 
0.5 – 7 0.9 
0.8 - 10 0.7 
genomic DNA 0.5 
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Required buffers: 
 TAE (50×)  252.3 g  (2 M)  Tris 
    20.5 g   (250 mM) NaOAc/HOAc, pH 7.8 
    18.5 g  (50 mM) EDTA 
    Add ddH2O to 1 l 
 
 EDTA (0.5 M)  18.6 g  (0.5 M)  EDTA/NaOH, pH 8.0 
    Add H2O to 100 ml 
 
 DNA loading dye 500 µl  (50 mM) Tris/HCl, pH 7.8 
 DNA-LD (5×)  500 µl  (1%)  SDS (20%) 
    1 ml  (50 mM) EDTA (0.5 M), pH 8.0 
    4 ml  (40%)  Glycerol 
    10 mg  (1%)  Bromophenol blue 
    Add H2O to 10 ml, store at 4°C 
 
 1.0% Agarose  1 g  (1%)  Agarose (Biozym) 
 
Add 1×TAE to 100 ml and heat in a microwave until agarose is completely dissolved. 
Cool to 50°C and add 2.5 µl ethidium bromide (10 mg/ml) (Sigma). 
 
4.3.3.4 Restriction endonuclease digestion 
Digestion of genomic DNA was performed overnight with 1.5 U/µg DNA in 30 µl reaction 
volume. 
 
4.3.3.5 Quantification of DNA 
The exact DNA concentration was determined either by using the PicoGreen dsDNA 
Quantitation Reagent (Molecular Probes) or by using the NanoDrop spectrophotometer. 
 
4.3.4 Polymerase chain reaction (PCR) 
The polymerase chain reaction (PCR) allows in vitro synthesis of large amounts of DNA by 
sequence-specific polymerization of nucleotide triphosphates catalyzed by DNA polymerase 
(Mullis et al., 1986). The polymerization reaction is “primed” with small oligonucleotides that 
anneal to the template DNA strand through base pairing, giving the reaction its specificity by 
defining the borders of the segment to be amplified. Standard applications of PCR reactions 
are explained in the following and are used unless otherwise mentioned. More specialized 
applications are explained in more detail within the specific method. 
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4.3.4.1 Primer design 
Unless otherwise mentioned sequences for generating primers were extracted using the 
UCSC Genome Browser. In general primers were designed using PerlPrimer Software and 
controlled using PCR and BLAT functions of the UCSC Genome Browser and GeneRunner 
Software. Following settings were used to design primers: 
 
Primer Tm: 65-68°C 
Primer length: 18-28 bp 
Amplicon size: 80-150 bp 
 
4.3.4.2 Standard PCR for cloning or sequencing of gDNA 
PCRs were generally performed in “thick” PCR tubes with a reaction volume of 20-100 µl in a 
MJ research PTC 200 thermocycler (Biozym). The "calculated temperature" feature was 
used to decrease temperature hold times and additionally the lid was heated to 105°C to 
prevent vaporisation. The nucleotide sequences of the utilized primers are given in 
section 3.6. The primer annealing temperatures varied between 57 and 65°C. For a typical 
reaction the PhusionTM Hot Start High-Fidelity DNA Polymerase (Finnzymes; Espoo, 
Finnland) was used with the following basic reaction conditions: 
 
Component Volume Final concentration 
H2O Add 50 µl  
5×Phusion HF buffer 10 µl 1× 
10 mM dNTPs 1 µl 200 µM each 
Primer S 1 µl 0.2 µM 
Primer AS 1 µl 0.2 µM 
Template DNA X µl  
Phusion Polymerase (2 U/ml) 0.5 µl 0.02 U/µl 
 
 
General parameter settings for analytical PCR are summarized in Table 4-5 Reaction 
parameter for analytical PCR. 
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Table 4-5 Reaction parameter for analytical PCR 
PCR step Cycling parameter 
Initial melting 95°C, 2 min 
20 - 35 cycles 
Melting 95°C, 15 s 
Annealing 65°C, 15 s 
Extension 72°C, 60 s 
Final extension 72°C, 5 -7 min 
Cooling 15°C, forever 
 
4.3.4.3 Real-time PCR 
Quantitative real-time PCR (qPCR) enables both detection and quantification (as absolute 
number of copies or relative amount when normalized to DNA input or additional normalizing 
genes) of a specific sequence in a DNA sample. The procedure follows the general principle 
of polymerase chain reaction; its key feature is that the amplified DNA is quantified as it 
accumulates in the reaction in real-time after each amplification cycle. On the one hand, this 
method was used to quantify cDNA after reverse transcription (see section 4.3.5.3), on the 
other hand to quantitatively analyze genomic DNA after fragmentation by methyl-CpG 
immunoprecipitation (MCIp, see section 4.4.4) or after chromatin immunoprecipitation. PCR 
reactions were performed using the Quantifast SYBR Green Kit from Qiagen either in glass 
capillaries using the LightCycler system from Roche (total volume: 20 µl) or in 96-well format 
adapted to the Eppendorf Realplex Mastercycler EpGradient S (Eppendorf, Hamburg, 
Germany). The relative amount of amplified DNA is measured through the emission of light 
by the SYBR green dye when it is intercalated in double-stranded DNA. 
 Reaction setup:  5 µl SYBR Green mix (2×) 
    2 µl ddH2O 
    0.5 µl sense primer 
    0.5 µl antisense primer 
    2 µl DNA 
Table 4-6 Reaction parameter for real-time PCR 
PCR step Cycling parameter 
Initial melting 95°C, 5 min 
45 cycles 
Melting 95°C, 8 s 
Annealing & extension 60°C, 20 s 
Final cycle 
Melting 95°C, 15 s 
Annealing & extension 60°C, 15 s 
Melting curve 10 – 20 min 
 95°C, 15 s  
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To calculate amplification efficiency, a standard curve was generated for each primer pair by 
amplifying four dilutions (1:10, 1:50, 1:100, 1:1000). Realplex software calculated 
automatically DNA amounts based on the generated slope and intercept. Specific 
amplification was controlled by melting-curve analysis and data was imported and processed 
in Microsoft Excel 2007. All samples were measured in duplicates and normalized to the 
ß-actin or the HPRT housekeeper when analyzing mRNA expression. Duplicates of ChIP 
samples were normalized to the input or a not affected upstream control region. 
 
4.3.4.4 MassARRAY quantitative gene expression (QGE) analysis 
4.3.4.4.1 Principle 
The MassARRAY QGE method combines real-competitive PCR (rcPCR) with the iPLEX 
primer extension reaction, followed by matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF MS). cDNA or MCIp-enriched DNA is spiked 
with a competitor, which matches the sequence of the targeted cDNA region in all positions 
except a single base and serves as an internal standard. DNA and competitor are 
PCR-amplified and then SAP (shrimp alkaline phosphatase) -treated to dephosphorylate 
remaining nucleotides. After SAP inactivation, a primer extension cocktail is added. The PCR 
products from the competitor and the cDNA now serve as templates for the iPLEX reactions. 
After primer extension, the products are desalted using clean resin and then dispended on a 
SpectroCHIP for subsequent MALDI-TOF MS. During mass spectrometric analysis, the peak 
areas of the distinct mass signals for the competitor and DNA extension products are 
resolved and peak area ratios are calculated. The QGE Analyzer software plots cDNA 
frequency versus competitor concentration for each assay and sample. DNA concentrations 
(expressed as LOGEC50 or EC50) are automatically calculated via non-linear regression 
analysis and represent the competitor concentration at which the allele frequencies of cDNA 
and competitor are equal (0.50:0.50). A workflow for conducting MassARRAY QGE 
experiments is shown in Figure 4-1. Detailed description of the method is given in the 
MassARRAY QGE-iPLEX Application guide (www.sequenom.com).  
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Figure 4-1 Schematic outline of the MassARRAY QGE process 
cDNA or MCIp-enriched DNA is spiked with a synthetic DNA molecule (competitor), which matches the sequence 
of the targeted cDNA region in all positions except a single base and serves as internal standard. The 
cDNA/competitor is PCR-amplified and subjected to a SAP treatment. After inactivation of the SAP, a primer 
extension cocktail is added. The PCR products from the competitor and the cDNA now serve as templates for the 
iPLEX reactions. After primer extension, the products are desalted using clean resin and then dispended on a 
SpectroCHIP for subsequent MALDI-TOF MS (www.sequenom.com). 
 
4.3.4.4.2 Protocol 
Primer and competitive template designs were created using the MassARRAY QGE Assay 
Design software v1.0 (Sequenom, San Diego, CA). Preparing of the competitor plates, PCR, 
SAP addition, iPLEX reaction, desalting of the iPLEX reaction and MALDI-TOF analysis were 
performed as described in the Sequenom protocols. Raw data were then processed using 
the MassARRAY QGE Analyzer software v3.4. 
 
4.3.4.5 Nested PCR for quantitative methylation analysis 
Methylation analysis of specific DNA fragments was performed using a nested PCR after 
bisulfite treatment of genomic DNA (see section 4.4.3). 10 µl of bisulfite-treated DNA were 
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used for the first nested PCR reaction, generated with an outer primer pair. Afterwards the 
PCR products are used as a template for a second PCR using a different set of primers 
inside of the first PCR product (inner primer pair). The reaction was performed as follows: 
 
Components 1st PCR 2nd PCR 
Bisulfite DNA 10 µl  
DNA from 1
st
 PCR  0.5 µl 
10×Taq-Buffer 5 µl 5 µl 
dNTPs (10 mM each) 1 µl 1 µl 
Out S (10 µM) 2 µl  
Out AS (10 µM) 2 µl  
In S (10 µM)  2 µl 
In AS (10 µM)  2 µl 
Taq 0.5 µl  
FastStart-Taq  0.5 µl 
H2O Ad 50 µl Ad 50 µl 
 
 
Table 4-7 Reaction parameter for nested PCR 
step 1st PCR  2nd PCR 
 Temp Time cycle  Temp Time cycle 
Initial denaturation 93°C 5 s 1  94°C 3 min 1 
Denaturation 
Annealing 
Extension 
93°C 
55°C 
72°C 
15 s 
15 s 
70 s 
 
30 
 
 
94°C 
55°C 
72°C 
15 s 
15 s 
80 s 
 
30-35 
 
 
 
Final extension 72°C 5 min 1  72°C 5 min 1 
 
After the second amplification reaction, products were cloned into a TOPO vector and 
transformed in TOP10 cells (one shot chemical transformation) (see section 4.3.1.2). After 
preparation of plasmid DNAs, samples were then sent to Entelechon or Geneart for 
sequencing. 
 
4.3.5 Preparation and analysis of RNA 
4.3.5.1 Isolation of total RNA 
Total RNA was isolated using the Qiagen RNeasy Midi, Mini or Micro Kit according to the 
available number of cells. RNA concentration was then determined with the NanoDrop 
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spectrophotometer and quality was assessed by agarose gel electrophoresis or using the 
Agilent Bioanalyzer according to the manufacturer’s instructions. 
 
4.3.5.2 Formaldehyde agarose gel 
The agarose was dissolved in MOPS/H2ODEPC by heating in a microwave oven and cooled to 
60°C. Formaldehyde was added while stirring the solution under a fume hood and the gel 
was cast, mounted in an electrophoresis tank and overlaid with 1×MOPS as electrophoresis 
buffer. RNA samples were heated to 37°C for 30 min to control RNase contamination and 
placed on ice afterwards. Samples were subsequently diluted with four volumes RNA loading 
buffer (1:4), denatured for 20 min at 65°C and briefly incubated on ice. Following 
centrifugation, the samples were loaded into the gel slots. Gels were run at 40-60 V. 
 
Required buffers 
 MOPS (20×)  42 g (0.4 M)  MOPS/NaOH, pH 7.0 
    4.1 g (100 mM) NaOAc 
    3.7 g (20 mM) EDTA 
    Add H2ODEPC to 500 ml, store in the dark 
 
 RNA loading buffer 10 ml (50%)  Formamide, deionized 
    3.5 ml (2.2 M)  Formaldehyde (37%) 
    1 ml (1×)  MOPS (20×) 
    0.8 ml (0.04%) Bromophenol blue (1% in H2O) 
    0.2 g (1%)  Ficoll 400, Pharmacia (dissolve in 2 ml H2O) 
    Add H2ODEPC to 20 ml, store in 1 ml aliquots at -20°C 
 
    Add 5 µl/ml ethidium bromide (10 mg/ml) before use 
 
4.3.5.3 Reverse transcription PCR (RT-PCR) 
To quantify mRNA transcripts of genes, total RNA was reverse transcribed using the MMLV 
reverse transcriptase (Promega, Germany) combined with random decamers (Ambion, 
Germany) in a total reaction volume of 20 µl. 
 Reaction setup: : 1 µg Total RNA 
    1 µl Random decamers 
    1 µl  dNTPs (10 pmol/ml) 
    Add H2OUSB 
 
    Incubate for 5 min at 65°C, cool on ice and centrifuge 
 
    4 µl  M-MLV Buffer (5×)  
    Mix and incubate for 2 min at 42°C 
 
    1 µl M-MLV Reverse transcriptase 
    Incubate for 50 min at 42°C followed by 15 min at 70°C 
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The resulting cDNA was then quantified with specific primers by real-time PCR (see section 
4.3.4.3). 
 
4.3.5.4 Whole genome gene expression 
4.3.5.4.1 4 × 44K Agilent whole human genome expression array 
Labeling, hybridization and scanning of high quality RNA were performed using the Agilent 
Gene Expression system according to the manufacturer’s instructions. In brief, 200 ng to 
1000 ng high-quality RNA were amplified and Cyanine 3-CTP labeled with the One colour 
Low RNA Input Linear Amplification Kit from Agilent. Labeling efficiency was controlled using 
the NanoDrop spectrophotometer and 1.65 µg labeled cRNA was fragmented and hybridized 
on the whole human genome expression array (4 × 44K, Agilent). After 17 hours of 
hybridization at 65°C, the microarrays were washed and subsequently scanned with an 
Agilent scanner. Data were then extracted with Feature Extraction 9.5.1 software (GE1 
v5_95_Feb07 protocol, Agilent) and finally analyzed using GeneSpring G 7.3.1 software 
(Agilent). To validate microarray data, several genes were selected and verified by RT-PCR 
followed by qPCR (see sections 4.3.5.3 and 4.3.4.3). 
 
4.3.5.4.2 Affymetrix microarray analysis 
RNA from KG-1, U937, and THP-1 cells as well as from freshly isolated human blood 
monocytes of healthy donors were alternatively (formerly) analyzed using Affymetrix 
HG-U133_Plus_2 arrays. Hybridization, cRNA labeling and data handling was done by the 
KFB (Regensburg). 
 
4.3.6 ChIP-on-chip 
Chromatin immunoprecipitation (ChIP) is a method to investigate interactions between 
proteins and DNA in vivo. Therefore DNA is covalently bound to proteins with formaldehyde, 
fragmented by sonication and precipitated with suitable antibodies. Hereafter, the covalent 
cross-links are broken up to free the precipitated DNA. The quality of each ChIP was 
controlled at known target sites by qPCR. If the ChIP was successful the fragments were 
amplified with a ligation-mediated PCR (LM-PCR, see section 4.3.6.2), fluorescence-labeled 
and hybridized on a microarray (ChIP-on-chip, microarray handling see section 4.4.5) against 
a fractional amount of the input to correct background noise. This approach allows the 
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identification of binding sites of DNA-binding proteins in all areas covered on the microarray 
platform. 
 
4.3.6.1 Chromatin immunoprecipitation (ChIP) 
Preparation of cross-linked chromatin was performed as described previously with some 
modifications. In summary, 2 million cells were used per immunoprecipitation. The cells were 
treated with 1% formaldehyde solution for 10 min at room temperature and quenched by 
0.125 M glycine. After washing with PBS including 1 mM PMSF, 2×106 cells were 
resuspended in 50 µl lysis buffer 1A (L1A: 10 mM, HEPES/KOH, pH 7.9, 85 mM KCl, 1 mM 
EDTA, pH 8.0) and lysed by adding 50 µl lysis buffer 1B (L1A + 1% Nonidet P-40) for 10 min 
on ice. Note that lysis buffers were supplemented with phosphatase inhibitors (50 mM 
ß-glycerophosphate and 1 mM Na2OV4) when phosphorylated proteins had to be 
precipitated. The lysate was centrifuged (700×g, 5 min), the supernatant discarded and the 
nuclei were resuspended in 400 µl L2. If more cells were available, up to 20×106 cells were 
treated with the same procedure to concentrate the chromatin. Cross-linked chromatin was 
sheared to an average DNA fragment size around 400 – 600 bp using a Branson Sonifier 
250 (Danbury, CT). The sonicated lysate was cleared by centrifugation (13,000 rpm, 5 min, 
4°C) and the supernatant was transferred into a new 1.5 ml tube. To monitor successful 
fragmentation of the DNA an aliquot was taken for agarose gel analysis (which was 
incubated overnight with 200 mM NaCl at 65 °C to reverse the formaldehyde cross-links and 
purified with the QIAquick PCR purification kit (Qiagen)) and a 5 % volume aliquot of the 
lysate was kept as the input. To pre-clear the lysate 50 µl/precipitation sepharose CL-4B 
beads were washed twice with TE pH 8.0, filled up with dilution buffer to the previous volume 
and incubated with 25 µl 20% BSA and 4 µl glycogen per ml CL4Beads on a rotator for a 
minimum of 2 hours at room temperature. The lysate was diluted 1:1.5 with DB and 50 µl of 
the CL-4B beads/ IP were added, rotating for 2 hours at 4 °C. 
Following this the pre-cleared lysate was recovered by centrifugation (13,000 rpm, 5 min, 
4°C) and 200 µl supernatant for each IP was transferred in a new 0.5 ml PCR tube. 
Antibodies were added (2-5 µg each, depending on the used cell numbers) and incubated on 
a rotator at 4 °C overnight. 
To bind the antibody complexes to beads, 55 µl nProtein A sepharose beads per IP were 
washed twice with TE pH 8.0, filled up to the previous volume with DB and blocked with 
0.4 µl glycogen and 2.5 µl BSA (20%) per 100 µl beads overnight on a rotator at 4°C. Then 
50 µl of the blocked beads were added to the antibody complexes, rotated at 4°C for 2 hours, 
centrifuged (4,000 rpm, 5 min, 4 °C) and the supernatant was discarded. The beads were 
transferred on Millipore Ultrafree-MC columns and washed twice with WBI, WBII, WBIII and 
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three times with TE pH 8.0, shaking the beads for 5 minutes in between. The DNA was 
eluted in two steps by adding 100 µl EB each, incubating for 20 minutes and 10 minutes 
respectively, shaking up the beads every 5 minutes. 200 µl EB was added to the input as 
well, and all samples were incubated overnight at 65 °C with added Proteinase K (0.5 µg/µl 
final concentration, Roche) to reverse the cross-links. RNase (0.33 µg/µl, Qiagen) digestion 
for 2 hours at 37 °C degraded RNA that could interfere with downstream applications. Finally, 
the samples were purified with the QIAquick PCR purification kit following the manufacturer’s 
instructions with small variations: binding buffer PB was incubated for 30 minutes, binding 
DNA to the column by centrifugation was carried out at 10,000 rpm and elution was done 
with 100 µl pre-warmed elution buffer EB. 
 
Required buffers and solutions: 
 Glycine    9.85g (2.625 M)  Glycine 
     Ad 50 ml with ddH2O 
 
 Cell Buffer Mix   20 µl (10 mM)  HEPES / KOH (1 M), pH 7.9 
     57 µl (85 mM) KCl (3 M) 
     4 µl  (1 mM)  EDTA (0.5 M, pH 8.0) 
     Ad 1.98 ml with ddH2O 
     
     Add just prior to use: 
     20 µl (1 mM)  PMSF (100 mM in Iso-prop, nostalgia) 
     2 µl (1 µg/ml) Pepstatin (1 µg/µl) 
     2 µl (2 µg/ml) Aprotinin (2 µg/µl) 
 
 Nuclear Lysis Buffer (L2) 100 µl (50 mM) Tris/HCl (1 M), pH 7.4 @ 20°C 
     100 µl (1%)  SDS (20%) 
     33.3 µl (0.5%)  Empigen BB (30%)  
     40 µl (10 mM)  EDTA (0.5 M), pH 8.0 
     Ad 1.98 ml with ddH2O 
       
     Add just prior to use: 
     20 µl (1 mM)  PMSF (100 mM in Iso-prop, nostalgia) 
     2 µl (1 µg/ml) Pepstatin (1 µg/µl) 
     2 µl (2 µg/ml) Aprotinin (2 µg/µl)   
 
 Dilution Buffer (DB)  50 µl (20 mM) Tris/HCl (1 M), pH 7.4 @20°C 
     50 µl (100 mM) NaCl (5 M) 
     10 µl (2 mM)  EDTA (0.5 M, pH 8.0) 
     125 µl  (0.5%)  Triton X-100 (10%) 
     Ad 2.47 ml with ddH2O 
 
     Add just prior to use: 
     25 µl (1 mM)  PMSF (100 mM in Iso-prop, nostalgia) 
     2.5 µl (1 µg/ml) Pepstatin (1 µg/µl) 
     2.5 µl (2 µg/ml) Aprotinin (2 µg/µl) 
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 Wash Buffer I (WB I)  200 µl (20 mM) Tris/HCl (1 M), pH 7.4 @ 20°C 
     300 µl (150 mM) NaCl (5 M) 
     50 µl (0.1%)  SDS (20%) 
     1 ml (1%)  Triton X-100 (10%) 
     40 µl (2 mM)  EDTA (0.5 M, pH 8.0) 
     To 10 ml with ddH2O 
 
 Wash Buffer II (WB II)  200 µl (20 mM) Tris/HCl (1 M), pH 7.4 @ 20°C 
     1 ml (500 mM) NaCl (5 M) 
     40 µl   SDS (20%) 
     1 ml (1%)  Triton X-100 (10%) 
     40 µl (2 mM)  EDTA (0.5 M, pH 8.0) 
     To 10 ml with ddH2O 
 
 Wash Buffer III (WB III)  100 µl (10 mM) Tris/HCl (1 M), pH 7.4 @ 20°C 
     250 µl (250 mM) LiCl (10 M) hard to dissolve, try 2.5 M 
     1 ml (1%)  NP-40 (10%) 
     1 ml (1%)  Deoxycholate (10%) 
     20 µl (1 mM)  EDTA (0.5 M, pH 8.0) 
     To 10 ml with ddH2O 
 
 Elution Buffer (EB)  450 µl  (0.1 M)  NaHCO3 (1M) 
     225 µl (1%)  SDS (10%) 
     To 4.5 ml with ddH2O 
 
4.3.6.2 LM-PCR 
Ligation mediated PCR (LM-PCR) was used to amplify the chromatin immunoprecipitated 
DNA. Adaptors are ligated to all fragments in the precipitation, and primers specific for these 
adaptors are used to amplify all fragments independent of their sequences. All reagents were 
purchased from New England Biolabs (NEB) unless otherwise mentioned. 
 
To prepare the 60 mM linker, 10 ml Tris-HCl (1 M) pH 7.9, 15 µl oligo JW102_sticky and 
15 µl oligo JW103 (160 µM each, Metabion) were mixed and incubated in a thermocycler 
with the following program:  
 
   Step 1   95°C   5 min 
   Step 2   70°C   1 min 
   Step 3   Ramp down to 4°C  
      (0.4°C /min) 
   Step 4   4°C   HOLD  
 
To start, the overhangs were converted into phosphorylated blunt ends, using T4 DNA 
polymerase, E.coli DNA Pol I large fragment (Klenow polymerase), and T4 polynucleotide 
kinase (PNK). The 3’ to 5’ exonuclease activity removes 3’ overhangs, the polymerase 
activity fills in the 5’ overhangs and the PKN adds the phosphate group to the 3’ end. 
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ChIP enriched DNA (about 10 ng) was brought to a volume of 40 µl with ddH2O. Then 10 µl 
of the reaction mix was added: 
 
T4 DNA Ligase buffer with 10 mM ATP     (5 µl) 
dNTP mix        (2 µl) 
T4 DNA polymerase       (1 µl) 
Klenow DNA polymerase diluted with water to 1 U/µl  (1 µl) 
T4 PNK        (1 µl) 
 
The mixture was incubated in a thermocycler for 30 minutes at 20°C, then purified with the 
QIAquick PCR purification kit (Qiagen) and finally eluted in 34 µl elution buffer (EB). The 
eluate was then incubated with 1 µl of Klenow fragment (3’ to 5’ exo minus), 5 µl NEB 
buffer II and 10 µl dATP (1 mM) for 30 minutes at 37 °C, followed by clean-up with the 
MinElute kit (Qiagen), eluting in 10 µl EB. In this process an adenine overhang was added to 
the DNA fragments’ 3’ ends to facilitate the ligation with the adapters, which have a single “T” 
base overhang at their 3’ site (see oligo JW102_sticky). DNA Quick-Ligase buffer 2 (15 µl), 
linker 60 µM preparation (1 µl) and DNA Quick-Ligase (4 µl) were mixed with the DNA 
sample and incubated for 15 minutes at room temperature. The reaction was cleaned up with 
the QIAquick PCR purification kit (Qiagen) and eluted in 25 µl EB. For large-scale 
amplification of IP samples two buffer mixes were prepared: 
 
Mix A: 
Stock 1× Mix Final Concentration 
5×Phusion polymerase buffer 8.00 µl 1× 
dNTP mix (10 mM each) 1.25 µl 250 µM 
Oligo JW102_sticky (160 µM) 0.31 µl 1 µM 
Betaine 5.44 µl  1.5 M 
Total 15µl  
 
Mix B: 
Stock 1× Mix Final Concentration 
5×Phusion polymerase buffer 2.00 µl 1× 
Phusion Polymerase(2 U/µl) 0.50 µl 1 U 
Betaine 7.50 µl 1.5 M 
Total 10.00 µl  
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15 µl of Mix A was added to the sample and on a thermocycler the following program was 
started: 
Table 4-8 Reaction parameter for 1st LMPCR 
PCR step Cycling parameter 
Initial heating 55°C, 4 min 
End-filling 72°C, 30 s 
Initial melting 98°C, 30 s 
15 cycles 
Melting 98°C, 10 s 
Annealing 68°C, 30 s 
Elongation 72°C, 30 s 
Final elongation 72°C, 5 min 
Cooling 4°C, forever 
 
Midway through step 1 (initial heating) the program was paused and 10 µl Mix B was added 
to “hot start” the reaction. The PCR product was diluted with 475 µl ddH2O, and 5 µl were 
used for a second expansion using the following mixture: 
 
Stock 1x Mix Final concentration 
5× Phusion polymerase buffer 10.00 µl 1× 
dNTP mix (10 mM each) 1.25 µl 250 µM 
Oligo JW102_sticky (160 µM) 0.31 µl 1 µM 
ddH2O 19.94 µl  
Phusion Polymerase (2 U/µl) 
HOT START 
0.50 µl 1 U 
PCR dilution (first amplification) 5 µl  
Betaine 13 µl 1,5 M 
Total volume 50 µl  
  
 
The PCR program for the second expansion was: 
Table 4-9 Reaction parameter for 2nd LMPCR 
PCR step Cycling parameter 
Initial melting 98° C, 30 s 
25 cycles 
Melting 98°C, 10 s 
Annealing 68°C, 30 s 
Elongation 72°C, 30 s 
Final elongation 72 °C, 5 min 
Cooling 4°C, forever 
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The product was cleaned up with the QIAquick PCR purification kit (Qiagen) and eluted in 
50 µl EB. DNA concentration was measured with the NanoDrop instrument (Peqlab). 
 
4.3.6.3 Labeling and hybridization 
Amplified ChIP material and genomic input were labeled with Alexa Fluor 5-dCTP and Alexa 
Fluor 3-dCTP, respectively. Comparative ChIP-versus-input hybridizations on CpG island 
oligonucleotide microarrays (Agilent) were performed using the recommended, stringent 
protocol (see section 4.4.5.2). 
 
4.4 Analysis of DNA methylation 
4.4.1 In vitro methylation of DNA 
10-20 µg plasmid or genomic DNA were incubated with 2.5 U/µg Sss I methylase in the 
presence of 160 µM S-adenosylmethionine (SAM; methyl group donor) for 4 hours at 37°C. 
After 2 hours the reaction was supplied with another 160 µM SAM. Simultaneously, control 
reactions were treated as above but without addition of SAM and methylating enzymes. After 
the methylation reaction, DNA was purified using the NucleoSpin® Plasmid Quick Pure Kit 
from Macherey-Nagel or by phenol-chloroform extraction followed by ethanol precipitation 
and finally quantified using a NanoDrop spectrophotometer. Completeness of methylation 
was controlled by digesting both methylated and unmethylated DNA using the 
methylation-sensitive restriction enzymes Hha I and Hpa II. 
 
4.4.2 Generation of an in vitro partially methylated gene locus 
A fragment of the CpG island promoter of CPM was subcloned into the CpG-free plasmid 
pCpG-mcs (Invivogen). The plasmid was linearized with Ase I to generate a fragment of the 
CpG island promoter flanked with CpG-less sequences on either side. The DNA fragment 
was then treated with Sss I (New England Biolabs) and decreasing amounts of the methyl 
donor S-adenosylmethionine (160 µM, 40 µM, 10 µM, 2.5 µM, 0.7 µM). Samples were 
combined to obtain a mixture of DNA fragments with varying density of CpG methylation. 
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4.4.3 Bisulfite sequencing 
A common method for analyzing cytosine methylation is bisulfite conversion of DNA followed 
by sequencing. Cytosine-derivates undergo reversible reactions with bisulfite yielding a 
5,6-Dihydro-6-sulfonate, which deaminates spontaneously. After that the sulfate is eliminated 
under alkaline conditions, leaving uracil.   
5’-methylcytosine is not affected by this reaction. Modification of gDNA with sodium bisulfite, 
leading to conversion of unmethylated cytosine residues into uracil while not affecting 
5-methylcytosine (Frommer et al., 1992a), was performed using the Qiagen EpiTect Bisulfite 
Kit as recommended by the manufacturer. 10 µl of bisulfite-treated DNA were used for the 
nested PCR reaction (see section 4.3.4.5). 
 
4.4.4 Methyl-CpG immunoprecipitation (MCIp) 
The MCIp is a method that allows the rapid and sensitive screening of DNA methylation. The 
application consists of the binding of methylated DNA fragments to the bivalent, antibody-like 
fusion protein MBD-Fc (a methyl binding domain fused to an Fc-tail) in an 
immunoprecipitation-like approach. The affinity to DNA is increased with the density of 
methylated CpGs and lowered with higher salt concentrations in the buffer. Washing with 
buffers containing increasing NaCl concentrations and collection of according flow-throughs 
leads to the fragmentation of DNA depending on the methylation status of CpG 
dinucleotides. Enriched methylated DNA fragments can be efficiently detected on single 
gene level or on a genome-wide level. The recombinant MBD-Fc protein was produced as 
previously described (Gebhard, 2005; Gebhard et al., 2006b; Gebhard et al., 2006a) (see 
also section 4.1.2) and MCIp was performed with slight modifications. A schematic 
representation is given in Figure 5-1 and Figure 5-8. 
 
Required buffers and solutions: 
 
TME (10×) 200 mM Tris-HCl (1 M) pH 8.0 
 20 mM MgCl2 (1 M) 
 5 mM EDTA (500 mM) 
   
Buffer A 1× TME (10×) 
(300 mM NaCl) 300 mM NaCl (5 M) 
 0.1% NP-40 (10%) 
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Buffer X 1× TME (10×) 
(300 mM NaCl) 300 mM NaCl (5 M) 
 0.1% NP-40 (10%) 
   
Buffer B-G 1× TME (10×) 
 0.1% NP-40 (10%) 
 350 (B), 400 (C), 450 (D), 500 (E), 600 (F), 1000 mM (G) 
 
4.4.4.1 DNA fragmentation 
Genomic DNA was either restriction digested with Mse I or sonicated to a mean fragment 
size of 350-400 bp. Before sonication gDNA was initially sheared using a 20 gauge needle 
attached to a 2 ml syringe (BD) before quantification using the NanoDrop ND 1000 
spectrophotometer (Peqlab). Sonication was carried out with the Branson Sonifier 250 
(Danbury) using the settings shown below. After sonication the sample was immediately 
cooled on ice. The fragment range was controlled using agarose gel electrophoresis. 
 
For 5 µg DNA in 500 µl TE Duty cycle 30% 
 Output 3 
 Sonication time 60 s 
   
For 2.5 µg DNA in 500 µl TE Duty cycle 80% 
 Output 0.5 
 Sonication time 2×30 s 
 
4.4.4.2 Binding MBD2-Fc to beads 
For small-scale reactions, typically 13-18 µg purified MBD-Fc protein per 40 µl nProtein 
A-Sepharose 4 Fast Flow beads (Amersham Biosciences) were rotated in 2 ml TBS 
overnight at 4°C in order to bind the Fc-part of the protein to the beads. For large-scale 
reactions 60-80 µg MBD-Fc protein was bound to 150-200 µl nProtein A–Sepharose 4 Fast 
Flow beads. On the next day, the MBD2–Fc-bead complexes (40 µl/assay) were transferred 
and dispersed equally into 0.5 ml (for large-scale reaction: 2 ml) Ultrafree-MC centrifugal 
filter devices (Millipore) and spin-washed twice with buffer A. 
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4.4.4.3 Enrichment of highly methylated DNA 
For small-scale reactions digested or sonicated DNA (150-300 ng) was added to the washed 
MBD2–Fc beads in 350 µl buffer and rotated for 3 h at 4 °C. Beads were centrifuged to 
recover unbound DNA fragments (300 mM fraction) and subsequently washed twice with 
200 µl and 150 µl of buffers containing increasing NaCl concentrations (350-1000 mM, see 
buffers B-G). The flow-through of each washing step was collected in separate tubes and 
desalted using a QIAquick PCR Purification kit (Qiagen). In parallel, 150-300 ng fragmented 
input DNA was resuspended in 350 µl buffer and desalted using a QIAquick PCR Purification 
kit (Qiagen) as a control. 
To generate DNA fragments for direct labeling for microarray hybridization this MCIp protocol 
was scaled up. For large-scale reactions, for each sample, 60-80 µg purified MBD2–Fc 
protein was added to 150-200 µl Protein A–Sepharose beads (Amersham Biosciences) in 
15 ml TBS and rotated overnight at 4°C. For the precipitation, 2 ml Ultrafree-MC centrifugal 
filter devices (Millipore) were used and 2 or 4 µg of sonicated DNA (in large scale reactions 
no digested DNA was used). The flow-throughs were collected and desalted using a 
QIAquick PCR Purification kit (Qiagen) or the MinElute Kit. In parallel, 1/10 of the DNA used 
for precipitation was also desalted using the respective kit and used as input DNA. The 
separation of CpG methylation densities of individual MCIp fractions was controlled by qPCR 
using primers covering the imprinted SNRPN gene and a region without any CpGs 
(Empty 6.2), respectively. For the microarray approach a threshold was defined and 
flow-throughs were combined to a hypermethylated fraction for subsequent labeling and 
microarray analysis. 
 
4.4.5 DNA Microarray handling and analysis 
4.4.5.1 Human CpG 12K arrays  
To generate fluorescently labeled DNA for CpG island microarray hybridization, 
Mse I-compatible uni-directional LMPCR linker (LMPCR_S-L 5’-GCG GTG ACC CGG GAG 
ATC TCT TAA G-3’ and LMPCR_AS-L: 5’-TAC TTA AGA GAT C-3’, 20 µM) were ligated to 
the MCIp-eluted DNA and in a separate reaction to an equal amount of input DNA (0.5 µl 
linker /ng DNA) in 60 µl reactions using 1,200 U T4 Ligase (NEB) at 16°C O/N. Linker-ligated 
DNA was desalted using QIAquick PCR Purification kit (Qiagen). Amplification of 
linker-ligated DNA preparations was performed using LMPCR primer (5’-GTG ACC CGG 
GAG ATC TCT TAA G-3’) and Taq polymerase (Roche) in the presence of 1.3 M betaine. 
Amplicons were desalted using QIAquick PCR Purification kit (Qiagen) and quantified 
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(PicoGreen dsDNA Quantitation Reagent, Molecular Probes). Labeling and hybridization of 
MCIp amplicons were done by the KFB (Regensburg) according to the protocol provided by 
the CpG island microarray manufacturer (Microarray Centre UHN, Toronto, Canada) with 
modifications. Briefly, four microgram of normal and tumor MCIp-amplicons were directly 
labeled with Cy5- and Cy3-dCTP, respectively, using the BioPrime® Array CGH Genomic 
Labeling System (Invitrogen). Ten microgram of each fluorescently labeled and purified DNA 
amplicon in 300 µl DIG Easy Hyp Solution (Roche) supplemented with 25 µg Cot-1 DNA 
(Invitrogen) and 30 µg Yeast tRNA were hybridized to Human CpG 12K Arrays (HCGI12K, 
Microarray Centre, UHN, Toronto, Canada) in 6021 mm Gene Frames (ABgene) at 37°C for 
O/N. Slides were washed three times in 1×SSC, 0.1% SDS at 50°C for 10 min. After two 
more rinses with 0.1×SSC, slides were dried and scanned using the Affymetrix 428 Scanner. 
Images were analyzed using the ImaGene 5.6 and Gene Sight Lite software (BioDiscovery, 
Inc., EL Segundo, CA). Locally weighted scatter plot smoothing normalization was used to 
normalize Cy3 and Cy5 signals. Clones that produced reproducible differential signals on the 
CpG island microarray were sequenced by the University Health Network Microarray Centre. 
 
4.4.5.2 Human 244K Agilent CpG island microarrays 
4.4.5.2.1 Labeling reaction 
Enriched methylated DNA fragments of the high salt MCIp fractions were labeled with Alexa 
Fluor 5-dCTP (cancer cells) and Alexa Fluor 3-dCTP (normal cells) using the BioPrime Total 
Genomic Labeling System (Invitrogen) as indicated by the manufacturer. Amplified ChIP 
material was labeled with Alexa Fluor 5-dCTP and the genomic input with Alexa Fluor 
3-dCTP. Labeling efficiency was controlled using the NanoDrop Nd-1000 spectrophotometer 
(PeqLab, Erlangen, Germany).  
 
4.4.5.2.2 Microarray hybridization 
The differently labeled DNA fragments or pools of two samples were combined and 
supplemented with human Cot-1 DNA, Agilent blocking agent (10-fold) (Agilent 
Technologies, Böblingen, Germany), Agilent hybridization buffer (2-fold) as supplied in the 
Agilent oligo aCGH Hybridization Kit. For more stringent hybridization conditions deionized 
formamide was additionally added in order to prevent cross-hybridization of GC-rich DNA 
sequences.  
 
 
Methods 
- 68 - 
Component 1x Mix Final concentration 
DNA samples combined in 80 µl TE 80 µl  
Cot-1 DNA (1.0 mg/ml) 50 µl 0.1 mg/ml 
Agilent Blocking agent (10×) 52 µl 1× 
Deionized formamide 78 µl 15% 
Agilent Hybridization Buffer (2×) 250 µl 1× 
 
The sample was heated to 95°C for 3 min, mixed, and subsequently incubated at 37°C for 
30 min and spun down afterwards for 1 min. Hybridization on microarray slides (Agilent) was 
then carried out at 67°C for 40 h using an Agilent SureHyb chamber and an Agilent 
hybridization oven. Slides were washed in Wash I (6×SSPE, 0.005% N-lauroylsarcosine) at 
room temperature for 5 min and in Wash II (0.06×SSPE; prewarmed to 37°C for stringent 
protocol) for additional 5 min. Afterwards slides were dried and incubated using acetonitrile 
for 30 s. Images were scanned immediately and analyzed using a DNA microarray scanner 
(Agilent). Microarray images were processed using Feature Extraction Software 9.5.1 
(Agilent) using the standard CGH protocol for samples from MCIp. Processed data were 
imported into Microsoft Office Excel for further analysis. Graphical presentations of datasets 
were obtained using Spotfire Decision Site Software 7.0 (Spotfire). 
 
4.4.6 Quantitative DNA methylation analysis using the MassARRAY 
system (SEQUENOM) 
4.4.6.1 Principle 
Quantitative assessment of DNA methylation in target genomic regions was performed using 
the Sequenom MassCLEAVE™ assay. DNA samples for analysis are initially 
bisulfite-treated, resulting in the conversion of unmethylated cytosines to uracil, whereas 
methylated cytosines remain unchanged. This conversion reaction allows for accurate 
discrimination between methylated and unmethylated cytosines at CpG dinucleotides. 
Following bisulfite treatment, genomic DNA consists of two non-complementary 
single-stranded DNA populations. Subsequently, PCR primer pairs for a region of interest are 
designed to amplify both the forward and reverse strand of double-stranded genomic DNA. A 
T7 polymerase promoter tag is added to the 5′ end of the reverse primer to facilitate in vitro 
transcription and a 10-mer tag is added to the 5′ end of the forward PCR primer to minimize 
melting temperature differences between both primers during PCR cycling. Following PCR, 
unincorporated dNTPs are dephosphorylated by treatment with SAP. Reverse transcription is 
performed using a chemically modified T7 RNA polymerase which utilizes a mixture of 
 Methods 
 - 69 -    
ribonucleotides and deoxyribonucleotides when synthesizing the RNA strand. In parallel with 
the reverse transcription the cleave reaction is achieved using the pyrimidine specific 
Ribonuclease A (RNaseA) enzyme which cleaves at pyrimidines (C and T) only on the newly 
synthesized transcript. By incorporating a non-cleavable dCTP (deoxyribonucleotide) into the 
transcript, RNaseA is unable to cleave at C and can only cleave at T (T specific cleavage) 
yielding a population of single-stranded cleavage fragments (Figure 4-2). A methylated 
cytosine is represented by a G nucleotide in the cleavage fragment, whereas an 
unmethylated cytosine is represented by an A nucleotide. The mass difference of 16 Da 
between G (329 Da) and A (313 Da) is easily detected by MALDI-TOF MS. Depending on 
the number of methylated CpG sites within a cleavage fragment, the difference in mass will 
increase in 16 Da units.  
As already mentioned, in the following procedure this methylation specific difference is not 
used for sequencing (see section 4.4.3) but for generating methylation depending mass 
differences to be analyzed by mass spectrometry. A detailed description of the method is 
given in Ehrich et al., 2005 and in the EpiTYPER User Guide (www.sequenom.com). 
 
 
Figure 4-2 Schematic outline of the EpiTYPER process 
Genomic DNA is treated with bisulfite and amplified using specific primers with one primer tagged with a T7 
promoter sequence. PCR products are subsequently transcribed into RNA, followed by RNase cleavage after 
every uracil residue. Cleavage products are then analyzed by MALDI-TOF MS. In the example shown here, PCR 
products are transcribed from the reverse strand. In the unmethylated template (illustrated in red) cytosine 
residues are deaminated into uracil and therefore appear as adenosine residues after PCR. Cytosine residues of 
a methylated template (indicated in yellow) are not affected and remain cytosines. The conversion of guanine to 
adenine yields 16 Da mass shifts. Cleavage product 1 comprises 2 CpGs and the mass difference constitutes 
32 Da if both CpGs are either methylated or unmethylated. Cleavage products 2 and 3 each contain only one 
CpG site that is differentially methylated and therefore yield a 16 Da mass shift (Ehrich et al., 2005).  
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4.4.6.2 Primer design 
Genomic DNA sequences were downloaded from the University of California, Santa Cruz 
genome browser (http://www.genome.ucsc.edu). In order to maximize coverage, both the 
forward and reverse strand of a target region were included for amplicon design. The 
selected genomic sequence was subsequently exported to the primer design software 
MethPrimer (http://www.urogene.org/methprimer). Once genomic DNA is uploaded into this 
application, an in silico bisulfite conversion is performed to facilitate the primer design. PCR 
primer design criteria consist of the following: An optimal primer melting temperature of 62°C 
(range: 56-64°C); Primer length ranges from 20-30 nucleotides, excluding tag addition. 
Amplicons vary from 100-500 bp in length, with a desired length of 400 bp. All primers 
designed for methylation analysis using the MassCLEAVE assay are online (Gebhard et al., 
2010) or will be available upon publication. 
Primers were ordered in 96-well format at 100 µM concentration (Integrated DNA 
Technologies, California, USA or SIGMA). Prior to PCR set up, a 96-well primer mix plate 
(Sarstedt V-bottom, Newton, USA) was assembled, with each well containing 1 µl of both the 
forward and reverse primers of a primer pair and 198 µl ddH2O to give a final concentration 
of 0.5 µM each. 
 
4.4.6.3 Bisulfite conversion 
Bisulfite treatment of genomic DNA was performed using a commercially available kit from 
Zymo Research Corporation (California, USA). The EZ DNA Methylation KitTM facilitates the 
conversion of cytosine to uracil due to the reaction that takes place between cytosine and 
sodium bisulfite. The conversion reaction was performed, using 1 µg of genomic DNA, 
according to the manufacturer’s protocol, but with the following alternative conversion 
parameter: 
 
Step 1: 95°C 30 s 
Step 2: 50°C 15 min 
Step 3: Repeat steps 1-2 for 20 cycles  
Step 4: 4°C hold 
 
4.4.6.4 PCR amplification 
PCR master mixes were prepared in 384 well plates (ABgene) and made as follows per 
reaction: 
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Component Volume for single reaction Final concentration 
ddH2O 1.42 µl N/A 
10x HotStarBuffer 0.5 µl 1× 
dNTP mix 25 mM each 0.04 µl 200 µM 
5 U/µl Hot Star Taq 0.04 ml 0.2 U 
DNA Template 1 µl 5-10 ng 
 
To each reaction 2 µl primer mix was added, giving a final reaction volume of 5 µl, with the 
concentration of 500 pM of the forward and reverse primer. Then the plate was sealed with 
AB-0558 spun down, centrifuged and incubated in a Veriti 384 well thermal cycler (Applied 
Biosystems) with the following program: 
Table 4-10 Reaction parameter for bisulfite conversion 
PCR step Cycling parameter 
Initial melting 94°C, 4 min 
45 cycles 
Melting 94°C, 20 s 
Annealing 59°C, 30 s 
Elongation 72°C, 1 min 
Final elongation 72°C, 3 min 
Cooling 4°C, forever 
 
4.4.6.5 Shrimp alkaline phosphatase (SAP) treatment 
Unincorporated nucleotides can disturb downstream applications and are therefore 
enzymatically inactivated. Under alkaline conditions SAP removes phosphate groups from 
several substrates including deoxynucleotide triphosphates, rendering it unavailable for 
further polymerase catalyzed reactions. The SAP solution was prepared as follows: 
Component Volume for single reaction 
RNAse free water 1.7 µl 
SAP 0.3 µl 
 
2 µl of the SAP solution was added to each PCR reaction with the 96 channel pipetting robot 
MassARRAY Liquid Handler and FusioTM Chip Module (Matrix). The plate was sealed with 
AB-0558, centrifuged and incubated as follows on a Veriti 384 well thermal cycler (Applied 
Biosystems): 
Step 1: 37°C 20 min 
Step 2: 85°C 5 min 
Step 3: 4°C hold 
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4.4.6.6 Reverse transcription and RNA base-specific cleavage 
Transcription and Cleavage were performed using a single mix containing: 
 
Component Volume for single reaction 
RNase free water 3.21 µl 
5× T7 Polymerase buffer 0.89 µl 
Cleavage Mix (T mix) 0.22 µl 
DTT (100 mM) 0.22 µl 
T7 R&DNA Polymerase (50 U/µl) 0.4 µl 
RNaseA 0.06 µl 
Total volume 5 µl 
 
5 µl of the mix and 2 µl of the SAP-treated PCR reaction were transferred into a new 386-well 
plate with the 96 channel pipetting robot MassARRAY Liquid Handler and FusioTM Chip 
Module (Matrix), sealed with AB-0558, centrifuged and incubated on a Veriti 384 well 
thermocycler C (Applied Biosystems) for three hours at 37°C. 
 
4.4.6.7 Desalting the cleavage reaction 
Salt ions are co-vaporized when acquired during MALDI-TOF analysis and are therefore 
visible in the mass spectra. This would irritate the analysis of the mass spectra. Therefore 
the reactions need to be desalted. For desalting of the transcription/cleavage mix 20 µl water 
was added to each reaction with the MassARRAY Liquid Handler (Matrix) followed by the 
addition of 6 mg CLEAN resin per reaction. The plates were rotated slowly for 10 minutes 
and spun down to collect the resin at the bottom of the wells. 
 
4.4.6.8 Transfer on SpectroCHIP and acquisition 
The SpectroCHIP contains the matrix on which the sample probes are spotted and consists 
of a crystallized acidic compound. When the analyte is spotted onto the matrix its solvent 
dissolves the matrix, and when the solvent evaporates the matrix recrystallizes with analyte 
molecules enclosed in the crystals. The DNA samples are transferred on a SpectroCHIP 
either with the Phusio Chip Module or the 24 pin-head nanodispenser and are analyzed with 
the MassARRAY Compact System MALDI-TOF MS (all from Sequenom). The co-crystallized 
analyte is acquired with a laser while the matrix is predominantly ionized, protecting the DNA 
from the disruptive laser beam. Eventually, the charge is transferred to the sample and 
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charged ions are created which are accelerated in a vacuum towards a detector that 
measures the particle’s time of flight. 
 
4.4.6.9 Interpretation of data output and quality control 
Acquired data was processed with the EpiTYPER Analyzer software (version 1.0.5, 
Sequenom). The MS is calibrated with a four point calibrant (Sequenom) with 1479, 3004, 
5044.4 and 8486.6 kDa particles. Relative to this calibration the accelerated analytes 
generate signal intensity (y-axis) versus mass (kDa, x-axis) plots. With the sequence of every 
amplicon known, the software can virtually process the sequence and predict the fragments 
from the in vitro transcription/RNase digestion and relocate CpG units. If expected and 
incoming information match, the signal intensities of the methylated and unmethylated DNA 
templates are compared and quantified. A normal calibrated system is able to measure 
fragments between a range of 1500 and 7000 Dalton. Fragments outside of this range and 
fragments whose mass peaks are overlapping with multiple other fragments cannot be 
analyzed. 
 
As an additional control feature to assess the quality of DNA samples and the consistency of 
the technology employed in this study, DNA methylation values for each assay were 
determined in fully methylated DNA and completely unmethylated DNA. A mixed control was 
also assembled by combining equal quantities of fully methylated and unmethylated control 
DNA. 
In order to generate fully unmethylated genomic DNA in vitro, genomic DNA was amplified 
using the REPLI-g Mini/Midi kit (Qiagen) according to the manufacturer’s instructions. 
Purification of amplification products was performed using QIAamp DNA Micro Kit (Qiagen) 
as indicated in the manufacturer’s manual. Secondary, to generate fully methylated DNA as 
a control for methylation analysis, genomic DNA was methylated using Sss I 
methyltransferase (see section 4.4.1). 
A desired percentage of methylation was generated by mixing an appropriate amount of 
unmethylated (0%) and fully methylated (100%) DNA.  
 
4.4.6.10 Calculation of EpiTYPER methylation score ratio 
To compare the high resolution mass spectrometry data with intermediate resolution 
microarray data, we assigned each microarray probe with a so-called EpiTYPER methylation 
score ratio which basically represents a mean scaled log10 ratio of all measured CpGs in a 
region 300 bp upstream and downstream of a microarray probe center. EpiTYPER 
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methylation values for individual CpGs were transformed into log10 ratios using the formula: 
(log10((T+0.01)/M+0.01) where T and M represent EpiTYPER methylation ratios of the cell 
line and normal monocytes, respectively (0.01 was added to each value to avoid division by 
zero). To account for the non-linear enrichment obtained by MCIp and to adjust the 
EpiTYPER methylation score ratio to the range of MCIp log10 ratios, the log10 ratio of 
individual CpGs was corrected by an empirically determined factor that weighted for 
methylation strength (log10(ABS(T-M))/2+1.01)*2). The EpiTYPER methylation score of a 
microarray probe was then calculated as the mean scaled log10 ratio of all measured CpGs in 
a region 300 bp upstream and downstream of a microarray probe center.  
 
4.5 De novo motif discovery 
4.5.1 Algorithm for de novo motif finding 
Motif discovery was performed using a comparative algorithm similar to those previously 
described (Barash Y. et al., 2001). An in-depth description and benchmarking of the software 
suite HOMER (Hypergeometric Optimization of Motif EnRichment; 
http://biowhat.ucsd.edu/homer/) that was developed for motif discovery will be published 
elsewhere (Benner et al., in preparation). Briefly, sequences were divided into target and 
background sets for each application of the algorithm. Background sequences are then 
selectively weighted to equalize the distributions of CpG content in target and background 
sequences to avoid comparing sequences of different sequence content. Motifs are found 
separately by first performing exhaustively screening all oligo sequences for enrichment in 
the target set compared to the background set using the cumulative hypergeometric 
distribution. Up to two mismatches were allowed in oligo sequences to increase the 
sensitivity of the method. The top 50 sequences of each length with the lowest P values were 
then converted into probability matrices and heuristically optimized to maximize 
hypergeometric enrichment of each motif in the given data set. As optimized motifs are found 
they are removed from the data set to facilitate the identification of additional motifs. 
 
4.5.2 ChIP-on-chip peak calling and motif annotation 
Transcription factor-bound regions were identified using a sliding window approach and the 
averaged data sets from two independent experiments (correlation coefficients for log10 ratios 
of replicate ChIP-on-chip experiments: r2Sp1=0.95; r
2
YY1=0.88; r
2
NRF1=0.75). The window 
included five probes with a maximal distance of 500 bp between two neighboring probes. A 
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cumulative log10 ratio of ChIP/input over the five probes of 1.5 was used as a lower threshold 
for detecting a binding event. To study the correlation between motif presence and actual 
transcription factor binding, we annotated each motif for Sp1, NRF1 and YY1 with mean 
signal intensity ratios (log10) of all microarray probes from the corresponding ChIP-on-chip 
experiments in the range of ± 150 bp around it. The lower limit for binding of a motif in normal 
blood monocytes was set at a mean signal intensity log10 ratio of 0.4. A motif was grouped as 
bound if both, the sliding window approach and the motif centered approach indicated 
binding. A motif was grouped as not bound if both methods indicated non-binding. 
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5 Results 
Due to space limitations, this section only contains parts or summaries of the expression, 
MCIp-on-chip and MassARRAY data. Complete figures, tables, lists and UCSC tracks are or 
will be available online within the supplementary information of the corresponding 
publications.  
 
5.1 Detection of methylated DNA by methyl-CpG 
immunoprecipitation (MCIp) 
To date, the investigation of aberrant CpG island methylation has primarily taken a candidate 
gene approach. However, in order to assess the clinical potential of hypermethylation profiles 
and to identify relevant marker genes, methods for the genome-wide detection of 
hypermethylation are required. Because there were no suitable methods available, we 
developed a sensitive approach in our lab that enabled the detection of methylated CpG 
dinucleotides using only very little DNA quantities but which still allows for global detection of 
DNA methylation. 
 
The basis for detection of methylated DNA is provided by a recombinant antibody-like fusion 
protein that consists of the human methyl-CpG binding domain 2 (MBD2), a flexible linker 
polypeptide and the Fc-proportion of human IgG1. Design and generation of the MBD-Fc 
protein is described in section 4.2 (for further details see also Gebhard, 2005 and Gebhard et 
al., 2006). In previous studies performed in our own lab it could be shown that the MBD-Fc 
protein is able to bind methylated DNA in an antibody-like manner. As previously shown, in 
vitro methylated or unmethylated PCR fragments with different CpG density could be 
detected by MBD-Fc on nylon membranes in a linear fashion and dependent on the 5mC 
content (Gebhard, 2005 and Gebhard et al., 2006b).  
 
Based on the recombinant MBD-Fc a novel technique was developed in our lab that enables 
the unbiased genome-wide detection of CpG methylation, the so-called methyl-CpG 
immunoprecipitation (MCIp). The approach allows for the detection of the methylation status 
of specific CpG island promoters (in combination with real-time PCR) and also allows for the 
generation of genome-wide promoter methylation profiles (in combination with microarray or 
next generation sequencing technology).  
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In contrast to another recently developed immunoprecipitation approach using 5-methyl 
specific antibodies (called MeDIP or mDIP) that specifically enriches for methylated 
fragments (Weber et al., 2005), MCIp can divide the bulk of genomic DNA fragments into 
separate fractions of increasing methylation density. This is due to the fact, that MBD-Fc 
recognizes the hydration of methylated DNA rather than 5mC itself (Ho et al., 2008). 
Therefore using increasing salt concentrations allows for the fractionation of genomic DNA 
fragments according to their methylation degree (Gebhard et al., 2006b; Gebhard et al., 
2006a; Schilling and Rehli, 2007). A schematic representation of the MCIp approach is 
shown in Figure 5-1. 
 
 
 
 
Figure 5-1 Schematic presentation of the methyl-CpG immunoprecipitation approach (MCIp) 
Fragmented genomic DNA is incubated with saturating amounts of MBD-Fc Protein A-Sepharose matrix at a low 
NaCl concentration. The column is spin-washed with increasing salt concentrations leading to fractionation of the 
fragments according to the methylation density. The flow-through consists of fragments with little or no CpG 
methylation, while high salt fractions contain strongly methylated and CpG-rich fragments.  
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5.1.1 Detection of in vitro methylated DNA promoter fragments 
An initial characterization of the MBD-Fc protein and its ability to bind CpG-methylated DNA 
had already been done before starting this dissertation (Gebhard, 2005; Gebhard et al., 
2006b). To further describe the properties of MBD-Fc, we also tested whether this approach 
allows for the detection of different degrees of methylation for a single gene locus. Therefore 
a CpG island fragment (CPM) was cloned into the CpG-free vector pCpG-mcs, linearized 
and in vitro methylated using increasing amounts of the methyl donor S-adenosylmethionine 
to obtain fragments with varying methylation densities (see section 4.4.2). Subsequently, the 
fragments with different methylation levels were combined, fractionated by MCIp and 
subjected to bisulfite sequencing (see section 4.4.3). If genomic DNA is treated with sodium 
bisulfite, unmethylated cytosines are deaminated into uracil and transformed into thymidine 
residues during PCR, whereas methylated cytosines still appear as cytosines after 
amplification (Frommer et al., 1992b). Figure 5-2 demonstrates that partially in vitro 
methylated DNA fragments can be separated according to their methylation degree in the 
developed methyl-CpG immunoprecipitation approach using increasing salt concentrations. 
 
 
 
Figure 5-2 Bisulfite sequences of an in vitro partially methylated gene locus after MCIp 
A mixture of Sss I-methylated CPM CpG island promoter fragments (schematic representation on the top of A) 
with varying methylation density was fractionated using MCIp. Fragments were recovered from each fraction, 
subjected to bisulfite treatment and cloned. Several independent inserts were sequenced. Results are 
represented schematically. (A) Squares mark the position of CpG dinucleotides (empty, unmethylated; filled, 
methylated). 300-1000 indicates the salt concentration (mM) used to elute the different fragments. (B) The results 
are represented as a graph where each point represents the number of methylated CpGs in one clone. Horizontal 
bars represent the median number of methylated CpG dinucleotides at one specific salt concentration. 
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This and previous test experiments performed with specific methylated and unmethylated 
DNA fragments showed that the recombinant MBD-Fc fusion protein binds CpG-methylated 
DNA. The binding capacity is contingent on the NaCl concentration as well as on the CpG 
methylation density of the bound DNA.  
 
5.1.2 Detection of methylated genomic DNA fragments 
To test, whether the MCIp procedure could be applied to discriminate methylated and 
unmethylated DNA fragments from genomic DNA, the newly developed approach was used 
to precipitate Mse I-restricted genomic DNA. Mse I was chosen for DNA fragmentation, 
because it is known to preferentially cut in regions of low CpG content while leaving many 
CpG islands uncut (Cross et al., 1994). 
 
5.1.2.1 Combination of MCIp and real-time PCR to detect the methylation 
status of specific CpG island promoters 
To explore this type of application on a single gene level, Mse I-restricted genomic DNA of in 
vitro Sss I-methylated and untreated normal DNA from monocytes of a healthy donor were 
subjected to MCIp. The enrichment of four different CpG island promoters and one promoter 
with low CpG density in the different fractions was determined relative to the input DNA using 
LightCycler real-time PCR. As a positive control the SNRPN CpG island promoter was used. 
This gene is subject to maternal imprinting with one of its two copies being methylated also in 
normal cells (Zeschnigk et al., 1997). As expected, in normal DNA, the two differentially 
methylated allele-fragments were enriched in two separate fractions. The unmethylated 
allele-fragment was mainly eluted at 400 mM NaCl, whereas the methylated allele fragment 
was eluted at 1000 mM NaCl. However, with Sss I methylated DNA only one positive elution 
fraction could be observed because both alleles are methylated and were detected in the 
1000 mM NaCl fraction (Figure 5-3A). In the case of the CDKN2B gene (also known als 
p15INK4b) the promoter fragment was mainly recovered in the low salt fractions from normal 
DNA and in the high salt fraction from Sss I-methylated DNA (Figure 5-3B). Similar results 
were obtained for the human estrogen receptor 1 (ESR1) gene and the human Toll-like 
receptor 2 gene (TLR2) (data not shown). Another test locus used was the promoter 
fragment of the CHI3L1 gene. This gene fragment however, showed different elution profiles: 
the untreated normal fragment was mostly detected at low salt concentrations (400 and 500 
mM). When the DNA was in vitro methylated only a slight shift towards higher NaCl 
concentrations was observed (Figure 5-3C). This is due to the lower CpG density of the 
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CHI3L promoter. The detected fragment only contains 12 CpG dinucleotides and the 
difference between methylated and unmethylated fragment is only five to six methylated CpG 
residues. Together, these data show that the MCIp approach is able to discriminate even 
slight differences in CpG methylation. 
 
Analysis of elution profiles shown in Figure 5-3 suggests that (i) a 200- to 300-fold 
enrichment of stronger over less methylated genomic fragments can be obtained in either 
low or high salt fractions, (ii) fragments with low CpG density are largely excluded from the 
high salt fraction, and (iii) the fractionated MCIp approach may allow for the resolution of 
relatively small differences in CpG methylation density.  
 
 
Figure 5-3 MCIp detection of CpG methylation in specific CpG island promoters using real-time PCR 
Fractionated MCIp was used in combination with LightCycler real-time PCR to detect the methylation status of 
specific CpG island promoter fragments from untreated (blue bars) and Sss I-methylated (red bars) 
Mse I-restricted genomic DNA fragments. Recovered gene fragments from MCIp eluates (different salt 
concentrations are indicated) and an equivalent amount of input DNA are amplified using LightCycler real-time 
PCR. Values (mean ± SD, n=4 using at least two different preparations of MBD-Fc) of the different fractions 
represent the percentage of recovery and are calculated relative to the amount of the respective input DNA 
(100%). Above each figure a 3 kb region of the corresponding CpG island is schematically represented. Each 
CpG dinucleotide is represented by a vertical line. Black boxes indicate the position of the Mse I fragments that 
are detected with the number indicating the number of CpG dinucleotides within the fragment. The positions of 
exons are indicated as grey boxes and transcription start sites by an arrow. The white box represents a 100 bp 
fragment.  
 
 
In the next step it was determined whether the fractionating MCIp approach is able to detect 
aberrant hypermethylation in tumor samples. Mse I-digested genomic DNA from three 
leukemia cell lines KG-1 (acute myeloid leukemia), U937 (histiocytic lymphoma, monocytic), 
THP-1 (acute monocytic leukemia) as well as from monocytes of a healthy donor were 
subjected to MCIp. Using LightCycler real-time PCR the enrichment of four different CpG 
island promoters in the 1000 mM NaCl fraction was detected relative to the input DNA. The 
imprinted SNRPN gene promoter was used as a positive control. Another test locus, the 
promoter of the human Toll-like receptor 2 gene (TLR2) was chosen, because our group had 
previously shown that this promoter fragment is strongly methylated in U937 cells, but not in 
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THP-1 cells (Haehnel et al., 2002). The promoters of the human estrogen receptor 1 (ESR1) 
(Dodge et al., 2001) gene and the human CDKN2B (p15INK4b) (Chim et al., 2003; Dodge et 
al., 1998; Haehnel et al., 2002) gene were used because they are known to be frequently 
methylated in leukemic cells. The results are summarized in Figure 5-4. The SNRPN gene 
promoter was significantly enriched in all leukemia cell lines as well as in normal cells which 
is in concordance with its imprinting-related methylation status. The TLR2 locus was 
enriched and therefore methylated in KG-1 and U937 cells, but not in THP-1 or normal cells. 
The methylation pattern of the TLR2 promoter fragment was confirmed by bisulfite 
sequencing (Haehnel et al., 2002). The results for ESR1 (KG-1) and CDKN2B (KG-1 and 
U937) were also in line with previously published studies (Chim et al., 2003; Dodge et al., 
2001; Gebhard, 2005; Issa et al., 1996). In THP-1 cells the PCR amplification of the 
CDKN2B promoter fragment failed due to a deletion of this locus. None of the three Mse I 
fragments (with an exception of the imprinted SNRPN gene locus) were significantly enriched 
in the DNA from normal monocytes which correlates with the normally unmethylated state. 
From these results it can be concluded that MCIp fractionates genomic DNA according to the 
degree of methylation and specifically enriches strongly methylated DNA fragments in the 
high salt fraction. 
 
 
Figure 5-4 MCIp detection of CpG island methylation in specific CpG island promoters using real-time 
PCR 
SNRPN, TLR2, ESR1, and CDKN2B gene fragments in the high salt fraction of three human myeloid leukemia 
cell lines (KG-1, U937, THP-1) as well as normal blood monocytes (N) were analyzed using real-time PCR as 
described in Figure 5-3. 
 
5.1.2.2 Sensitivity and linearity of the MCIp approach 
To test the sensitivity of the fractionation approach, decreasing amounts of Mse I-treated 
U937 DNA were subjected to MCIp. The enrichment of the TLR2 (strong methylation in 
U937) and CDKN2B gene fragments (no methylation in U937) were determined by 
LightCycler real-time PCR. Figure 5-5A shows that a significant enrichment of the TLR2 
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fragment could be achieved using as little as 1 ng DNA, which corresponds approximately 
150 tumor cells.  
 
Samples derived from tumors may contain a specific and variable number of normal cells 
that would be expected to be unmethylated at most CpG islands. To test the linearity of the 
MCIp approach with respect to cell purity, mixtures of Mse I-treated DNA from normal 
monocytes and the leukemia cell line KG-1 were fractionated using increasing salt 
concentrations and again analyzed by real-time PCR with specific primers for the TLR2 locus 
(methylated in KG-1 and unmethylated in normal blood cells). As shown in Figure 5-5B the 
TLR2 fragment was only detected in samples containing KG-1 DNA and the signal increased 
gradually with increasing amount of KG-1 cells in the mixture.  
 
 
 
Figure 5-5 Sensitivity (A) and linearity (B) of the MCIp approach 
(A) Decreasing amounts of Mse I-treated U937 DNA were subjected to MCIp. TLR2 and CDKN2B gene 
fragments were analyzed by LightCycler real-time PCR as described in Figure 5-3. (B) MCIp was performed with 
mixtures of Mse I-treated normal blood monocytes (N) and increasing amounts of KG-1 cells. TLR2 enrichment in 
the 1000 mM salt fraction was determined by LightCyler real-time PCR.  
 
 
As demonstrated above, MCIp combined to real-time PCR was very sensitive. However, for 
early diagnosis as well as methylation detection from body fluids and trace amount analysis 
in the post therapy, a method for an ultrasensitive methylation detection may be necessary 
and suggestive. Because MassARRAY Quantitative Gene Expression (QGE) provides orders 
of magnitude greater sensitivity than real-time quantitative PCR, and permits very closely 
related genes to be assayed reliably and quantitatively, MCIp was combined with QGE. This 
type of assay could provide an alternative method for the methylation specific PCR (MSP) 
which suffers from many disadvantages. Firstly, MSP is based on bisulfite treatment, 
secondly it requires very extensive validation, thirdly it is only an indirect measurement of 
DNA methylation and finally, it has only limited possibilities for quantitation. Using MCIp and 
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subsequent MassARRAY (QGE), we wanted to circumvent the disadvantages of the MSP 
method and create a system to detect methylated DNA in an ultrasensitive and reproducible 
manner.  
In the QGE assay, quantitation is based on a competitive PCR in which a cDNA template of 
interest and a competitor (internal standard) are co-amplified in the same reaction. Each 
competitor molecule matches its target cDNA sequence at all nucleotide positions except a 
single base so the two can be resolved using mass spectrometry-based genotyping. Titration 
of competitor concentrations is used to determine the competitor concentration at which 
amplification between cDNA and competitor is equal. This point, termed the EC50, is 
determined by plotting cDNA allele frequency vs. competitor concentration. Non-linear 
regression is used to calculate the point at which the cDNA and competitor are at a 1:1 ratio. 
Each assay uses a single base extension to distinguish between the target cDNA and 
competitor template (for more detailed information see section 4.3.4.4, primers and 
competitors are listed in section 3.6.7). 
 
First, it was tested whether MCIp combined with QGE is able to detect the correct number of 
copies of methylated and unmethylated DNA fragments subjected to MCIp in the lower or 
higher salt fractions, respectively. As a test system, the MGMT (O-6-methylguanine-DNA 
methyltransferase) locus of unmethylated DNA from normal monocytes as well as the same 
locus of in vitro methylated monocyte DNA was used. In a first step, both unmethylated and 
methylated DNA from monocytes were restricted using Msp I. Afterwards 1,500 copies of 
unmethylated DNA and methylated DNA, respectively, and in addition two times a 50:50 
mixture (750 copies of each, methylated and unmethylated DNA) were subjected to MCIp. 
DNA fragments were separated using increasing salt concentrations (200, 300, 350, 400, 
450, 500, 600 and 1000 mM NaCl) and the different fractions were analyzed for enrichment 
of the MGMT gene locus using QGE and primers as well as competitors specific for the 
MGMT Msp I-restricted gene fragment. As illustrated in Figure 5-6 MCIp is able to detect the 
copies of unmethylated as well as methylated DNA with high specificity and accuracy.  
The MassARRAY system allows for the detection of almost all DNA fragments from the input 
DNA. 70-80% of the unmethylated DNA fragments were detected in the lower salt 
concentrations. A similar percentage of methylated DNA fragments were recovered and 
detected in the high salt fractions. The remainder of the DNA probably got lost during the 
procedure. 
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Figure 5-6 MCIp detection of the MGMT locus using quantitative gene expression (QGE) 
Fractionated MCIp was used in combination with QGE to detect the methylation status of the MGMT locus from 
untreated (blue bars) and Sss I-methylated (red bars) Msp I-restricted genomic DNA fragments. In (A) 1500 
copies of the unmethylated, in (B) 1500 copies of the methylated genome and in (C) and (D) 750 copies of the 
unmethylated genome mixed with 750 copies of the methylated genome were subjected to MCIp. Recovered 
gene fragments from MCIp eluates (different salt concentrations are indicated) were quantified using QGE. 
Values of the different fractions represent the measured number of copies and were calculated related to the 
competitor concentration using the EC50 value. Above each figure the exact number of detected copies is 
represented.  
 
To test the sensitivity of the approach, a 10% mixture of DNA (150 copies of methylated DNA 
together with 1363 copies of unmethylated DNA) and a 1:2 ,1:4 and 1:8 dilution of the same 
mixture were subjected to MCIp and subsequently to QGE. 16 replicates proofed the high 
reproducibility of the approach. After inactivating the outliers, the values were averaged. As 
shown in Figure 5-7 the method allows the detection of as little as 24 copies of methylated 
DNA. Furthermore the graph illustrates again the accuracy of the method: the correct copy 
number of unmethylated and methylated DNA fragments is detected dependent on the 
degree of dilution in a linear fashion (r2=0.99) in a range of more than three logarithmical 
stages.  
A future aim would be to further improve this method and to achieve a multiplexing for 
high-throughput screening of patient samples for risk assessment.  
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Figure 5-7 Sensitivity and linearity of the MCIp approach combined to QGE 
(A) MCIp was performed with decreasing amounts of Msp I-treated 10% mixtures (1363 copies unmethylated 
monocyte DNA mixed with 150 copies Sss I-methylated DNA). Enrichment of the MGMT gene fragments (the 
unmethylated fragments in the lower salt concentrations, the methylated ones in the higher salt concentrations) 
were analyzed by QGE. (B) Correlation between methylated and unmethylated copy numbers within the dilution 
series of a 10% mixture (r
2
=0.99). Values are mean ± SD (n=4). 
 
5.2 Combination of MCIp and 12K CpG island microarray 
analysis  
Data from this section have been published in the journal Cancer Research. Microarray data 
were deposited with GEO (gene expression analyses: GSE 3280; comparative MCIp 
hybridizations: GSE).  
 
To achieve a genome-wide identification of aberrant methylation patterns, the MCIp 
approach was combined with microarray technology. For unbiased genome-wide analysis of 
aberrant methylation profiles, the MCIp technique had to be adapted to the microarray 
technology and a series of optimization steps in terms of amplification, labeling as well as 
hybridization were already performed previously (Gebhard, 2005).  
Methyl-CpG immunoprecipitations were performed with 300 ng Mse I-restricted DNA from 
three leukemia cell lines (KG-1, U937, THP-1) as well from normal blood monocytes. The 
high salt fractions (600-1000 mM) containing the strongly methylated CpG island promoter 
fragments were spin purified and afterwards amplified using ligation-mediated PCR. The 
resulting amplicons were directly labeled with Cy5-dCTP (normal DNA) and Cy3-dCTP 
(tumor DNA) using the Exo-Klenow enzyme. Subsequently each leukemia sample was 
cohybridized with the normal control sample to CpG island microarrays (UHN Microarray 
Centre, Toronto, Canada). Figure 5-8 represents the schematic workflow of the procedure for 
DNA methylation profiling.  
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Figure 5-8 Schematic representation of DNA methylation profiling using MCIp and CpG island microarrays 
(A) Global methylation levels were determined using MCIp (steps 1-3) and subsequent cohybridization of 
amplified tumor (Cy3-labeled) and normal DNA (Cy5-labeled) on microarrays (steps 4-6). (B) Frequently 
methylated U937 DNA shows a higher fluorescence for Cy3 (blue color) and normal DNA for Cy5 (yellow color). 
(C) Representative two-dimensional scatter plots are shown for a control hybridization experiment of human blood 
monocytes DNA (normal/normal) (left)  and a hybridization displaying the differentially methylated CpG fragments 
between U937 (tumor) and human blood monocytes (normal) (right). 
 
The CpG island array contains 12,192 CpG island clones from a Mse I-CpG DNA library that 
was originally prepared by MeCP2-column purification of non-methylated CpG island 
fragments (Cross et al., 1994). Representative scatter plots of microarray hybridizations are 
presented in Figure 5-8C. On the left side the scatter plot for the control hybridization 
experiment is shown: Cy3-labeled normal monocytes are plotted against Cy5-labeled normal 
monocytes. On the right side the Cy3-labeled U937 tumor sample is plotted against 
Cy5-labeled normal monocytes. Comparing the two plots, differently methylated CpG 
fragments between the U937 tumor cell line and normal human blood monocytes are 
displayed. Signals corresponding to both hypo- and hypermethylated fragments in the tumor 
sample were observed. This work focused on the analysis of hypermethylated fragments. To 
identify possible tumor suppressor genes or other marker genes that are affected by 
hypermethylation, results of three independent MCIp experiments (using two different 
MBD-Fc preparations and three independent DNA preparations) were analyzed in 
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conjunction. Hybridization signals that were more than twofold enriched in the leukemia 
sample and consistently different in at least one cell line were selected for further analysis.  
In total, THP-1, U937 and KG-1 cells showed 277, 454 and 330 differential hybridization 
signals, respectively. 191 out of 535 spots analyzed were unambiguously annotated and 
located within close proximity (approximately ± 3,000 bp) to predicted transcriptional start 
sites and were chosen for further analysis. Since some sequences were represented more 
than once on the CpG island microarray, the final, non-redundant list of differentially 
methylated DNA fragments contained 131 entries that were in close proximity of 134 genes 
(Table 5-1). The hypermethylated genes shown in Table 5-1 are involved in many important 
biological functions. Most strikingly, half of the genes with an assigned biological function (46 
of 89) are involved in DNA binding and transcriptional regulation. Nine of the listed genes 
have been previously identified as hypermethylation targets in cancer: LMX1A (Paz et al., 
2003), TFAP2A (Douglas et al., 2004), CR2 (Schwab and Illges, 2001), DCC (Sato et al., 
2001), MYOD1 (Jones et al., 1990), DLEC1 (Yuan et al., 2003), AKAP12 (Choi et al., 2004), 
SSIAH2 (LOC28314) and FOXF1 (Weber et al., 2005).  
 
Table 5-1 Hypermethylated gene fragments in myeloid leukemia cell lines 
Gene                           CpG-methylation               mRNA expression 
Name Symbol Location KG1 U937 THP1  Positon KG1 U937 THP1 N Probe Set ID 
hypothetical gene LOC400027 12q12 1.82 1.16 1.19 down NC/P NC/P NC/P A 226413_at 
branched chain aminotransferase 2, mitochondrial BCAT2 19q13 1.24 1.18 1.29 proximal 1 1.8 NC/P P 203576_at 
chondrolectin CHODL 21q11.2 1.52 1.49 1.44 down NC/A NC/A NC/A A 219867_at 
collagen, type XIV, alpha 1 (undulin) COL14A1 8q23 2.02 2.97 2.03 down NC/A NC/A NC/A A 1562189_at 
cytochrome P450, family 27, subfamily B, polypeptide 1 CYP27B1 12q13.1-q13.3 1.55 1.87 2.15 down NC/A NC/P 0.8 A 205676_at 
v-erb-a erythroblastic leukemia viral oncogene homolog 4 ERBB4 2q33.3-q34 1.63 1.34 1.36 down NC/A NC/A NC/A A 241581_at 
family with sequence similarity 5, member B FAM5B 1q24.1-q25.3 2.55 1.32 1.92 proximal NC/A NC/A NC/A A 214822_at 
fibroblast growth factor 12 FGF12 3q28 1.20 1.76 1.52 proximal/down NC/A NC/A NC/A A 240067_at 
hypothetical gene FLJ13192 15q14 1.79 1.49 1.37 down NC/A NC/A NC/A A 233382_at 
hypothetical gene FLJ20366 
8q23.2 1.90 1.39 1.45 
up/down NC/A NC/A NC/A A 218692_at 
hypothetical gene FLJ36633 up ND ND ND ND NA 
hypothetical protein FLJ20972 1p34.2 1.46 1.29 1.82 down NC/M NC/P NC/P P 230897_at 
hypothetical protein FLJ35074 
6p24 2.07 1.09 1.59 
down NC/A 1.6 NC/A A 1560503_a_at 
transcription factor AP-2 alpha  TFAP2A up NC/A 2.4 NC/A A 204653_at 
laeverin FLJ90650 5q23.1 2.14 3.00 2.77 up/down NC/A NC/A NC/A A 235382_at 
forkhead box F1 FOXF1 16q24 1.40 1.84 2.72 down 2.7 NC/A NC/A A 205935_at 
glycoprotein M6A GPM6A 4q34 1.30 2.05 1.19 down NC/A NC/A NC/A A 209469_at 
GS homeobox 2 GSH2 4q11-q12 1.34 2.29 1.26 down NC/A NC/A NC/A A 230338_x_at 
hypocretin (orexin) receptor 2 HCRTR2 6p11-q11 1.08 1.46 1.62 down NC/A NC/A NC/A A 207393_at 
Hey-like transcriptional repressor HELT 4q35.1 1.37 3.51 1.52 up ND ND ND ND NA 
homeo box C10 HOXC10 12q13.3 1.13 1.62 1.01 up NC/A 0.8 NC/P A 214562_at 
iroquois homeobox protein 1 IRX1 5p15.3 2.20 2.32 2.07 down NC/A NC/A NC/A A 230472_at 
hypothetical protein KIAA1024 15q25.1 1.04 2.06 1.73 down NC/A NC/A NC/A A 215081_at 
LIM homeobox transcription factor 1, alpha LMX1A 1q22-q23 2.42 2.08 2.29 down NC/A NC/A NC/A A 1553541_at 
similar to seven in absentia 2 (SSIAH2) LOC283514 13q14.13 2.43 2.73 1.54 proximal NC/A NC/A NC/A A 1560676_at 
hypothetical protein MGC12982 
1p33 2.17 2.36 1.92 
up NC/P NC/A NC/A A 207653_at 
forkhead box D2  FOXD2 down NC/P NC/A NC/A A 224457_at 
hypothetical protein MGC42090 7p21.1 2.62 4.03 1.97 proximal NC/A NC/A NC/A A 1552293_at 
hypothetical protein MGC4767 12q24.31 1.68 2.58 2.23 proximal 1 1.2 NC/P P 223114_at 
myogenic differentiation 1 MYOD1 11p15.4 2.49 2.57 1.14 down NC/A NC/A NC/A A 206657_s_at 
NK2 transcription factor related, locus 3 (Drosophila) NKX2-3 10q24.2 2.96 4.06 1.30 down NC/A NC/A 3.3 A 1553808_a_at 
one cut domain, family member 1 ONECUT1 15q21.1-q21.2 1.58 2.64 2.49 up NC/A NC/A NC/A P 210745_at 
protocadherin gamma subfamily B, 1 PCDHGB1 5q31 1.12 1.69 3.19 proximal ND ND ND ND NA 
phospholipase A2, group VII  PLA2G7 6p21.2-p12 1.39 1.36 2.27 proximal -8.9 -5.1 -5.7 P 206214_at 
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Gene                           CpG-methylation               mRNA expression 
Name Symbol Location KG1 U937 THP1  Positon KG1 U937 THP1 N Probe Set ID 
phospholipase D family, member 5 PLD5 1q43 1.43 1.69 1.92 down NC/A NC/P NC/A A 1563933_a_at 
scinderin SCIN 7p21.3 1.52 1.42 1.15 proximal/up NC/A NC/A NC/A A 239365_at 
SLIT and NTRK-like family, member 3 SLITRK3 3q26.1 2.56 1.42 2.56 down NC/A NC/A NC/A A 206732_at 
Sp5 transcription factor SP5 2q31.1 1.30 1.89 1.00 down NC/A NC/A NC/A A 235845_at 
transcription factor AP-2 gamma  TFAP2C 20q13.2 1.60 1.02 1.07 up NC/P NC/A NC/A A 205286_at 
transmembrane protein 39A TMEM39A 3q13.33 1.61 1.48 1.64 prom NC/P NC/P 0.6 P 222690_s_at 
zinc finger protein 483 ZNF483 9q31.3 1.98 1.71 2.43 down NC/A NC/P NC/P A 1570534_a_at 
zinc finger protein 565 ZNF565 19q13.12 2.08 1.74 1.80 down NC/P NC/P 0.9 P 228305_at 
hypothetical gene AF086288 9p24 1.75 1.34 -0.52 proximal NC/A NC/A NC/A A 237421_at 
hypothetical gene AY358245 15q24 1.02 1.33 0.01 proximal ND ND ND ND NA 
hypothetical gene BC026095 11q12.1 1.40 1.26 -0.11 down NC/A NC/A NC/A A 1570068_at 
bone morphogenetic protein 4 BMP4   14q22-q23 2.07 1.10 0.82 down NC/A NC/A NC/A A 211518_s_at 
chromosome 16 open reading frame 45 C16orf45 16p13.11 1.00 1.17 -0.23 proximal NC/A NC/A NC/A A 239971_at 
chromosome 1 open reading frame 126 C1orf126 1p36.21 1.84 1.44 -0.40 proximal ND ND ND ND NA 
chromosome 20 open reading frame 39 C20orf39 20p11.21 1.08 1.70 0.08 down NC/P NC/A NC/A A 231619_at 
calponin 1, basic, smooth muscle CNN1 19p13.2-p13.1 1.31 1.27 -0.37 proximal NC/A NC/A NC/A A 203951_at 
hypothetical gene CR611340 6p22.1 2.15 1.70 0.38 proximal ND ND ND ND NA 
chemokine (C-X-C motif) ligand 5 CXCL5 4q12-q13 1.22 1.35 0.84 proximal NC/A NC/A NC/A A 207852_at 
cytochrome P450, family 1, subfamily B, polypeptide 1 CYP1B1 2p21 1.25 2.83 0.90 down 1.7 -6.6 -2.1 P 202435_s_at 
fatty acid desaturase 3 FADS3 11q12-q13.1 1.01 1.15 -0.13 up NC/A NC/A NC/A A 204257_at 
hypothetical protein FLJ42262 8q12.3 2.67 2.22 0.96 up NC/A NC/A -3.4 A 242193_at 
homeo box D10 HOXD10 2q31.1 1.91 1.70 0.72 up -1,5 -1,2 NC/A A 229490_at 
hypothetical protein KIAA1465 15q24.1 1.34 1.49 0.30 up/down NC/A NC/A NC/A A 232208_at 
Kruppel-like factor 5 KLF5 13q22.1 1.82 2.09 0.29 down -3.7 NC/A NC/A A 209212_s_at 
ladybird homeobox homolog 1 (Drosophila) LBX1 10q24 1.03 1.64 0.97 up NC/A NC/A NC/A A 208380_at 
LIM homeobox 9 LHX9 1q31-q32 2.65 1.60 0.59 up/down NC/A NC/A NC/A A 1565407_at 
hypothetical protein LOC282992 10q24.32 1.52 2.34 0.60 down NC/A NC/A NC/A A 244209_at 
myeloid leukemia factor 1 MLF1 3q25.1 1.68 1.79 0.23 proximal -2.9 -1.3 2 A 204784_s_at 
5'-nucleotidase, cytosolic IA NT5C1A 1p34.3-p33 1.53 1.57 0.80 up NC/A NC/A NC/A A 224529_s_at 
phosphodiesterase 4B, cAMP-specific  PDE4B 1p31 1.64 1.01 -0.28 proximal -4.7 -3.6 -4.8 P 211302_s_at 
properdin P factor, complement PFC Xp11.3-p11.23 1.31 1.79 0.44 down -5.9 -7.8 -8.2 P 206380_s_at 
retina and anterior neural fold homeobox RAX 18q21.32 1.54 1.27 -0.26 down NC/A NC/A NC/A A 208242_at 
RGM domain family, member A RGMA 15q26.1 1.33 1.92 0.46 up -0.9 -0.8 NC/A A 223468_s_at 
Rap2-binding protein 9 RPIB9 7q21.12 1.31 1.68 0.20 up 6.7 NC/A NC/A A 215321_at 
SHC (Src homology 2 domain containing) family, member 4 SHC4 15q21.1-q21.2 1.45 1.48 -0.11 up NC/A NC/P NC/A A 230538_at 
SET binding protein 1 SETBP1 18q21.1 1.47 1.75 -0.07 down -0.9 -0.7 -2.8 P 205933_at 
SRY (sex determining region Y)-box 9 SOX9 17q24.3-q25.1 1.49 1.00 0.71 up NC/A NC/A NC/A A 202935_s_at 
transcription factor 2, hepatic TCF2 17cen-q21.3 1.99 2.92 -0.35 up NC/A NC/A NC/A A 205313_at 
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2  ELAVL2 9p21 1.15 0.61 1.55 up/down NC/A NC/A NC/A A 1560905_at 
forkhead box A1 FOXA1 14q12-q13 1.03 0.92 1.47 up NC/A NC/A NC/A A 204667_at 
potassium channel, subfamily T, member 2 KCNT2 1q31.3 2.52 0.63 1.45 up NC/A NC/A NC/A A 244455_at 
multiple PDZ domain protein MPDZ 9p24-p22 2.14 0.93 1.79 down NC/A NC/A NC/A A 213306_at 
paired box gene 9 PAX9 14q12-q13 1.41 0.59 1.48 up NC/M NC/A NC/A A 207059_at 
serum deprivation response  SDPR 2q32-q33 1.19 0.52 1.61 down 1.9 -5.4 -1.9 P 222717_at 
complement component (3d/Epstein Barr virus) receptor 2 CR2 1q32 1.45 0.55 -0.17 down NC/A NC/A NC/A A 244097_at 
hypothetical protein FLJ40542 22q11.21 1.36 0.43 0.60 down -1.5 -1 -2.8 P 1556072_at 
glial cell derived neurotrophic factor GDNF 5p13.1-p12 1.35 0.37 0.04 up/down NC/A NC/A NC/A A 221359_at 
Kruppel-like factor 11 KLF11 2p25 1.79 0.86 -0.18 up -3.8 -3.1 -1.4 P 218486_at 
LIM homeobox 4 LHX4 1q25.2 2.26 0.89 0.51 down NC/A NC/P NC/A A 1553157_at 
zinc finger protein 215 ZNF215 11p15.4 1.82 0.78 0.43 proximal NC/A NC/A NC/A A 1555510_at 
A kinase (PRKA) anchor protein (gravin) 12 AKAP12 6q24-q25 0.90 1.50 1.66 up -3.3 -6.1 -5.4 P 210517_s_at 
hypothetical gene LOC389372 6p22.1 0.46 2.99 2.21 proximal NC/A NC/A NC/A A 1568826_at 
hypothetical protein FLJ10159 6q21 0.78 2.25 1.46 up NC/A NC/A NC/A A 1563906_at 
formin binding protein 1 FNBP1 9q34 0.47 1.18 1.09 up NC/P -2.7 -3 P 230389_at 
homeo box A9 HOXA9 7p15-p14 -0.02 2.14 1.09 up 5.8 6.3 4.6 A 209905_at 
zinc finger protein 312-like LOC389549 7q31.32 ND 1.78 1.09 up ND ND ND ND NA 
v-maf musculoaponeurotic fibrosarcoma oncogene B  MAFB 20q11.2-q13.1 0.40 1.38 1.12 up -10.9 -10.6 -6.1 P 218559_s_at 
hypothetical protein MGC33530 7p11.2 0.99 1.06 1.84 proximal NC/A NC/A NC/A A 1554530_at 
netrin 4 NTN4 12q22-q23 0.91 2.82 2.43 up NC/A NC/A NC/A A 234202_at 
orthopedia homolog (Drosophila) OTP 5q13.3 0.89 1.45 1.40 down NC/A NC/A NC/A A 237906_at 
protocadherin 19 PCDH19 Xq13.3 0.45 1.45 1.51 down NC/A NC/A NC/A A 227282_at 
protein tyrosine phosphatase, receptor type, K PTPRK 6q22.2-23.1 0.80 1.52 1.75 down NC/A NC/A NC/A A 233770_at 
toll-IL 1 receptor (TIR) domain containing adaptor protein TIRAP 11q24.2 0.83 1.12 1.46 up NC/P NC/P NC/P P 1552360_a_at 
zinc finger protein 37 homolog (mouse) ZFP37 9q32 0.91 1.71 1.24 proximal NC/A NC/A NC/A A 207068_at 
zinc finger protein 229 ZNF229 19q13.31 0.23 2.64 1.37 proximal NC/P NC/A NC/A A 1562789_at 
zinc finger protein 312 ZNF312 3p14.2 0.22 2.02 1.05 up NC/A NC/A NC/A A 221086_s_at 
zinc finger protein 629 ZNF629 16p11.2 0.98 1.27 1.50 down -1.7 NC/P 1.2 P 213196_at 
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Gene                           CpG-methylation               mRNA expression 
Name Symbol Location KG1 U937 THP1  Positon KG1 U937 THP1 N Probe Set ID 
deleted in colorectal carcinoma DCC 18q21.3 0.71 1.30 0.34 proximal NC/A NC/A NC/A A 206939_at 
deleted in lung and esophageal cancer 1 DLEC1 3p22-p21.3 0.91 1.32 -0.12 proximal NC/A NC/A NC/A A 207896_s_at 
distal-less homeo box 3 DLX3 17q21 0.21 1.22 -0.03 down NC/A NC/A NC/A A 231778_at 
dual oxidase 2 DUOX2 15q15.3 0.82 1.97 -0.25 down NC/A NC/A NC/A A 219727_at 
endothelial PAS domain protein 1 EPAS1 2p21-p16 0.21 2.57 -0.46 down -3.9 1.8 1.6 P 200878_at 
EPH receptor A10 EPHA10 1p34.3 0.65 1.15 0.54 up NC/A NC/A NC/A A 243717_at 
ES cell expressed Ras ERAS Xp11.23 0.99 1.00 0.62 up ND ND ND ND NA 
FERM, RhoGEF and pleckstrin domain protein 1 FARP1 13q32.2 0.44 2.57 0.44 proximal/up NC/A NC/A NC/A A 227996_at 
hypothetical protein FLJ42461 17p13.2 0.45 2.18 0.40 proximal NC/A NC/A NC/A A 229730_at 
gamma-glutamyl hydrolase  GGH 8q12.3 0.28 3.10 -0.10 proximal 4.4 -2.9 2.6 P 203560_at 
glycoprotein V (platelet) GP5 3q29 0.08 1.36 -0.18 down NC/P NC/P NC/A A 207926_at 
hyperpolarization activated cyclic nucleotide-gated K+4  HCN4 15q24-q25 0.68 1.28 0.53 up NC/A NC/A NC/A A 206946_at 
histone 1, H4l HIST1H4L 6p22-p21.3 -0.63 3.21 ND proximal NC/A NC/A NC/A A 214562_at 
v-jun sarcoma virus 17 oncogene homolog (avian) JUN 1p32-p31 0.11 2.07 -0.08 up -4.5 -5.1 -4.3 P 201466_s_at 
potassium channel beta 3 chain KCNAB1 3q26.1 0.66 1.48 0.98 down/down NC/A 5.4 NC/A A 210471_s_at 
protocadherin 8 PCDH8 13q14.3-q21.1 0.79 1.66 -0.09 up NC/P NC/P NC/P A 206935_at 
RAB38, member RAS oncogene family RAB38 11q14 0.53 1.37 0.55 down NC/P NC/P NC/P A 234666_at 
RAB3C, member RAS oncogene family RAB3C 5q13 0.00 1.57 0.19 proximal NC/A NC/A 1.7 A 242328_at 
ribonuclease P/MRP 30kDa subunit RPP30 10q23.31 -0.22 1.68 -0.14 up 0.4 -1 NC/P P 203436_at 
secretogranin III SCG3 15q21 0.96 2.30 0.12 down NC/A NC/A NC/A A 219196_at 
sonic hedgehog homolog (Drosophila) SHH 7q36 0.99 1.29 0.50 down NC/A NC/A NC/M A 207586_at 
synaptojanin 2 SYNJ2 6q25.3 0.01 1.15 0.07 up 2.3 2.2 1.3 P 212828_at 
zinc finger protein 36, C3H type-like 1 ZFP36L1 14q22-q24 -0.02 2.07 -0.03 down -1.2 -5.5 -3.8 P 211965_at 
zinc finger protein 222 ZNF222 19q13.2 0.06 1.56 0.00 proximal 2.2 NC/A 3.4 A 206175_x_at 
zinc finger protein 516 ZNF516 18q23 -0.51 1.86 -0.12 down NC/P -1.6 NC/P P 203604_at 
zinc finger protein 582 ZNF582 19q13.43 0.10 1.27 0.47 proximal NC/P NC/P NC/P A 1553221_at 
zinc finger protein 610 ZNF610 19q13.41 0.96 1.72 0.47 up/down 1.9 NC/A NC/P A 235953_at 
hypothetical gene AK055761 12q24.2 0.43 0.75 2.18 down ND ND ND ND NA 
doublesex and mab-3 related transcription factor 2 DMRT2 9p24.3 0.03 0.12 2.08 up NC/A NC/A 2.9 A 223704_s_at 
NK6 transcription factor related, locus 1 (Drosophila) NKX6-1 4q21.2-q22 -0.09 0.86 2.02 down NC/A NC/A NC/A A 221366_at 
 
Hybridization results of CpG island microarrays are presented as mean log2 ratios between normal and tumor cell 
lines of three independent microarray experiments (log2 ratios above 1 are boxed in black). Results of expression 
array analysis are presented as mean log2 ratios between normal and tumor cell lines if a significant change was 
detected (negative log2 ratios indicate lower expression in tumor cell lines and are boxed in black). P, present;  A, 
absent; NC, no change (boxed in gray); ND, not detected. Genes that were independently analyzed by MCIp and 
real-time PCR (see Figure 5-9 and Figure 5-10) are indicated in bold lettering. Confirmed targets of aberrant 
hypermethylation are indicated in bold italics. Genes that have been shown to be hypermethylated in other types 
of tumors are in italics and boxed in yellow. 
 
5.2.1 Experimental validation of microarray results 
A representative number of gene fragments that were identified using combined 
MCIp-on-chip analyses were selected for further validation. Mse I-digested DNA from three 
different myeloid cell lines (KG-1, THP-1, U937) was subjected to MCIp. Afterwards 
LightCycler real-time PCR was chosen to validate the MCIp enrichment in the 1000 mM 
fraction of 29 candidate genes. Out of these, no significant differences were detected at the 
LDLR, TGIF and CBX6 gene fragments. However, 26 gene fragments were enriched in a 
manner comparable to the results obtained by microarray analyses. The results for the 26 
gene fragment validations are represented in Figure 5-9.  
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Figure 5-9 Validation of CpG island microarray results by MCIp and real-time PCR 
Detection of the methylation status of the indicated human genes in three Mse I-restricted human myeloid cell 
lines (KG-1, U937, THP-1) as well as normal human blood monocytes (N) after MCIp. The corresponding 
CpG island is represented on top of each figure as described in Figure 5-3. Results are shown relative to the PCR 
product generated from the input DNA (100%) of each cell type. Values are mean ± SD (n≥3) using at least two 
different preparations of MBD-Fc. Genes framed in red were validated by bisulfite sequencing (Figure 5-11). 
 Results 
 - 91 -    
 
Figure 5-9 continued from page- 90 - 
 
In several cases, the Mse I fragment represented on the microarrays did not include the 
proximal promoter. Since transcription factors may play an important role in leukemogenesis, 
DNA fragments that include transcriptional start sites of the transcription factor genes JUN, 
MAFB, KLF11 and ZNF516 were additionally analyzed using MCIp and real-time PCR. While 
JUN promoter fragments were not significantly detected in any of the samples (data not 
shown), MAFB, KLF11 and ZNF516 promoter fragments also showed significant methylation 
(Figure 5-10).  
 
 
Figure 5-10 Real-time PCR of DNA fragments including transcription start sites 
Schematic representation of the MCIp enrichment detected by single gene real-time LightCycler PCR for MAFB, 
KLF11 and ZNF516 Mse /Csp6 I promoter fragments in the three leukemia cell lines (KG-1, THP-1 and U937) as 
well as normal human blood monocytes (N). The corresponding CpG island is represented on top of each figure 
as described in Figure 5-3. Results are shown relative to the PCR product generated from the input DNA (100%) 
of each cell type. Values are mean ± SD (n≥3) using at least two different preparations of MBD-Fc. 
 
To validate the MCIp detected methylation differences using an independent approach, the 
methylation status of six CpG island fragments (JUN, RAB3C, MAFB, KLF11, ZNF516 and 
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SSIAH2 (LOC283514)) was additionally analyzed using bisulfite sequencing. As shown in 
Figure 5-11 the degree of methylation as determined by bisulfite sequencing correlated well 
with the results obtained by MCIp and real-time PCR validation. 
 
 
Figure 5-11 Bisulfite sequencing of six differentially methylated gene loci 
DNA methylation was analyzed in genomic DNA from three human myeloid leukemia cell lines (KG-1, THP-1, 
U937) as well as normal blood monocytes (N) at the represented loci by bisulfite sequencing. The CpG islands 
are represented on top of each figure as described in Figure 5-3. The gray boxes represent the regions that were 
amplified from bisulfite-treated DNA and cloned. Several independent inserts were sequenced and results are 
presented schematically. Squares mark the position of CpG dinucleotides (empty: unmethylated; filled: 
methylated).  
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5.2.2 Global comparison of CpG island methylation and mRNA 
expression 
RNA from KG-1, U937, and THP-1 cells as well as from freshly isolated human blood 
monocytes of a healthy donor was isolated and complementary mRNA expression data were 
generated by microarray experiments using the human HGU-133 Plus 2 Array from 
Affymetrix. Table 5-1 represents a side by side comparison of CpG methylation and mRNA 
expression concerning the identified CpG island fragments. Interestingly, more than half of 
the genes (69/125) were undetectable in all samples using the microarray approach. In 
cases where significant mRNA levels were detected, transcription was often downregulated 
in tumor cell lines compared to normal monocytes when the gene was methylated. Examples 
include PLA2G7, FNBP1, MAFB, or ZNF516. In some cases there was no correlation 
between the degree of methylation and gene expression (e.g. HOXA10, EPAS1, or SYNJ2). 
In those cases CpG methylation probably targets regions not relevant for enhanced 
transcription.  
To confirm the downregulation of a few representative genes with hypermethylated CpG 
islands (JUN, MAFB, KLF11, SSIAH2, and ZNF516) in leukemia cell lines compared to 
human blood monocytes, reverse transcription and quantitative real-time PCR analysis were 
performed (data not shown). A significant derepression in U937 cells could be achieved 
when treated with 5 µM decitabine (5-aza-2’-deoxycytidine). Figure 5-12 demonstrates the 
effect of demethylation which was most striking for MAFB and SSIAH2 that were induced up 
to 100-fold in treated cells.  
 
 
 
Figure 5-12 Derepression of hypermethylated target genes by decitabine 
Quantitative real-time PCR of MAFB, JUN, KLF11, SSIAH2, and ZNF516 detects the mRNA expression levels in 
myeloid leukemia cell lines at the time point 0 and after 2 and 4 days of decitabine treatment (5 µM). Expression 
levels are relative to HPRT expression. Value are mean ± SE of two experiments. ND, not detected. 
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5.2.3 Aberrant hypermethylation in patients with acute myeloid 
leukemia 
Tumor cell lines only represent in vitro models of primary tumors. Cell lines often have 
acquired additional alterations both on genetic and epigenetic levels. It has been reported 
that a large proportion of genes are hypermethylated across multiple cancer cell lines, 
suggesting that these differences are due to intrinsic properties in generating cell lines 
(Smiraglia et al., 2001). The potential role of culture effects has been further highlighted by a 
recent study demonstrating that DNA methylation profiles of human embryonic stem cells 
vary over time in culture, with different genes affected in different cell lines (Allegrucci and 
Young, 2007).  
To test whether genes that were found to be hypermethylated in the leukemia cell lines are 
also affected in primary tumors, DNA from blast cells derived from twelve AML patients was 
analyzed for hypermethylation at 21 different promoter loci (Figure 5-13). For each locus a 
number of patients showed significant hypermethylation compared to normal donors. In the 
case of the PFC gene, nine AML patients were markedly hypermethylated whereas at the 
RAB3C or RPIB9 loci at least two patients showed significant enrichment. These results 
suggest that the CpG island fragments identified in tumor cell lines can also be subject to 
hypermethylation in primary tumor cells and may represent novel disease markers for 
leukemias. It is well established that regional methylation levels tend to increase with age in 
the mammalian genome. Notably, the youngest patient (20 years old, P20) was 
hypermethylated at 15 (out of 21) loci, whereas the eldest patient (67 years old, P07) was 
significantly hypermethylated only at the PFC locus, indicating that methylation of the above 
tested loci does not correlate with aging.  
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Figure 5-13 Methylation profiles of AML patients 
Schematic representation of the MCIp enrichment detected by single real-time LightCycler PCR for the 21 
indicated promoter fragments in Mse I/Csp6 I-restricted DNA in the twelve AML samples (AML-Patient number. 
(age in years)) as well as two normal human blood monocytes (N1, N2). Results are shown relative to the amount 
of PCR product generated from the input DNA (100%) of each cell type. Values are mean ± SE of at least two 
LightCycler amplifications using at least two different preparations of MBD-Fc. p means that the fragment is 
located within the promoter region and n is the number of experiments performed.  
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5.3 Global profiling of cancer-associated CpG island 
hypermethylation using MCIp combined to 244K CpG 
island arrays 
5.3.1 Establishment of a new microarray platform 
In our early studies the MCIp technique in combination with human 12K CpG island 
microarrays (HCGI12K, Microarray Center, UHN, Toronto, Canada) was used to identify 
more than one hundred genes with aberrantly methylated CpG islands in three myeloid 
leukemia cell lines. These results showed that the MCIp technique discriminates DNA 
fragments according to the methylation degree and allows an unbiased genome-wide 
detection of hypermethylation. 
 
However, the initial experiments performed with the Human CpG 12K microarrays 
highlighted several issues. Besides quality problems, many other aspects encouraged us to 
switch to another microarray platform. The previously used 12K microarray platform 
contained many genomic Mse I fragments with high variation in fragment length. In addition, 
the array contained repetitive fragments leading to unwanted cross-hybridization events 
(non-specific binding), which possibly gave rise to misleading results. Furthermore, the 
number of the representative genes on the array was relatively small. Thus, for global 
analysis of patient samples, another array platform provided by the company Agilent seemed 
to be better suited for this purpose. This array contains 244,000 probes (50-60 mer 
oligonucleotides) covering about 23,000 CpG islands within coding and non-coding regions 
of the human genome (Agilent 244K CpG island microarrays). 
 
To adapt the fractionation approach to the new Agilent DNA microarrays, several 
modifications were required. Instead of the previously used Mse I digestion, genomic DNA 
was sonicated to a mean fragment size of 350-400 bp. Sonication of genomic DNA leads to a 
statistical fragmentation which is necessary for an unbiased genome-wide methylation 
profiling. Moreover, large-scale MCIp (4 µg DNA instead of 300 ng) was used in order to 
provide sufficient amount of gDNA for subsequent labeling and microarray hybridization. 
Therefore PCR bias caused by ligation-mediated amplification (LM-PCR) (see section 
4.3.6.2) could be avoided. Empirical evidence showed that the coating of the protein A 
sepharose beads influences the fractionation behavior. In order to compensate for possible 
variations concerning the coating (due to varying quality of different protein batches) prior to 
each set of fractionation of the normal and tumor samples, a test MCIp with DNA derived 
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from the U937 cell line was performed with a part of the freshly coated beads to define the 
cut-off for highly methylated DNA. The individual MCIp fractions from U937 were spin-
purified (PCR purification kit, Qiagen) and eluted in 100 µl EB buffer. Subsequently the 
fractionation of U937 DNA was controlled by qPCR using control primers covering the 
imprinted region of SNRPN as well as a genomic region lacking CpGs (Empty 6.2) and the 
CpG island region RPIB9 (strongly methylated in U937). While both alleles of the imprinted 
SNRPN are eluted in different fractions (the unmethylated one with a low salt buffer, the 
methylated one with a high salt concentration), the bulk of the unmethylated CpG empty 
region (negative control) is enriched in the low salt fractions due to the complete absence of 
CpGs (data not shown). In contrast, the RPIB9 fragments which are highly methylated in the 
U937 cell line were detected in the high salt fractions. According to these results a threshold 
is defined at a salt concentration which separates the strongly methylated DNA fragments 
from the intermediate and low methylation fragments. Assuming that the other samples were 
enriched for methylated DNA in the same manner, MCIp was performed with the actual 
samples (tumor and normal samples) according to the determined cut-off. The high salt 
fractions containing the highly methylated CpG island fragments were directly labeled for 
microarray hybridization. Cancer cell DNAs were labeled with Alexa Fluor 647 and DNA from 
normal cells was labeled with Alexa Fluor 555 using the Bioprime Plus Array CGH Genomic 
labeling System (Invitrogen, Carlsbad, CA, USA). Efficiency of the labeling reaction was 
controlled with UV-spectroscopy and comparative hybridization on CpG island 
oligonucleotide microarray was performed using the recommended protocol (Agilent). Image 
data was extracted with Agilent feature extraction software and imported to Microsoft Excel 
for further analysis.  
 
Because the signal intensities were quite low compared to the background noise and the 
method was not as robust as expected, the application had to be further improved. Different 
conditions were tested to achieve optimal results. First, after MCIp, each fraction was purified 
using MinElute Columns to reduce the volumes (elution in 20 µl EB). Therefore loss of DNA 
by lyophilization could be circumvented. To achieve a better control after MCIp, not only a 
pretest with U937 DNA was performed, but all individual samples were controlled by qPCR 
with control primers to determine the cut-off. Moreover to attain improved labeling, a new Kit 
from Invitrogen was used (Bioprime total Genomic Labeling System). Consequently, 
enriched methylated DNA fragments of the high salt MCIp fractions were labeled with Alexa 
Fluor 5-dCTP (cancer cells) and Alexa Fluor 3-dCTP (normal cells).  
Since GC-rich probes have the tendency to cross-hybridize, the stringency of hybridization 
was increased by a combination of a higher incubation temperature (67°C instead of 65°C) 
and by addition of formamide (15%) to the hybridization reaction mix. Therefore misleading 
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results such as false positive and false negative signals should be minimized. This step 
probably had the major impact on better results. Figure 5-14 demonstrates that using 
stringent hybridization conditions, many more probes could be detected as hypermethylated 
in the tumor cell line.  
 
 
 
Figure 5-14 Comparison of both hybridization protocols 
(A) The two diagrams demonstrate the difference between the standard (65°C, without formamide) and the 
stringent (67°C, 15% formamide) hybridization protocol. The signal ratio between U937 and monocytes is shown 
as a function of the average signal intensity. (B) The diagrams demonstrate the difference when the signal ratios 
of both protocols are directly compared showing that with the stringent protocol much more probes are detected 
as hypermethylated than with the standard hybridization conditions, especially when the probes have a high GC 
content (˃60%).  
 
 
To explore if the signal intensities increased with greater quantities of DNA, MCIp and 
subsequent microarray analysis were performed with 1 µg, 2 µg and 4 µg DNA. Figure 5-15 
and Figure 5-16 compare data using different amounts of DNA and different hybridization 
protocols. Figure 5-15 illustrates a comparison of genome-wide hypermethylation profiles, 
whereas Figure 5-16 depicts three selected regions (FOXP3, MARVELD2, IRX3). The 
studies showed that robust methylation profiles could be obtained with as little as 1 µg of 
genomic DNA using the stringent (new) protocol. Best results were achieved with 4 µg of 
genomic DNA while 2 µg DNA were sufficient for good, reproducible results.  
Because we were limited in patient material, all following experiments were performed with 
2 µg DNA instead of 4 µg DNA.  
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Figure 5-15 Major modifications of the MCIp-on-chip protocol in global screening for tumor-specific 
hypermethylation 
The old hybridization protocol using standard hybridization conditions (65°C and no formamide) was compared to 
the newer stringent hybridization protocol (67°C and 15% formamide). The new stringent protocol was performed 
with three different amounts of input DNA (1 µg, 2 µg, 4 µg subjected to MCIp). The signal ratios between tumor 
and normal DNA were plotted as a function of the average signal intensity.  
 
 
Figure 5-16 Examples of microarray results using different hybridization conditions and increasing 
amounts of DNA 
Shown are data points for three CpG island regions of FOXP3, MARVELD2 and IRX3 using different hybridization 
conditions. Each data point represents one microarray probe. The old standard protocol involved hybridization at 
a temperature of 65°C, whereas in the new stringent protocol the hybridization temperature was increased to 
67°C and 15% formamide was added. The log ratio (tumor/normal) is plotted as a function of the relative position 
on chromosome 1. 
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5.3.2 Comprehensive validation of genome-wide CpG island 
methylation profiles for two human leukemia cell lines 
Data from this section have been published in the journal Cancer Research. Comparative 
MCIp hybridization data were deposited with the GEO Data Library under Series Entry: 
GSE17455, GSE17510, GSE17512. 
 
To establish and test the newly adapted and improved MCIp-on-chip technique, the first 
genome-wide methylation analyses using Agilent 244K CpG island microarrays were 
performed with MCIp-enriched methylated fragments of the well-established leukemia cell 
lines U937 and THP-1 in comparison with enriched fragments of blood monocytes of a 
healthy donor.  
Because the signal intensities were biased in correlation to their GC content (higher GC 
content lowered the average signals), the probe signals were GC normalized. Three 
independent replicates of each cell line were highly similar (mean r2=0.79 and 0.87 for log10 
ratios of THP-1- and U937-monocyte comparisons, respectively). A typical scatter plot 
(Figure 5-17) of a comparative hybridization of MCIp-enriched material from U937 cells 
highlights the three types of hybridization behavior: probes that show low signal intensities in 
both samples (absence of DNA methylation), probes indicating specific enrichment (aberrant 
DNA methylation) in the leukemia samples, and probes that show high signal intensities but 
low signal ratios in both samples (methylated in both samples). Altogether, more than one 
third of all microarray probes showed significant enrichment in the U937 cell line. 
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Figure 5-17 Comparative DNA methylation analysis of U937 cells and normal human blood monocytes 
using methyl-CpG immunoprecipitation (MCIp) 
Representative scatter plot of a comparison of MCIp-enriched material from 2 µg genomic DNA of a leukemia cell 
line (U937) and a pool of normal human blood monocytes from healthy donors on human 244K CpG island 
arrays. Signal intensity ratios are plotted against average signals (MvA plot, log10 scale). More than one third of all 
microarray probes show significant enrichment in the cell line. 
 
All CpG islands that were validated as hypermethylated in the first study (with 12K CpG 
island arrays) were again detected as hypermethylated in these experiments (performed with 
244K Agilent arrays). In total, approximately 11,300 or 8,700 (out of 23,000) independent 
regions were significantly enriched or depleted (>2.5-fold different) in U937 or THP-1, 
respectively. The majority of differentially enriched regions showed signs of hypermethylation 
(or amplification) in both cell lines. In U937 cells 10,700, in THP-1 cells 6,800 differential 
methylated regions (DMR) were detected. Hypomethylation or deletion of individual regions 
were mainly found in THP-1 cells.  
Large-scale validation of MCIp microarray data using mass spectrometry analysis was 
performed to quantify methylation differences at the resolution of single CpGs. Therefore a 
representative set of differential methylated regions (DMRs) as well as regions without 
methylation difference between cell lines and monocytes as a negative control were chosen 
to be analyzed by the MassARRAY system. This method is based on Matrix-Assisted Laser 
Desorption/Ionization Time-Of-Flight Mass Spectrometry (MALDI-TOF MS) measurement of 
bisulfite converted DNA using the EPITYPER platform (Sequenom, San Diego, US). Bisulfite 
treatment generates methylation dependent sequence variations, which can be measured by 
the MassARRAY system. Moreover, this procedure allows the analysis of multiple CpGs in 
one amplicon and the comparison of their methylation status between different samples (for 
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more details see section 4.4.6). The validation panel comprised a set of 140 genes that were 
selected based on the comparative MCIp methylation profiles of 23,000 CpG islands from the 
two myeloid leukemia cell lines (U937 and THP-1). In total, 1,150 primer pairs, which cover 
about 13,500 CpG sites, were designed for the amplification of bisulfite-treated DNA. 
Besides THP-1 and U937, MALDI-TOF MS was also performed with DNA derived from 
monocytes of three different healthy donors and with unmethylated and fully methylated 
DNAs as controls. The complete MALDI-TOF MS data are provided in the supplementary 
part of the corresponding publication (Gebhard et al., 2010).  
Validation using mass spectrometry analysis of bisulfite-treated DNA (MassARRAY System 
Sequenom) was highly consistent with the microarray data. Figure 5-18 shows examples of 
microarray-MassARRAY comparisons for four genes (MLL, SMAD6, HOXB5 and EPAS1) 
which demonstrate a high degree of correlation between both approaches.  
 
 
Figure 5-18 Examples for correlation between MCIp and bisulfite data 
The panel on top shows microarray results (log10 ratios; blue: U937 versus monocytes; red: THP-1 versus 
monocytes) for selected CpG island regions (MLL, Chr 8: 9798000-97992000; SMAD6, Chr 15: 
64781200-64783000; HOXB5, Chr 17: 44025400-44026600; EPAS1, Chr 2: 46378600-46380800). The middle 
panel depicts the GC-content of microarray probes. The bottom panel shows quantitative MALDI-TOF MS 
(EpiTYPER) methylation levels for individual CpG residues within the analyzed region. Each spot represents one 
CpG unit.  
 
 
In a next step all results extracted from both data sets were compared. To correlate 
differential signal intensities on CpG island microarrays with data points for individual CpG 
dinucleotides, the mean methylation difference between tumor cell lines and monocytes of all 
measured CpG dinucleotides that are located in a 300 bp radius around a microarray probe 
was calculated (“EpiTYPER methylation ratio”, for further information see section 4.4.6.10). 
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Figure 5-19 illustrates the high consistency of both approaches regarding the comparison of 
the two leukemia cell lines THP-1 and U937. 
When plotting the “methylation ratio” against the probes’ signal ratio, a good correlation 
(r2 = 0.51 for U937 and r2 = 0.67 for THP-1) was observed between microarray probe 
intensity ratios on microarrays and mean bisulfite methylation ratios of CpG dinucleotides 
located around the microarray probe for the U937 as well as the THP-1 cell line. The high 
reproducibility of both approaches is shown exemplary for U937 leukemia cells and normal 
monocytes in Figure 5-20A.  
 
 
Figure 5-19 Correlation of microarray and mass spectrometry data 
Differential methylation between the two cell lines THP-1 and U937 can be reliably detected using both methods, 
MCIp combined to microarray analysis and MALDI-TOF MS. Differential methylation of the microarray data is 
illustrated by plotting the signal ratios from one cell line against the signal ratios from the other cell line. For the 
EpiTYPER data methylation ratios for both cell lines are calculated and plotted against each other. In the lower 
graph, the high consistency between microarray signal ratios and EpiTYPER methylation ratios is illustrated on 
probe level. 
 
A similar comparison was performed to correlate both data sets based on region level 
instead of probe level. Here, mean methylation ratios (log10) for 225 regions (covering more 
than 300 bp each) (see section 5.4.2) based on the above amplicons were calculated and 
then plotted against mean signal ratios of all microarray probes within each region. As shown 
in Figure 5-20C and D, a good correlation between microarray and EpiTYPER data was 
observed (r2 = 0.62 for U937 and r2 = 0.75 for THP-1).  
The correlation between both methods increased on the region level compared to the probe 
level, mainly because the resolution of the microarray approach dropped at extremely 
GC-rich microarray probes which tended to cross-hybridize, even under stringent 
hybridization conditions. Mass spectrometry data was also able to provide higher resolution 
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of the boundaries between methylated and unmethylated domains. Stretches of 
unmethylated DNA in close vicinity to metylated domains were often detected as methylated 
due to the DNA fragmentation range. Nevertheless, the MCIp approach clearly discriminated 
methylation levels between the two leukemia cell lines U937 and THP-1 (Figure 5-20B and 
Figure 5-19). Thus, our comprehensive validation demonstrates a good overlap of MCIp and 
MALDI-TOF MS data and suggests that our technique allows for reproducible and valid 
detection of comparative CpG methylation levels.  
 
 
Figure 5-20 Methyl-CpG immunoprecipitation and its validation using MALDI-TOF MS 
(A) Microarray probe-based correlation of MALDI-TOF MS (EpiTYPER) and MCIp microarray results of 
U937/monocyte comparisons. Microarray probe signal log10 ratios were plotted against an EpiTYPER score that 
consists of a scaled, average methylation level of all CpGs located in a radius of 300 bp around the microarray 
probe (r
2
 = 0.51 for U937 and r
2
 = 0.67 for THP-1, data not shown). (B) Microarray probe-based correlation of 
differential CpG methylation ratios measured by MALDI-TOF MS (EpiTYPER) and MCIp microarray. MCIp reliably 
detects differential methylation between the two cell lines (r
2
 = 0.65). Correlation of MALDI-TOF MS (EpiTYPER) 
and MCIp microarray results of U937/monocyte (C) and THP-1/monocyte (D) comparisons for regions covered by 
the EpiTYPER analysis. Mean probe signal log10 ratios are plotted against mean log10 transformed EpiTYPER 
methylation ratios (r
2
 = 0.62 for U937 and r
2
 = 0.75 for THP-1).  
 
5.3.3 Genome-wide hypermethylation profiling in AML and patients 
with colorectal carcinoma 
Cancer is associated with disease-related epigenetic abnormalities, including the aberrant 
hypermethylation of CpG islands which can lead to the abnormal silencing of tumor 
suppressor genes. A major challenge of current clinical research is to find ways of exploiting 
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the diagnostic and therapeutic implications of these abnormalities. Since hypermethylation of 
CpG islands seems to be a tumor-type specific event, the knowledge of global DNA 
methylation patterns of a given tumor might provide important information for risk 
assessment, diagnosis, monitoring and treatment. The design for a study to screen patient 
samples to find out new potential marker genes is shown in Figure 5-21. 
 
 
 
Figure 5-21 Study design for identifying disease markers for AML 
In principle, the study comprises three steps that should finally help to identify disease markers.  
 
Since global methylation profiling of tumor cell lines showed high sensitivity and 
reproducibility of the MCIp approach using the stringent (new) protocol, in a next step global 
comparative CpG island methylation profiling for more than 25 AML samples with mostly 
normal karyotype was performed, using MCIp in combination with 244K CpG island 
microarrays. As a reference a pool of DNA derived from three different healthy donors (male) 
was used. Image-data was extracted using Feature Extraction Software 9.5.1 (Agilent) and 
the standard CGH protocol. Processed signal intensities were further normalized using 
GC-dependent regression and imported into Microsoft Office Excel 2007 for further analysis. 
(Complete microarray data sets will be submitted with the corresponding publication.) 
Clustering of samples based exclusively on the X- and Y-chromosomal genes demonstrated 
that male and female samples can be clearly distinguished as expected due to an 
enrichment of the X-chromosomal gene fragments and simultaneous depletion of the 
Y-chromosomal genes (Figure 5-22). This resulted from the fact that the reference pool 
consisted of DNA derived from three different healthy male donors. 
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Figure 5-22 Hierarchical cluster analysis of AML samples in X- and Y-chromosomal genes only 
DNA methylation ratios (tumor/normal) from 244K CpG island microarray analyses are represented on a 
continuous scale from non-methylated (yellow) to fully methylated (blue). Male (♂) and female (♀) samples can 
be clearly distinguished due to an enrichment of the X chromosome gene fragments and depletion of the 
Y chromosome gene fragments.  
 
To evaluate differences in the methylation patterns between 27 AML patients and three 
leukemia cell lines (KG-1, U937, THP-1) as well as normal blood monocytes and colon cells 
from a healthy donor, a hierarchical cluster analysis was performed (Figure 5-23). The 
analysis was limited to autosomal genes in order to account for the effects introduced from 
X-chromosomal imprinting.  
 
Figure 5-23 Hierarchical clustering of tumor samples and one monocyte as well as one colon sample 
Two-way hierarchical cluster analysis of 27 AML samples, 1 colon sample from a healthy donor (CO; framed in 
red), 1 monocyte sample from a healthy donor (MO) and 3 leukemia cell lines (KG-1, U937, THP-1; framed in 
green) are shown in the different columns. CpG island regions are represented as lines on a continuous scale 
from non-methylated (yellow) to fully methylated (dark blue).  
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Hierarchical clustering revealed a complex methylation pattern of AML patients. The results 
demonstrate that more than 6,000 CpG island regions (out of 23,000) were hypermethylated 
in at least three AML patients. At this level there was no obvious correlation between 
karyotype, age and other parameters. Cell lines showed a much higher degree of 
methylation than primary tumors. About 3,000 CpG islands were methylated in cell lines but 
never in primary tumor cells. Furthermore, the methylation pattern of the normal colon tissue 
DNA showed that many CpG islands methylated in AML become also methylated in the 
colon during aging. This became apparent by comparing hypermethylation profiles of healthy 
colon samples (derived from 60-year-old donors) and monocyte samples (derived from 20- to 
30-year-old healthy donors). Colon samples showed a high degree of hypermethylation 
compared to monocytes: 6,000 out of 23,000 CpG island regions can be hypermethylated in 
AML samples, 3,000 (out of 6,000 CpG island regions) were also hypermethylated in normal 
colon samples. This high amount of hypermethylated regions cannot only be reduced to 
tissue-specific effects. They rather represent age-dependent differences. Genes affected by 
hypermethylation during aging are mainly genes involved in developmental processes like 
homeobox genes or Polycomb targets as demonstrated in Figure 5-24.  
 
 
Figure 5-24 Age-related hypermethylation correlates with developmental genes 
Hierarchical clustering revealed a group of 3,000 CpG islands that were methylated not only in U937 and THP-1 
cell lines but also in normal colon samples, however not in normal blood monocytes. Genes associated with this 
cluster are enriched for gene ontology (GO) terms including homeobox genes, developmental processes and 
transcription factors. Three independent experiments for THP-1 and four independent experiments for U937 
showed high consistency, as well as two independent experiments performed with different normal colon samples 
(CO) and three independent experiments performed with normal blood monocytes derived from different healthy 
donors (MO).  
 
One possibility to make sure that those differences are really age-dependent, would be the 
comparison with colon samples from a set of younger healthy donors. However, during the 
time of my thesis there were no samples available for such experiments. 
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Because a large number of CpG islands showed variable methylation aberrations in AML, we 
decided to focus on genes that are likely to include functionally relevant candidates. In total, 
400 target regions that are important for transcription, gene regulation, or signaling, were 
chosen for validation using the MassARRAY platform (MALDI-TOF MS). Although we include 
some examples for putative age-dependent methylation, the majority of amplicons did not fall 
into this category. 
 
So far, we concentrated on leukemia samples. To compare the methylation profiles obtained 
from AML samples with an independent tumor entity, about 20 DNA samples derived from 
colorectal carcinomas were analyzed using MCIp with subsequent microarray hybridizations. 
A reference pool of three different colon DNAs (50-, 56- and 63-year-old donors) purchased 
from Lonza were also used. Complete microarray data sets will be submitted with the 
corresponding publication. The data analysis of the colon patients has not been completed at 
time of writing this thesis. Future aims are the mass spectrometric analysis and validation of 
hypermethylated genes to define potential marker genes for this tumor entity. 
 
5.3.4 Confirmation by MassARRAY (EpiTYPER) data 
Mass spectrometry yields quantitative methylation data of short stretches of subsequent 
CpGs in a high-throughput manner and consequently allows for the validation of large 
genomic regions. Approximately 350 genes that were differentially methylated between AML 
patients and normal monocytes were selected based on the array results (Figure 5-23). For 
all genes a total of 670 PCR amplicons were designed. Before analyzing the patient 
samples, all primers were tested with the cell lines (THP-1 and U937). The results of all 
amplicons were screened for selection for follow-through methylation analysis in the AML 
samples. Several criteria were considered when choosing the best amplicons: 
1. Spectral quality: All amplicons designed across a CGI were assessed for spectral 
quality from the MALDI-TOF MS output to determine the success of PCR 
amplification and the presence / absence of primer dimers or amplification bias. 
 
2. Cleavage pattern: The cleavage pattern of each amplicon following base-specific 
cleavage was also assessed to determine whether a sufficient amount of cleavage 
fragments fell within the mass range of detection for MALDI-TOF MS 
(1,500 Da - 6,500 Da). In some situations, a large proportion of cleaved fragments 
were either too small or too large for detection. 
 
 Results 
 - 109 -    
3. CpG density and length: Larger (>400 bp), CpG-dense amplicons were preferable, in 
order to maximize the quantity of data available. 
 
4. Location: Amplicons adjacent to or upstream of the transcription start site were 
considered ideal, in order to cover any putative transcription factor binding sites. 
 
5. Methylation levels: When methylation ratios were considered across several 
amplicons covering a CGI, amplicons in regions where methylation levels changed 
dramatically between samples (from unmethylated to methylated or vice versa) or 
where tumor sampes were methylated were preferable, rather than amplicons where 
no methylation was observed. 
Following manual inspection of all methylation data quality, a final set of about 400 amplicons 
(˃7000 CpG sites) in about 300 genes were chosen for validation of the microarray data with 
AML patient samples.  
Again, MassARRAY EpiTYPER data correlated well with microarray data. Examples for the 
excellent consistency of the two different techniques are shown in Figure 5-25.  
We finally asked, if specific markers for disease diagnosis or prognosis can be identified. To 
address this issue, a further 200 AML patients were screened using the 400 amplicons as 
described above to identify relevant disease markers. (The complete MALDI-TOF MS data 
will be available online upon publication.)  
Figure 5-26 shows exemplary methylation patterns of two different gene amplicons (CEBPA 
and RHOB) for 165 AML patients, CD34+ cells derived from three different healthy donors 
and monocytes derived from four healthy 20-year-old donors and eleven healthy 60-year-old 
donors. CEBPA (CCAAT/enhancer binding protein α) is a basic leucine zipper transcription 
factor that regulates differentiation-dependent genes during granulocyte differentiation. While 
hypermethylation of the CEBPA promoter has already been reported in AML as well as in 
other malignancies (Figueroa et al., 2009), the distal CpG island which is located about 20 kb 
downstream of the promoter was often hypomethylated in AMLs but methylated in normal 
monocytes and stem cells (Figure 5-26). In contrast, more than one third of the analyzed 
AML patients showed significant hypermethylation of an amplicon within the RHOB gene 
whereas hematopoietic stem cells (CD34+ cells) as well as monocytes of all healthy donors 
were unmethylated. It is already known that the expression of the RHOB gene, a member of 
the Rho family of small GTPases, is often downregulated in lung cancer (Sato et al., 2007). 
Computational analyses of the EpiTYPER data set was still in progress at the time of writing 
this thesis. Therefore, no correlations between methylation profiles and clinical parameters 
could be detected or, likewise, no potential marker genes could be identified at this time.  
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Figure 5-25 Examples of aberrantly methylated CpG islands in AML samples 
Microarray and MassARRAY data are shown for CpG islands of four different genes in AML samples and two 
blood monocytes from two different healthy donors. Each sample is represented by one column. Each line of the 
microarray results represents one probe and each line of the EpiTYPER results represents one CpG unit. The 
same region is detected by microarray or EpiTYPER analysis, respectively. DNA methylation values regarding 
EpiTYPER results are represented on a continuous scale from non-methylated (white) to fully methylated (dark 
blue) (non-detectable CpGs are marked in gray), whereas signal log ratios (tumor versus normal) are represented 
on a continuous scale from blue (strongly hypermethylated in tumor) to yellow (strongly hypomethylated in tumor). 
The top diagrams were extracted from the Genome Browser showing the relative position of transcripts, CpG 
islands (green) as well as position of amplicons detected by MassARRAY experiments. 
 
To find out if monocytes also show age-related differences in methylation patterns similar to 
colon samples, and therefore to make sure that the identified potential marker genes are 
really methylated due to tumorigenesis and not due to aging, DNA samples derived from 
monocytes of about 60-year-old donors were analyzed using MALDI-TOF MS for the 400 
CpG island regions. Unlike colon samples, monocyte samples did not show age-dependent 
changes in DNA methylation (Figure 5-26). One explanation could be that crypt stem cells 
possess an exceptionally high rate of proliferation, resulting in further DNA methylation due 
to the higher mitosis rate. 
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Figure 5-26 Examples of abnormal methylation patterns in AML patients 
Mass spectrometry analysis of CpG island fragments of two different genes (CEBPA (on the left) and RHOB (on 
the right)) in 165 AML patients, three CD34+ samples and monocytes derived from four healthy 20-year-old 
donors and eleven healthy 60-year-old donors. Samples (rows) are clustered according to the average 
methylation degree of all CpG units (columns) within the amplicon. DNA methylation values are depicted by a 
color scale as indicated (methylation increases from white (non-methylated) to dark blue (fully methylated)). Gray 
denotes data of poor quality. The top diagrams were extracted from the Genome Browser showing the relative 
position of transcripts (black), the transcription start sites (arrows), CpG islands (green) and the position of 
amplicons detected by MassARRAY experiments (red).  
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5.4 General transcription factor binding at CpG islands in 
normal cells correlates with resistance to de novo 
methylation in cancer 
 
The data from this section have been published in the journal Cancer Research. Microarray 
data were deposited with GEO (gene expression analyses: GSE16076; comparative MCIp 
hybridizations: GSE17455, GSE17510, GSE17512; ChIP-on-chip hybridizations: 
GSE16078). 
 
Cancer is associated with disease-related epigenetic abnormalities, including the aberrant 
hypermethylation of CpG islands leading to loss of tumor suppressor gene expression. 
Methylation profiling studies have demonstrated that although there may be hundreds of 
different CpG islands methylated in any one tumor, some are methylated in multiple tumor 
types, whereas others are methylated in a tumor-type specific manner. Moreover, each 
tumor type tends to exhibit a characteristic set of aberrantly methylated genes. However, 
despite numerous examples of methylation–associated gene silencing events in human 
cancer cells, the molecular pathways underlying aberrant DNA methylation remain elusive. 
Different mechanisms for cancer-dependent, aberrant de novo methylation have been 
proposed so far, largely based on the behavior of individual CpG islands (see section 1.7.2). 
Besides other proposed mechanisms, one possible mechanism suggests that Alu and other 
repetitive elements may serve as foci from which de novo methylation can spread (Feltus et 
al., 2003), whereas other elements could provide a “protective” function. The absence of 
such ”protective” transcription factors may lead to the spreading of DNA methylation into 
affected CpG islands (Turker, 2002). To address this issue, methylation-prone and 
methylation-resistant CpG islands were defined by analyzing the methylation status of 
23,000 CpG islands of the human genome in acute leukemia cell lines as well as normal 
blood monocytes. Understanding the nature of these differences could provide insight into 
the molecular basis for aberrant methylation. The corresponding MCIp-on-chip experiments 
as well as the extensive validation by bisulfite conversion and subsequent MALDI-TOF are 
described in 5.3.2.  
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5.4.1 Basic properties of hypermethylated CpG islands  
Analyzing the results obtained from three comparative microarray hybridizations from 
monocytes and two leukemia cell lines, about 9,000 CpG island regions were detected 
reproducibly different (p<0.05 for repeated measures, three replicates each) between any of 
the comparisons (monocyte - monocyte (MO), THP-1 - monocyte (THP-1), U937 - monocytes 
(U937)). Hierarchical clustering of these CpG island regions revealed a group of CpG islands 
that are commonly hypermethylated in the cell lines but not in normal monocytes. Genes 
associated with this cluster exhibited an enrichment for gene ontology terms related to 
developmental processes, transcription factor or receptor functions, as well as homeobox 
proteins, that are often targeted by Polycomb group repressors. These associations were 
highly significant and in line with earlier evidence suggesting a link between aberrant DNA 
methylation in cancer and Polycomb group repressors that often target genes involved in 
development like homeobox transcription factors (Bracken et al., 2006b). CpG islands that 
were specifically methylated only in one of two leukemia cell lines were not significantly 
enriched for functional properties (data not shown). The heatmap is represented in Figure 
5-27A. 
 
 
 
Figure 5-27 Functional analysis of commonly hypermethylated CpG island regions 
(A) About 9,000 CpG island regions were significantly different (p<0.05 for repeated measures) between any of 
the comparisons (monocyte - monocyte (MO), THP-1 - monocytes (THP-1), and U937 - monocytes (U937)). 
Hierarchical clustering of these CpG island regions reveals a group of CpG islands that are commonly 
hypermethylated in the cell lines. Genes associated with this cluster are enriched for gene ontology (GO) terms 
including developmental processes, transcription factors and homeobox genes. (B) Averaged microarray signal 
intensities were plotted as a function of distance towards the known transcription start sites (TSS; bin size 100 bp, 
motif in 5’-3’ orientation). 
 
 
 
Results 
- 114 - 
Plotting the average probe signal ratio between one of the two cell lines (THP-1 and U937) 
and normal blood monocytes as a function of the distance to the transcription start site (TSS) 
reflects that regions around known TSSs are less often targeted by de novo methylation in 
leukemia cells than promoter distal sites (Figure 5-27B). This is confirmed by previous 
observations suggesting that proximal promoters are less frequently de novo methylated 
than other genomic regions (Irizarry et al., 2009). 
 
5.4.2 Defining CpG island regions 
CpG methylation often spreads over large genomic regions. In order to perform a 
region-based analysis of comparative methylation data instead of a microarray probe-based 
analysis, regions were first mapped and a cumulative hypermethylation value based on 
probe behavior within the region was assigned. Based on the array design, CpG island 
regions were defined to include all neighboring microarray probes of a region with a 
maximum distance of 500 bp and a minimum of three microarray probes in total. For each of 
the approximately 23,000 CpG island regions an integral value for hypermethylation based 
on area size was calculated and log10 intensity ratios of microarray probe signals were 
smoothed above a threshold (2.5-fold enrichment) as described in Figure 5-28A. To 
normalize for region size, these integral values were divided by one hundredth of an arbitrary 
‘maximal’ integral value that was calculated for each region assuming a 100-fold enrichment 
of each microarray probe in leukemia versus normal DNA.  
Figure 5-28B shows a diagram of the cell line U937, where normalized integral 
hypermethylation ratios are plotted against the corresponding average signal intensities of 
individual areas. The comparative analysis on the region level (Figure 5-28B) also clearly 
separated the three different classes of CpG island regions as shown before on probe level 
(Figure 5-17): (i) CpG islands that show low signal intensities in both samples. Those were 
lost during the MCIp procedure and are thus unmethylated. (ii) CpG islands that are 
specifically enriched and therefore methylated specifically in the leukemia samples. (iii) CpG 
islands that show high signal intensities in both samples. They were enriched in both 
samples and are thus methylated in both. We could not identify specific properties 
associated with the latter type of CpG islands which is heterogeneous and includes 
monoallelic (e.g. imprinted regions) as well as biallelic (tissue- or soma-specific) DNA 
methylation events (Straussman et al., 2009) and therefore concentrated on properties of 
unmethylated or de novo methylated genes in the following analyses. 
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Figure 5-28 Integral hypermethylation values and DNA methylation status in CpG island regions 
(A) Calculation of integral hypermethylation values for a CpG island region. Probes (red boxes) within a region 
(except the ones located at the edges) were assigned mean log10 ratios of the center probe and the two 
neighboring probes. The integral hypermethylation value assigned to each CpG island region corresponds to the 
area in blue and is the sum of integral probe areas (green boxes) above the threshold: ∑[extended probe length x 
(smoothed log10 ratio-2.5)] All probes with a smoothed log10 ratio below the threshold (2.5, blue dotted line) were 
ignored. (B) Normalized integral hypermethylation values of CpG island regions are plotted against their average 
log signal intensities for a comparative MCIp of U937 cells and monocytes. Three populations are distinguished: 
CpG islands that show low signal intensities in both samples (low average log signal intensities and low integral 
hypermethylation values: lost during the MCIp procedure and thus unmethylated; CpG both, framed in red); CpG 
islands that are characterized by intermediate average log signal intensities and high integral hypermethylation 
values (specifically enriched and methylated in the leukemia samples; mCpG U937, framed in green); CpG 
islands that show high signal intensities (but low signal ratios) in both samples (high average log signal intensities 
and low integral hypermethylation values: enriched in both samples and thus methylated in both; mCpG both, 
framed in blue). 
 
 
To get insight into the correlation of DNA methylation and mRNA expression, the previously 
performed CpG island microarray hybridizations (U937-monocyte, THP-1-monocyte) were 
compared with global mRNA expression analyses, which were performed with RNA isolated 
from monocytes (CD14+ cells), CD34+ progenitor cells and the leukemia cell line U937.  
 
Confirming earlier observations (Gebhard et al., 2006b; Keshet et al., 2006), the comparison 
of global mRNA expression data of normal (CD14+ cells and CD34+ cells) and leukemia 
cells (U937) between the two major CpG island classes (unmethylated in cancer as well as 
normal cells and de novo methylated in cancer cells) demonstrated that the majority of de 
novo methylated CpG islands are characterized by low or absent transcription of neighboring 
genes irrespective of their position relative to TSS (promoters, intragenic or intergenic 
regions) in normal as well as in cancer cells. Box plots in Figure 5-29 illustrate the distribution 
of mRNA expression ratios. 
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Figure 5-29 Expression status of genes associated with CpG island regions 
The box plots show the distribution of mRNA expression ratios (CD34+ progenitor cells, CD14+ normal blood 
monocytes, U937) conditional on the methylation status (unmethylated in both: CpG; hypermethylated in 
leukemia: mCpG) for THP-1 and U937 at individual probes that were divided into the three position classes: 
promoters (prom), intragenic (intra) and intergenic (inter). The red lines denote medians, boxes the interquartile 
ranges, and whiskers the 5th and 95th percentiles. Pair wise comparisons of mRNA expression ratios associated 
with unmethylated and hypermethylated regions are significant (P<0.001, Mann–Whitney U test, two-sided). 
 
5.4.3 Strategies for de novo motif discovery 
If certain transcription factors are to be involved in establishing and/or maintaining the CpG 
methylation status of a certain CpG island region, it should be possible to isolate their 
respective binding motifs by comparing methylation-prone and methylation-protected CpG 
islands. A number of previous bioinformatics attempts indeed identified specific nucleotide 
sequences and general CpG island attributes (Das et al., 2006; Feltus et al., 2003; Feltus et 
al., 2006) or structural features (Bock et al., 2006) that contribute to the protection from or 
susceptibility to aberrant methylation. However, no defined consensus sites for known 
transcription factors could be identified so far. After analyzing the methylation status of 
23,000 CpG islands of the human genome we defined sequence patterns characteristic for 
methylation states in CpG island regions using de novo motif analysis. 
 
Motif discovery was performed using the comparative algorithm HOMER (Hypergeometric 
Optimization of Motif EnRichment) ( see section 4.5.1 for more details). Different strategies 
for the analysis of the data in this thesis were applied in order to avoid identifying biased 
results due to CpG island nucleotide content, length etc. CpG island regions intrinsically have 
a high CpG content (in contrast to a large fraction of the genome that is relatively CpG-poor) 
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and they differ in sequence lengths. De novo motif finding, however, requires target and 
background sequence sets of constant lengths and similar nucleotide compositions.  
 
The following approaches were used to isolate enriched motifs: We first searched for motifs 
in all selected CpG island regions (unmethylated in both or methylated only in tumor) in a 
fixed radius around the CpG island region center (± 250, 500, 750, and 1000 bp) against 
either a non-overlapping, CpG-matched background set from all known promoters, or from all 
microarray-defined CpG island regions. Independently, CpG island regions were divided into 
regions <750 bp, 750-1250 bp, 1250-1750 bp and >1750 bp and separately analyzed as 
above. These region sizes were chosen because the CpG islands in this study ranged in size 
from 0.2-3.2 kb and because cis-acting features might lie within or flanking CpG islands. The 
identified motifs as described below as well as slight modifications thereof generally 
appeared in most analyses. The region approach is always associated with some degree of 
impreciseness, since some CpG island regions (in particular the larger ones) tend to display 
heterogeneous methylation patterns. For example, if a CpG island is methylated on one side, 
but unmethylated on the other side, the whole region will be considered as methylated. When 
compared with our large bisulfite data sets (see section 5.3.2), approximately 10% (U937) or 
20% (THP-1) of the CpG island regions’ overall hypermethylation score did not match the 
methylation status of the actual sequence around the motif (data not shown).  
 
Because the resolution of region data is relatively low, we applied a more accurate motif 
centered approach to improve resolution and accuracy of motif-methylation status 
correlations. For this purpose each of the identified motifs on the CpG island array was 
annotated with the mean signal intensities of all microarray probes in the range of ± 150 bp 
around it. The lower limit for hypermethylation of a motif in the tumor cell line was set at the 
mean signal intensity log10 ratio of 0.8. A motif was counted as unmethylated if it had the 
mean signal intensity log10 ratio between 0.4 and -0.4 and an average log10 signal intensity 
below 3.0-3.5 depending on the overall microarray probe behavior in individual 
hybridizations. In comparison with the bisulfite data, this approach was much more accurate: 
in U937, 135/140 motifs (97%) and in THP-1 124/135 motifs (92%), were correctly classified 
as hypermethylated or unmethylated.  
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5.4.4 Sequence motifs associate with CpG island regions that 
remain unmethylated or become hypermethylated in cancer 
The hypothesis that CpG islands differ in their inherent susceptibility to aberrant methylation 
presupposes that there are cis-acting features that distinguish methylation-prone and 
methylation-resistant CpG islands. To address this question, the de novo motif discovery 
algorithm HOMER was used to search for sequence patterns associated with CpG island 
regions that are either specifically and highly methylated in leukemia cell lines or not 
methylated in any sample. Altogether a set of eight non-redundant sequence motifs could be 
identified that were highly enriched in either population in comparison with all CpG island 
regions on the array (Figure 5-30A). These motifs were highly similar to known matrices from 
the TRANSFAC database. Hypergeometric P values for the enrichment of the indicated 
sequence motifs were assigned based on motif-centered methylation data. The calculation 
was performed with the mean signal intensities of all microarray probes in the range of 
± 150 bp around each motif (see section 5.4.3). Two repetitive motifs were highly enriched in 
the hypermethylated CpG island set, one of them (GAGA) (P value = 5.7×10-51 for U937) 
resembling the consensus motif for Drosophila GAGA-binding factor, a trithorax group 
member that has been implicated in preventing heterochromatin spreading. CA-repeats 
(CACA) (P value = 7.5×10-76 for U937) may play a role in RNA splicing and are bound by the 
heterogeneous nuclear ribonucleoprotein (hnRNP) L in a repeat length dependent manner. 
But there is no known link to DNA methylation or chromatin structure. More strikingly, the de 
novo motif algorithm revealed six sequences highly enriched in the unmethylated CpG island 
population. Five of them corresponded to consensus binding sites for known transcription 
factors, including nuclear transcription factor (NF) Y, GA binding protein (GABP), specific 
protein (SP) 1, nuclear respiratory factor (NRF) 1, ying-yang (YY) 1, whereas one of them 
was an unknown factor. The latter motifs were enriched with high significance with 
hypergeometric P values from 10-148 to <10-300 (motif distribution and P values are submitted 
with the corresponding publication). The ratios of expected versus observed motif 
appearance show the clear enrichment/depletion of the above motifs in unmethylated or 
methylated CpG island regions in U937 and THP-1 cells, respectively (Figure 5-30B). 
 
 Results 
 - 119 -    
 
Figure 5-30 Sequence motifs associated with aberrantly DNA methylated (mCpG) and commonly 
unmethylated CpG island regions (CpG) 
(A) P values (hypergeometric) for the enrichment of the indicated sequence motifs were assigned based on 
motif-centered methylation data (based on mean signal intensities of all microarray probes in the range of 
± 150 bp around each motif. Motifs identified de novo are shown in comparison to known matrices from the 
TRANSFAC database. (B) The two upper diagrams depict ratios of observed versus expected motif occurrences 
in CpG island regions that are aberrantly DNA methylated specifically in cell lines (mCpG, blue bars) or 
unmethylated in monocytes and the cell lines (CpG, red bars). The distribution of sequence motifs was also 
analyzed in acute leukemia samples (AML n=8) or colorectal carcinomas (CRC n=10). Here, median ratios of 
observed versus expected motif occurrences are shown as described above. Error bars mark the interquartile 
range. Hypergeometric P values for individual enrichments are listed in the supplementary material of the 
corresponding publication.  
 
Cell lines have been extensively cultured and may therefore have acquired genetic and 
epigenetic alterations that are not necessarily found in primary cells. To explore whether the 
sequence motifs identified in the two cell lines (individual motif distribution and P values are 
available online in the supplementary part of the corresponding publication) were also 
apparent in primary tumors, comparative methylation profiles of eight samples from acute 
leukemia (compared to normal monocytes) (see section 5.3.3) were analyzed concerning to 
the distribution of the above identified motifs. All sequence motifs were again significantly 
enriched in either unmethylated or methylated CpG island regions in primary AML samples 
(Figure 5-30B) indicating that the identified motifs are also relevant in vivo. 
To obtain evidence whether the protective role of the identified motif panel was also relevant 
in a different class of tumor, we analyzed ten colorectal carcinomas (compared to normal 
colon) (see section 5.3.3). Again, the same set of motifs showed a high enrichment in either 
unmethylated or methylated CpG island regions (Figure 5-30B). Thus, the provided data 
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strongly suggest that the identified consensus sequences are of general importance and may 
serve to protect CpG islands (preferably those acting as promoters) from aberrant 
methylation.  
 
Next, similar analyses were also performed with groups of unmethylated or methylated CpG 
island regions that were classified according to their genomic position (promoter: 
-1000 - +100 of RefGene TSS; intragenic (all exons and introns of RefGenes); intergenic: all 
non-transcribed regions). All six sequence motifs identified in CpG island regions that are 
unmethylated in normal cells and also remain unmethylated in tumor cells were enriched 
within the proximal promoter regions of known genes. Ratios of observed versus expected 
motif occurrence are demonstrated in Figure 5-31A. This is in line with previously published 
data that describe motifs isolated from unmethylated CpG islands as prominent constituents 
of proximal promoters (Rozenberg et al., 2008; Xie et al., 2005b). In Figure 5-31B the 
distribution of motifs is illustrated with respect to transcription start sites (TSS) of known 
genes. All motifs except the two repeat sequences are enriched within proximal promoters. 
Interestingly, most of the discovered promoter motifs (GABP, Sp1, NFY, NRF1 and the 
unknown motif) show positional bias with respect to TSS towards the 5’-direction.  
 
 
 
Figure 5-31 Motif enrichment in cell lines depending on genomic location 
(A) The distribution of sequence motifs was analyzed conditional on their genomic location. Enrichments or 
depletions at the three position classes were highly significant (hypergeometric test: P<0.001) except for the 
cases marked with a hash. (B) Distribution of motifs relative to transcription start sites of known genes (TSS). 
With the exception of the two repeat sequences, all motifs show strong peaks close to proximal promoters. 
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In contrast, the two repeat sequences (CACA, GAGA) showed no specific enrichment around 
transcription start sites (TSS), but both showed a higher enrichment in promoter proximal 
than in distal sites that acquired methylation during leukemic transformation (data not 
shown). Motif searches conditional on their genomic position additionally identified a CTCF 
consensus motif specifically enriched in the unmethylated intergenic CpG island regions 
(Figure 5-31). The 20 bp motif used for further analysis was extracted from published 
Chip-sequencing data (Barski et al., 2007) using HOMER: 
CTCF motif: 
 
 
 
 
 
Despite the significant over-representation of the “protective” motifs in promoters, they were 
also enriched with high significance in unmethylated CpG island regions that were located in 
intergenic or intragenic regions as shown in Figure 5-32 for U937 and THP-1 cells. In 
contrast, CTCF, a transcription factor which can act as a chromatin barrier by preventing the 
spread of heterochromatin structures, showed only enrichment in the intergenic regions in 
both cell lines.  
 
 
Figure 5-32 Sequence motifs associated with aberrantly methylated (mCpG) and commonly unmethylated 
CpG island regions (CpG) depending on their genomic location 
The diagrams depict ratios of observed versus expected motif occurrences at sequences that are 
hypermethylated specifically in cell lines (mCpG, blue bars) or unmethylated in monocytes and cell lines (CpG, 
red bars). Enrichments or depletions at the three position classes were highly significant (hypergeometric test: 
P<0.001) except for the cases marked with a hash. 
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If a certain factor was able to confer methylation protection, this property should be limited to 
its vicinity. Therefore distal sequences should be less protected than proximal ones. By 
plotting average MCIp signal intensities (normalized for GC-content) as a function of motif 
distance for each of the “protective” motifs, it could be demonstrated that each of the 
protective motifs showed a similar distribution of signal ratios: values were lowest at the 
center and progressively increased with distance. Curve progression was flat in primary, 
normal cells. However, distance-related differences in signal ratios markedly increased in 
leukemia cells, suggesting that these motifs are indeed associated with lower methylation 
levels and that this association depends on motif distance (Figure 5-33). Interestingly, the 
signal ratio distribution was not always symmetrical (e.g. at the unknown motif or the NRF1 
motif), implying that some factors may preferentially protect regions upstream or downstream 
of the element. Repeat elements showed an inverse distribution: mean signal ratios were 
usually higher at the motif center and tended to drop with distance. The distribution of signal 
ratios also appeared unsymmetrical. This is consistent with the preferential de novo 
methylation of CpG regions located up to 2 kb distant from CpG island promoters. Those 
so-called CpG island shores were previously detected in colon cancer (Irizarry et al., 2009).  
 
Figure 5-33 Distribution of DNA methylation relative to motif distance in monocytes and leukemia cell 
lines 
Averaged microarray signal intensities were calculated as a function of motif distance (bin size 100 bp, motif in 
5’-3’ orientation), distance dependent values were normalized for the average, GC-content matched signal 
intensities of all array microarray probes and ratios were plotted against motif distance. Negative values are below 
the average of all microarray probes (and therefore less methylated), whereas positive values imply that regions 
are methylated above the average of all regions. 
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This phenomenon was not only evident in the human genome but also in the murine 
genome. Averaged DNA methylation ratios of individual CpGs derived from high-throughput 
Reduced Representation Bisulfite Sequencing (RRBS) of mouse embryonic stem (ES) cells, 
ES-derived and primary neural cells, and eight other primary tissues (Meissner et al., 2008) 
were calculated for all available CpG dinucleotides and plotted as a function of motif distance 
(bin size 100 bp, motif in 5’-3’ orientation). As shown in Figure 5-34 a similar, motif 
distance-dependent distribution in the masked as well as in the unmasked mouse genome 
became obvious. Interestingly, on this global (less CpG island biased) scale, the relatively 
short NFY motif was less protective, especially when annotated on the unmasked mouse 
genome. A likely explanation may be that the ratio between actual factor binding and motif 
occurrence is lower in non-CpG island regions.  
 
 
Figure 5-34 Distribution of DNA methylation relative to motif distance in murine ES cells 
CpG methylation ratios were extracted from high-throughput Reduced Representation Bisulfite Sequencing 
(RRBS) data (GEO database accession no. GSE11034) of murine embryonic stem (ES) cells, ES-derived and 
primary neural cells, and eight other primary tissues. Average CpG methylation ratios were calculated for all 
available CpG dinucleotides and plotted as a function of motif distance (bin size 100 bp, motif in 5’-3’ orientation). 
Motifs are mapped against a repeat-masked (A) or unmasked (B) mouse genome. On this global (less CpG island 
biased) scale, the relatively short NFY motif was less “protective”, especially when annotated on the 
non-repeat-masked (unmasked) mouse genome which may be related to the fact that the ratio between actual 
NFY binding and motif occurrence is lower in non-CpG island regions. Total number of motifs is given in brackets. 
Gray areas represent distance-dependent standard deviations of CpG methylation ratios. 
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5.4.5 Sequence motifs and transcription factor binding in normal 
cells correlate with CpG methylation status in leukemia 
To study the correlation between motif appearance, transcription factor binding in normal 
cells and aberrant DNA methylation in the tumor cell lines, ChIP-on-chip (chromatin 
immunoprecipitation combined to microarray) analyses with antibodies for the transcription 
factors Sp1, NRF1 and YY1 in normal peripheral blood monocytes were performed. The 
distribution of binding events was analyzed based on their genomic location (promoter, 
intergenic and intragenic regions) (for ChIP-on-chip peak calling and motif annotation see 
section 4.5.2). As their consensus sites, these three general factors preferentially bound to 
promoter regions (Figure 5-35A). Enrichments or depletions at the three position classes 
were highly significant (hypergeometric test: P<0.001). Furthermore they often bound in the 
vicinity (± 250 bp) of each other as illustrated in Figure 5-35B. Using the bound regions 
defined by ChIP-on-chip experiments, de novo motif analysis revealed enriched consensus 
sequences for general transcription factors at a peak size of 200-500 bp (Figure 5-35C). In a 
distance of 100 bp to the Sp1-bound motifs all the other four motifs for the general 
transcription factors (NFY, GABP, YY1 and NRF1) as well as the unknown motif were 
significantly enriched. At NRF1-bound peaks, motifs for Sp1, NFY and GABP showed an 
enrichment with high significance in a radius of 100 bp around the bound motif. At 
YY1-bound peaks also with a peak size of 200 bp, consensus sites for YY1 and GABP and 
the unknown motif were enriched. Within a distance of ± 250 bp around the Sp1-bound motif, 
in addition to the other motifs, the consensus site for CREBP1 was enriched with high 
significance (P value: 2.7×10-101) and the YY1-bound peaks were additionally co-enriched 
with motifs for NRF1 and vJUN within the greater distance. 
 
 
 
  
Figure 5-35 Basic analysis of ChIP
(A) The distribution of binding events was analyzed 
depletions at the three position classes were highly significant (hypergeomet
diagram illustrates the overlap of bound regions between the three studied transcription factors. (Maximum 
distance between two peaks: 250
ChIP-on-chip experiments. Shown are enriched motifs and corresponding TRANSFAC motifs for each 
transcription factor analyzed at a peak size of 200 or 500
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The next question to be addressed was how the binding of specific factors to their consensus 
motif influences transcription of the respective gene. Comparing the expression data of 
CD34+, CD14+ and U937 cells with the ChIP-on-chip data revealed that genes associated 
with transcription factor-bound CpG islands generally showed significantly higher mRNA 
levels in CD34+ cells, CD14+ cells or the leukemia cell line as compared to all genes. The 
box plots showing the distribution of mRNA expression ratios are illustrated in Figure 5-37A. 
Moreover, the expression data were analyzed according to the number of bound transcription 
factors. Figure 5-37B demonstrates that binding of more factors generally increased overall 
expression levels of associated genes. 
 
 
Figure 5-37 Expression status dependent on the binding of general transcription factors 
(A) The box plots show the distribution of mRNA expression ratios (CD34+ progenitor cells, CD14+ normal blood 
monocytes, U937 cells) conditional on the binding status at individual, gene-associated peaks. The red lines 
denote medians, boxes the interquartile ranges, and whiskers the 5th and 95th percentiles. Pair wise 
comparisons of total mRNA expression ratios (all genes) and transcription factor-bound regions are significant 
(P<0.001, Mann–Whitney U test, two-sided). (B) The box plots show the distribution of mRNA expression ratios 
(CD34+ progenitor cells, CD14+ normal blood monocytes, U937 cells) conditional on the binding status (binding 
of one, two or three factors) at individual, gene-associated peaks. The red lines denote medians, boxes the 
interquartile ranges, and whiskers the 5th and 95th percentiles. Pair wise comparisons of total mRNA expression 
ratios (all genes) and transcription factor-bound regions are significant (P<0.001, Mann–Whitney U test, two-
sided). 
 
To directly compare transcription factor binding patterns in normal cells with aberrant 
methylation profiles of leukemia cell lines, the signal intensity ratios of ChIP enrichment for 
each transcription factor was plotted against the MCIp enrichment of the leukemia cell lines 
(THP-1 and U937) versus normal human blood monocytes. Figure 5-38 demonstrates that 
both events were mutually exclusive for all three transcription factors in U937 as well as 
THP-1 cells. This demonstrates that transcription factor binding protects from de novo 
methylation in leukemia cells. 
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Figure 5-38 Correlation between transcription factor binding in normal cells and aberrrant 
methylation in leukemia cells 
The three transcription factors Sp1, NRF1 and YY1 were
island arrays. In the diagrams the signal intensity ratios of ChIP
against the MCIp enrichment of the leukemia cell line (
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genes associated with transcription factor-bound motifs showed significantly higher mRNA 
levels as compared to genes that were associated with non-bound motifs. The mRNA 
expression levels in CD34+ progenitor cells, CD14+ normal blood monocytes and U937 cells 
conditional on the binding status of the associated motif (NRF1, Sp1, YY1) are demonstrated 
in Figure 5-39C. The data suggest that the stable binding of these general transcription 
factors (as measured by ChIP) to their consensus motif depends on the presence of 
neighboring motifs that are cooperatively bound by other general transcription factors. Thus, 
the combinatorial presence of two or more of the identified consensus sequences may serve 
to stabilize transcription factor binding and to confer the resistance of certain CpG islands 
(preferably those acting as promoters) to aberrant methylation. 
 
 
Figure 5-39 Properties of consensus sequences that are bound or not bound by the corresponding 
transcription factor 
(A) Based on ChIP-on-chip data, the motifs for Sp1, NRF1 and YY1 could be subdivided into those that are not 
bound and those that are actually bound by the corresponding factor in CpG islands. De novo motif searches of 
bound motifs against non-bound motifs revealed a highly significant association of bound motifs with consensus 
sites for other general factors within the range of ± 250 bp around each motif. (B) Ratios of observed versus 
expected motif occurrences are shown for sequence motifs that are either bound by the corresponding factor 
(blue bars) or not bound (green bars) and had at least one (top panel) or two other consensus sites (bottom 
panel) within a 250 bp distance. Enrichment in the bound fraction and depletion in the unbound fraction were 
highly significant (hypergeometric test: P<0.001) except for the cases marked with a hash. (C) The box plots show 
the distribution of mRNA expression ratios (CD34+ progenitor cells, CD14+ normal blood monocytes, U937 cells) 
conditional on the binding status of the associated motif. The red lines denote medians, boxes the interquartile 
ranges, and whiskers the 5th and 95th percentiles. Pair wise comparisons of mRNA expression ratios associated 
with bound and non-bound motifs are significant (P<0.001, Mann–Whitney U test, two-sided). 
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5.4.6 Properties of CpG island-associated genes in conjunction with 
CpG island methylation status and transcription factor binding 
We finally asked the question whether DNA methylation status or transcription factor binding 
events at CpG islands are associated with attributes or distinct properties of the 
corresponding genes or their products. In order to assess their biological interpretation the 
annotation tool in the HOMER software was used to determine enrichment or depletion of 
about 37,000 attributes. Since CpG islands were intrinsically enriched for many attributes as 
compared to the whole genome, enrichment and depletion as well as corresponding P values 
were calculated for individual gene groups against the total CpG island associated gene 
group. Hierarchical clustering of log10-transformed P values was performed using Genespring 
Software 10.0 (Agilent) using all attributes with enrichment or depletion P values <10-10 in at 
least one gene list. Thirteen databases (see section 3.12) were analyzed for enrichment of 
specific terms or properties including gene ontology terms, pathway association, protein 
domains or interactions, chromosomal localization and predicted miRNA targets in regions 
that were associated with a particular DNA methylation status or bound by any of the three 
transcription factors Sp1, NRF1 or YY1 (Figure 5-40).  
Hierarchical clustering of P values clearly separated the three classes of CpG islands into 
functional groups (Figure 5-40). DNA methylation-free and transcription factor-bound regions 
included properties and terms that were associated with basic cellular functions required for 
cell survival and proliferation. In line with earlier observations (Bracken et al., 2006a) (Figure 
5-27A), CpG island regions that are commonly targeted by aberrant DNA methylation in both 
myeloid cell lines exhibited highly significant associations with gene ontology terms related to 
developmental processes, transcription factor or receptor functions, as well as homeobox 
proteins, that are often targeted by Polycomb group repressors. Those regions are not bound 
by the three general transcription factors (NRF1, Sp1, YY1). Interestingly, these associations 
were also found in regions that contained unbound consensus motifs for at least one of the 
three above general transcription factors, and to a lesser extend in regions that were 
methylated also in normal somatic cells (human blood monocytes). (The complete list of 
gene attributes and properties and the correspondent P values is given within the 
supplementary material of the corresponding publication.) If a region is only bound by one 
transcription factor alone, the protection from de novo methylation is very low and no 
significant enrichment or depletion of the CpG island regions bound by a single transcription 
factor within the distinct CpG island classes (the CpG island regions which remain 
unmethylated in normal as well as in cancer cells and those CpG island regions that become 
methylated during tumorigenesis) could be observed.  
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Figure 5-40 Hierarchical clustering of significance values for gene ontology enrichment 
Enrichment or depletion was calculated for gene attributes and properties including gene ontology terms, pathway 
association, protein domains or interactions, chromosomal localization and predicted miRNA targets (a complete 
list of databases is given in the corresponding publication) in regions that were associated with a DNA methylation 
status (mCpG, methylated; CpG unmethylated), motif presence without DNA binding of the respective factor or 
transcription factor binding (any of the three transcription factors Sp1, NRF1 or YY1, in total (all), alone (only), or 
in combination). P values for enrichment or depletion of each attribute was calculated using the hypergeometric 
test (the complete list of P values is given within the supplementary material of the corresponding publication) and 
attributes with P < 10
-10
 were used to perform hierarchical clustering (Pearson centered, average linkage). Data is 
presented as a heatmap where red coloring indicates the significant depletion and blue coloring the significant 
enrichment of an attribute. Main clusters of attributes are indicated and top terms are given for each group.  
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6 Discussion & perspectives 
DNA methylation and modifications of histone tails are key cooperating mechanisms involved 
in maintaining epigenetic memory in mammalian cells. Along with genetic alterations, 
epigenetic abnormalities play an important role in gene deregulation in cancer (Jones and 
Baylin, 2007). Hundreds of genes show aberrant hypermethylation in specific tumor types. 
Initially, this was shown to be part of a silencing mechanism for tumor suppressor-like genes 
(Jones and Baylin, 2002), but subsequent experiments demonstrated that a large variety of 
different gene types (Costello et al., 2000; Yu et al., 2005) can be affected by this 
phenomenon. This aberrant methylation is set up early in tumor development. In order to 
identify potential disease markers, three cell lines as well as 25 AML and 10 colorectal 
carcinoma samples were screened for DNA methylation on a genome-wide level using the 
newly developed methyl-CpG immunoprecipitation (MCIp) approach. To get insights into the 
molecular basis for aberrant methylation profiles the MCIp data was analyzed using a 
powerful de novo motif search algorithm. 
 
6.1 MCIp in comparison with existing methods 
We developed a novel application allowing for the rapid and sensitive screening of DNA 
methylation. The central technique, called MCIp (methyl-CpG immunoprecipitation), is based 
on the binding of methylated DNA fragments to the bivalent, antibody-like fusion protein 
MBD-Fc (a methyl binding domain fused to an Fc-tail) in an immunoprecipitation-like 
approach. Enriched methylated DNA fragments can be efficiently detected both, on single 
gene level and throughout the genome. The power of this novel technique was demonstrated 
by the identification and subsequent validation of a large number of genes that are affected 
by aberrant hypermethylation in myeloid leukemias.  
 
At present, several techniques are applied for the detection of CpG methylation (Dahl and 
Guldberg, 2003). Commonly used assays rely on two basic principles to distinguish 
methylated and unmethylated DNA: digestion with methylation-sensitive restriction enzymes 
or bisulfite treatment of DNA (Ammerpohl et al., 2009; Dahl and Guldberg, 2003; Frommer et 
al., 1992b). Approaches based on methylation-sensitive restriction enzymes enrich 
fragments dependent on the digestion of methylated (Irizarry et al., 2008) or unmethylated 
DNA (Hatada et al., 2006) followed by size fractionation. A major disadvantage of these 
methods is that the enzyme pairs only recognize specific sequence motifs, thus the selection 
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of restriction enzymes automatically limits the number of detectable sequences – a global 
analysis of CpG methylation can therefore not be achieved (Ammerpohl et al., 2009; Dahl 
and Guldberg, 2003). In addition, when differences in global methylation patterns are 
reported between samples, it is impossible to decipher what proportion of these differences 
are located in promoter CpG islands (CGIs) rather than within intronic or repetitive elements. 
Treatment of genomic DNA with sodium bisulfite (NaHSO3) overcomes this limitation and 
allows the analysis of virtually any CpG position within the genome. If genomic DNA is 
treated with sodium bisulfite, unmethylated cytosines are deaminated into uracil and 
transformed into thymidine residues during PCR, whereas methylated cytosines still appear 
as cytosines (Frommer et al., 1992b). Consequently, bisulfite treatment results in methylation 
dependent sequence variations of C to T after amplification. The PCR product can then be 
sequenced, directly or after subcloning of the amplified fragment. Direct sequencing yields 
information about the average methylation of a CpG site in a sample, while sequencing of 
cloned DNA allows the analysis of individual CpG sites on independent half strand DNA 
molecules (Ammerpohl et al., 2009; Dahl and Guldberg, 2003). The major disadvantage of 
cloning and sequencing is that a high number of clones have to be sequenced to gain 
reliable results. Furthermore, artifacts relating to PCR infidelity, incomplete bisulfite 
conversion, or erroneous bisulfite conversion of 5’-methylcytosine to thymine can significantly 
influence the results of this method (Ammerpohl et al., 2009; Dahl and Guldberg, 2003). Until 
recently, it was thought that bisulfite-treated DNA cannot be analyzed on a genome-wide 
level. Technical advances, in particular the next generation sequencing approaches, now 
enable high-throughput analysis of bisulfite sequences and the determination of CpG 
methylation virtually across the whole genome. However, this approach is extremely 
resource and labour intensive and certainly not suited for the analysis of large sample 
numbers.  
Previous attempts to identify new genes that are differentially methylated in human disease 
have primarily taken candidate gene approaches relying on the use of techniques for 
gene-specific methylation analysis as described above. Within recent years, however, new 
high-throughput methods have made it possible to simultaneously analyze the methylation 
status of thousands of CGIs. However, most of those techniques like Restriction Landmark 
Genomic Scanning (RLGS) (Costello et al., 2002) or Methylated CpG Island Amplification 
(MCA) (Dahl and Guldberg, 2003; Smith et al., 2003) depend on methylation-sensitive 
restriction enzymes and suffer from the same limitations as described above.  
 
In contrast to the methods described above, which rely on a chemical reaction leading to a 
modification of the DNA molecules, the bases of DNA will stay unmodified when using methyl 
binding proteins to precipitate and thereby enrich methylated DNA (Ammerpohl et al., 2009). 
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The utility of naturally occurring methyl-CpG binding (MBD) proteins to separate methylated 
and unmethylated DNA fragments is known for more than a decade. Already in 1994, the 
laboratory of A. Bird developed a method for enrichment of methylated DNA fragments by 
means of affinity chromatography using recombinant MeCP2 (Cross et al., 1994) (Cross et 
al., 1994). The technique has been used, improved and combined with further techniques by 
other groups (Brock et al., 2001; Shiraishi et al., 1999). A disadvantage of MeCP2-affinity 
chromatography is the large amount of genomic DNA required (50-100 µg) and the relatively 
time-consuming procedure. Also, a recent report by Klose et al. (Klose et al., 2005) 
demonstrated that MeCP2 requires an A/T run adjacent to the methylated CpG dinucleotide 
for efficient DNA binding, suggesting that MeCP2-affinity chromatography may be biased 
towards certain CpG motifs. In contrast, MBD2 showed no binding requirements or 
preferences in these and previous studies. Fraga et al. could show that recombinant MBD2 
has a 50 to 100 times stronger affinity towards CpG-methylated DNA than recombinant 
MeCP2 (Fraga et al., 2003).  
 
Therefore, we believed that the high methyl-CpG affinity of MBD2 (Fraga et al., 2003) 
combined with the bivalent, antibody-like structure of the recombinant MBD-Fc polypeptide 
could largely increase its binding capacity, thereby enabling the efficient retention of DNA 
fragments in dependence on their methylation degree. We could show that an unmethylated 
DNA fragment may be 200- to 500-fold depleted and that up to 80% of a highly methylated 
fragment were recovered in the high salt MCIp fraction demonstrating the high affinity of our 
recombinant polypeptide. The fractionation procedure works efficiently with DNA fragments 
obtained by restriction digest or ultrasonication (data not shown).  
The properties of the recombinant MBD-Fc polypeptide allow for its application in small-scale 
assays requiring only little amounts of DNA (<300 ng) and therefore permit the profiling of 
DNA methylation of candidate genes from very limited cell numbers including biopsy samples 
or cells collected by laser-mediated microdissection. In addition, complete genome-wide 
methylation profiling is possible when a non-specific LM-PCR amplification step and 
subsequent hybridization to microarrays are performed. The PCR step causing potential 
amplification bias may be omitted if sufficient starting material (2 µg DNA) is available.  
At about the same time when we developed the MCIp approach, Weber et al. designed a 
related approach (MeDIP) using a 5-methylcytosine (5mC) antibody that requires a 
denaturing step before the immunoprecipitation of DNA fragments (Weber et al., 2005). Their 
analysis revealed only a small set of promoters being differentially methylated in a normal 
and a transformed cell line, suggesting that aberrant methylation of CpG island promoters in 
malignancy might be less frequent than previously hypothesized. In contrast to their 
observations, we detected a much higher percentage of differentially methylated genes, 
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much more in line with previous estimates, using the same CpG island microarray platform 
(12K microarrays). This may reflect an inherent property of the cell lines used, however, may 
also point to a lesser sensitivity of the 5mC antibody approach as compared to our 
fractionated MCIp approach. A further advantage of the MCIp approach compared to the 
MeDIP technique is that MBD-Fc can separate the bulk of genomic DNA fragments into 
different fractions of increasing methylation density. This is due to the fact, that MBD-Fc 
recognizes the hydration of methylated DNA rather than 5mC itself (Ho et al., 2008). 
Methylated and unmethylated DNA fragments show differential elution behaviors from the 
MBD-Fc fusion protein when using increasing salt concentrations and can be fractionated 
according to their methylation degree. Thus, during the MCIp procedure, not only the highly 
methylated DNA can be enriched, but also intermediately methylated or unmethylated DNA 
is recovered without detectable sample loss. This allows for the simultaneous analysis of the 
whole range of DNA methylation density, including both hyper- and hypomethylated DNA 
fragments either within CpG island promoters or within non-CpG island promoters (Schilling 
et al., 2009; Schmidl et al., 2009). In contrast, the MeDIP approach specifically enriches for 
methylated fragments and is dependent on the CpG content of the analyzed fragments, 
resulting in a strong bias towards CpG-rich DNA regions (Keshet et al., 2006; Suzuki and 
Bird, 2008; Weber et al., 2007).  
 
Recently, methods based on second generation sequencing such as 454 sequencing 
(Roche) or Solexa sequencing (Illumina) got into the focus of the epigenetic research 
(Ammerpohl et al., 2009; Lister and Ecker, 2009). As with bisulfite-modified DNA, 
MCIp-enriched material can be subjected to next generation sequencing technologies 
instead of hybridization to microarrays. The new sequencing technologies enable the global 
mapping of DNA methylation sites at single-base resolution. However, a high error rate is 
encountered when base-calling is performed with bisulfite-converted DNA, as after bisulfite 
conversion, the DNA being sequenced is effectively composed mainly of three bases. Since 
the resulting sequences are highly similar, this loss of complexity makes the subsequent 
aligning strategy much more difficult (Ammerpohl et al., 2009; Dahl and Guldberg, 2003; 
Lister and Ecker, 2009). Nevertheless, sequencing of bisulfite-converted DNA was feasible 
when using control lanes for autocalibration of the base-calling parameters to enable 
accurate base calling on the bisulfite-converted libraries (Lister and Ecker, 2009). 
Furthermore, in order to optimize the base calling performance, a multidimensional Gaussian 
mixtures model was developed (Cokus et al., 2008). Three techniques were recently used to 
generate bisulfite sequencing libraries compatible with next generation sequencing, namely 
MethylC-seq (Lister et al., 2008), BS-seq (Cokus et al., 2008) and Reduced representation 
BS sequencing (RRBS) (Meissner et al., 2008).  
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Comparable with microarrays, these sequencing technologies can also be restricted to 
distinct regions. Techniques that may be used prior to BS sequencing include not only 
binding of methylated DNA by proteins or an antibody (MCIp or MeDIP) but also capture of 
specific sequences by hybridization on a microarray or binding to beads in solution (Lister 
and Ecker, 2009). The disadvantage of these readout techniques is that they are still 
resource intensive compared with direct hybridization to microarrays. However, in contrast to 
large-scale sequencing approaches, microarrays produce data with only moderate 
resolution. To overcome resolution restrictions of the microarray platform in our studies the 
MCIp-microarray approach was combined with independent technologies (like MALDI-TOF 
MS) allowing the analysis of selected CGI at up to single CpG resolution. These validation 
experiments showed a high degree of consistency between both approaches.  
 
6.2 Hypermethylated genes in leukemia cell lines and 
primary tumor samples 
Aberrant hypermethylation in cancer cells may affect hundreds of CpG islands in a 
tumor-type specific manner (Issa, 2004; Kroeger et al., 2008). Therefore, DNA methylation 
patterns of a given tumor may offer important information for risk assessment, early detection 
and prognostic classification. Abnormal methylation patterns have been frequently described 
in acute myeloid leukemia (AML) (Issa, 2004; Toyota et al., 2001), and recent studies further 
support a crucial role for epigenetic changes in AML (Hackanson et al., 2008; Kroeger et al., 
2008; Whitman et al., 2008; Wouters et al., 2007). Epigenetic silencing by DNA methylation 
of cyclin-dependent kinase inhibitors (Herman et al., 1996; Kikuchi et al., 2002; Shen et al., 
2003), DNA repair genes (Scardocci et al., 2006), apoptosis mediators (Furukawa et al., 
2005; Murai et al., 2005), nuclear receptors (Liu et al., 2004; Rethmeier et al., 2006), 
transcription factors (Agrawal et al., 2007a), cell adhesion molecules (Roman-Gomez et al., 
2003), and many other genes have already been reported (Boumber et al., 2007; Kroeger et 
al., 2008; Toyota et al., 2001; Youssef et al., 2004). However, most epigenetic studies in 
hematological neoplasms focused on the analysis of few candidate tumor suppressor genes 
because of the lack of suitable technologies to quantitatively evaluate DNA methylation on a 
genome-wide level as well as in large sample sets. Until recently, this has prevented 
extensive exploration of the role of DNA methylation in leukemia and its impact in diagnosis 
and outcome prediction. 
 
For us, the establishment of the MCIp approach opened up new avenues towards unbiased 
genome-wide screening of methylated CpG islands. Using 12K CGI microarrays global 
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methylation profiles of three leukemia cell lines were generated and a large number of gene 
fragments (more than 100) that are likely to be methylated in neoplastic cells could be 
identified. Interestingly, most genes that were detected as hypermethylated in leukemia cell 
lines showed extremely low or undetectable mRNA expression levels in corresponding 
microarray experiments. A comparison with published expression profiles for human bone 
marrow, CD33 positive bone marrow cells, as well as mature myeloid cells from healthy 
donors (http://symatlas.gnf.org/SymAtlas/; data not shown) indicates that a large proportion 
of these genes may not be significantly transcribed in myeloid cell types. This is in keeping 
with a recent study showing that a series of studied genes had low or undetectable 
expression levels in blood or bone marrow cells (Kroeger et al., 2008). A hypothetical (so far 
unknown) targeting mechanism may therefore induce CpG methylation of genes independent 
of their transcriptional status during cellular differentiation. Although such genes may not 
have a significant suppressor role in tumor development and/or progression, they may still 
serve as valuable biomarkers, provided that the targeting mechanism is specific for the 
disease. 
 
Acute leukemia is characterized by a block of differentiation of early progenitors, which leads 
to the accumulation of immature cells in bone marrow and blood. The frequent mutation or 
downregulation of a relatively small number of transcription factors in AML patients suggests 
that the inactivation of transcriptional regulators may be critically involved in the malignant 
transformation process. Our methylation profiling of leukemia cell lines preferentially 
identified genes that are involved in transcriptional regulation. Half of the listed genes with an 
assigned molecular function (46/89) are involved in DNA-binding and transcriptional 
regulation, which indicates a significant over-representation. Aberrant hypermethylation of 
these transcription factor genes may lead to their epigenetic downregulation and likely 
contributes to the observed differentiation arrest in leukemia cells. This observation is in line 
with a previous study from Rush et al. (Rush and Plass, 2002) that investigated the 
methylation status of a large set of CpG islands in AML patients using RLGS and also found 
that a large proportion of the known methylated promoters (4/11) corresponded to genes 
involved in transcriptional regulation.  
The list of hypermethylation targets contains several transcription factor genes, including 
MAFB, JUN and KLF11 which are highly expressed in normal myeloid cells. A good tumor 
suppressor candidate e.g. is represented by the bZip transcription factor MAFB, which is 
expressed specifically in the myeloid lineage of the hematopoietic system. Its expression is 
upregulated successively during myeloid differentiation from multipotent progenitors to 
macrophages suggesting an essential role of MAFB in early myeloid and monocytic 
differentiation (Kelly et al., 2000b; Kelly et al., 2000a).  
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A major aim of this thesis was to develop methodology to enable screening of larger patient 
cohorts. Methylation profiling may help to clarify the pathophysiology of hypermethylation and 
provide new information on whether aberrant methylation of CpG islands in malignancies is 
random or specific and therefore help to identify new epigenetic marker genes. Experiments 
performed with the human CGI 12K microarrays, as described above, highlighted several 
technical limitations of this platform, including the presence of repetitive fragments leading to 
unwanted cross-hybridization events (non-specific binding which possibly gave rise to 
misleading results), and a relatively small number of representative genes. For global 
analysis of patient samples, another array platform provided by Agilent Technologies 
seemed to be better suited for this purpose. This array contains 244,000 probes (50-60 mer 
oligonucleotides) and covers about 23,000 CpG islands within coding and non-coding 
regions of the human genome (Agilent 244K CpG island microarrays). After improving and 
refining the MCIp method and its adaptation to the 244K microarray platform, the MCIp-on-
chip approach was much more sensitive and provided much more information. 
Using this newly adapted MCIp-on-chip approach, global methylation analysis of the cell 
lines was repeated. All CpG islands validated as hypermethylated in the first study (with 12K 
CpG island arrays) were again detected as hypermethylated in these experiments 
(performed with 244K Agilent arrays) provided they were included in the array design. In 
total, approximately 11,300 or 8,700 (out of 23,000) independent regions were significantly 
enriched or depleted (>2.5-fold different) in U937 and THP-1, respectively. Validation using 
mass spectrometry analysis (1,150 amplicons covering about 140 genes) showed high 
consistency for both approaches.  
To provide a general overview of global DNA methylation changes not only in tumor cell lines 
but also in primary tumor samples, we have characterized the DNA methylation profile of 25 
AML patients (of primary normal karyotype) as well as 10 colorectal carcinoma patients. 
Major findings of this study were: (i) more than 6,000 hypermethylated CGI regions common 
in at least three AML patients could be identified, (ii) the analyzed AML samples showed 
highly variable DNA methylation for the analyzed CGI regions, (iii) tumor cell lines showed a 
much higher degree of methylation than primary tumors, (iv) many genes that were 
hypermethylated in AML samples represent PcG targets, and (v) colon DNA derived from 
60-year-old healthy donors showed age-dependent methylation.  
The finding that tumor cell lines showed a notably higher degree of methylation than primary 
tumors is probably due to the fact that cell lines often acquire additional alterations both on 
genetic and epigenetic levels during prolonged in vitro culture. It has been reported that a 
large proportion of genes are hypermethylated across multiple cancer cell lines, suggesting 
that these differences are due to intrinsic properties in generating cell lines (Smiraglia et al., 
2001). The potential role of culture effects has been further highlighted by a recent study 
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demonstrating that DNA methylation profiles of human embryonic stem cells vary over time 
in culture, with different genes affected in different cell lines (Allegrucci and Young, 2007).  
A large number of genes hypermethylated in AML represent PcG targets which is in line with 
earlier studies (Grubach et al., 2008). The T-Box (TBX) 4 protein, for instance, is a classical 
PcG target that is often de novo methylated in leukemia and colorectal carcinoma but also in 
normal aged colon (Jin et al., 2009; Yasunaga et al., 2004). The encoded transcription factor 
is involved in the regulation of developmental processes and also showed a high degree of 
methylation in our studies: almost all AML patients were highly methylated within the 
promoter CpG island of this gene. 
Remarkably, the methylation pattern of the normal colon tissue DNA derived from older 
healthy donors showed that many CpG islands methylated in AML become also methylated 
in healthy colon epithelium during aging. This is in line with published studies confirming that 
molecular changes accumulate over time with a contribution of environmental influences 
resulting in methylation changes as shown for the promoter regions of MLH1 (Kurkjian et al., 
2008), ER, IGF2, N33 and MyoD (Ahuja and Issa, 2000) and eventual progression to 
colorectal cancer. Consistent with our study, Ahuja et al. reported that age-related 
methylation involves at least 50% of the genes which are hypermethylated in colon cancer 
(Ahuja and Issa, 2000). The association between aging and increased predisposition to 
develop cancer has long been noted (Kurkjian et al., 2008), however, there is no 
experimental or mechanistic evidence of a direct relationship (Fraga and Esteller, 2007). It 
has been demonstrated that normal aging cells and tissues show global hypomethylation 
(Calvanese et al., 2009), but there is also evidence for regional age-related increases in 
methylation of specific gene promoters (Calvanese et al., 2009) such as RUNX3, TIG1, 
E-cadherin, c-fos and collagen alpha 1 (Fraga and Esteller, 2007). Once a critical 
methylation density is reached, those promoters have the potential to permanently silence 
gene expression (Issa, 2003). 
The genes affected by hypermethylation during aging detected in this work were mainly 
those genes involved in developmental processes like homeobox genes or Polycomb 
targets. In contrast to colon, monocytes did not show age-dependent differences in 
methylation patterns at a large set (400) of typical de novo methylation targets. One 
explanation could be, that colon crypt stem cells may be characterized by an exceptionally 
high proliferation rate, resulting in a higher tendency to de novo DNA methylate certain CGIs. 
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6.3 Towards relevant disease markers for AML  
Despite considerable progress during recent years, AML still remains a highly fatal disease. 
Many patients who already achieved complete remission relapse and die of this 
heterogeneous disease. The main outcome predictors of AML include age, white blood cell 
count and a history of a preceding malignancy. However, to complete treatment stratification, 
in particular for AML with normal karyotype, molecular markers are necessary. 
Notwithstanding the advances in molecular genetics, the current classification system does 
not completely reflect the heterogeneity of AML (Bullinger et al., 2009). In order to improve 
the molecular AML classification global analysis approaches have been applied. Expression 
studies already achieved considerable results by identifying novel AML subgroups and 
prognostic gene expression signatures (Bullinger et al., 2004; Valk et al., 2004; Verhaak et 
al., 2009). However, expression analyses will not be sufficient for classification and 
therapeutic decision making of AML. Microarray expression analyses measure the 
abundance of mRNA, a molecule that is highly susceptible to degradation. Therefore, the 
standardization of microarray experiments is still challenging. In contrast, changes in DNA 
methylation represent a stable DNA modification which is conserved throughout sample 
preparation and therefore less prone to sample preparation-related changes. Thus, a 
DNA-based prognostic marker might provide a significant advantage to RNA-based methods 
(Bullinger et al., 2009). Several studies describing large-scale DNA methylation analysis to 
identify clinically relevant marker genes have been published recently. One publication by 
Martin-Subero et al. compared DNA methylation profiles of a wide range of different 
hematological neoplasies. Using bead arrays, they identified hypermethylation targets 
specific for the respective hematological tumor type as well as targets that were methylated 
in all hematological tumor types. But the study focused on candidate genes, selected from 
807 genes, previously reported to be differentially methylated (Martin-Subero et al., 2009). 
Another study defined a methylation-based outcome predictor for patient survival supporting 
the hypothesis for possible correlations. They reported that the most predictive region 
comprises the promoter sequence for KIAA1447 (BAHCC1) (Bullinger et al., 2009). However, 
this DNA methylation study is again based on the analysis of specific candidate genes, but 
nevertheless suggests that the integration of DNA methylation data into a clinically relevant 
prediction model might be possible. Furthermore, the methylation of tumor suppressor genes 
seems to be implicated in the relapse risk of AML (Agrawal et al., 2007b; Kroeger et al., 
2008). Using the HELP (Hpa II tiny fragment enrichment by ligation-mediated PCR) assay, 
Figueroa et al. performed genome-wide CGI promoter methylation studies with a set of 344 
newly diagnosed primary AML samples. The large-scale epigenetic analyses revealed 
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unique AML subgroups and methylation patterns that are associated with clinical outcome 
(Figueroa et al., 2010).  
All these published studies point to a role of DNA methylation as a molecular biomarker. 
However, most of the underlying experiments either depended on restriction enzymes and 
therefore on specific sequence motifs or they just focused on a panel of candidate genes. 
Using an unbiased genome-wide approach to detect global DNA methylation combined with 
validation by MALDI-TOF MS, the aim of our studies was to identify the most predictive 
epigenetic markers in AML. Furthermore the CpG islands in our studies were not restricted to 
promoter regions, but also covered intragenic and non-coding intergenic regions. We 
decided to investigate the methylation of CGIs as the vast majority of CpG islands are 
usually completely unmethylated in normal tissues in both active and inactive genes (with the 
exception of imprinted loci and the inactive X chromosome of females) and therefore do not 
relate to tissue-specific gene expression (Estecio and Issa, 2009; Esteller, 2002). 
Consequently, hypermethylation of normally unmethylated CGIs should be due to a 
tumor-specific event. 
Our comprehensive methylation profiling led to the identification of more than 6,000 
hypermethylated CGI regions common in at least three AML patients. In concordance with 
the heterogeneous expression patterns of AML samples (Valk et al., 2004), we detected very 
heterogeneous and highly variable methylation patterns throughout the analyzed AML 
samples. These results indicate that multiple mechanisms may operate to generate the 
observed epigenetic aberrations. 
However, despite the overall variable patterns, a large number of genes were affected by 
methylation in almost all AML patients. These genes are mainly involved in transcriptional 
regulation and support earlier reports that point to a role of HOX and Polycomb as target 
genes in leukemia (Bullinger et al., 2009; Grubach et al., 2008). Besides transcriptional 
regulation, hypermethylation targets in our studies were also involved in cell-cell adhesion, 
cadherins and peptide receptor activity or age-dependent methylation as described above. 
Some of the detected hypermethylated genes are already known as potential candidate 
genes of tumors (e.g. CDKN2B, CDKN2A, NPM2 (Kroeger et al., 2008), SLIT2) while most of 
them have not yet been described as commonly methylated genes (SMUG1, ZIC1, 
MAP3K13, FGF12). AML is one of the few neoplasms that show methylation of CDKN2B 
(also known as p15/INK4B) (Herman et al., 1997), a gene that plays an important role in 
TGF-β (transforming growth factor β)–induced growth arrest. In our study, the frequency of 
CDKN2B promoter methylation was relatively lower than previously reported (Herman et al., 
1997), but is in line with studies performed by Toyota et al. (Toyota et al., 2001).  
In order to define biomarkers specific for acute myeloid leukemia, 400 target regions (out of 
6,000 regions affected by hypermethylation in AML) that are important for transcription or 
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gene regulation or show age-dependent methylation, were chosen for screening a larger 
patient collection (200 AML patients) using the MassARRAY EpiTYPER approach. Both 
approaches (MCIp-on-chip and MALDI-TOF MS) were highly consistent and reliable results 
can be achieved using a combination of both techniques. The computational analysis of this 
data is not yet finalised. But the final objective will be to discover potential marker genes as 
well as correlations between methylation data and clinical parameters. Finally, such 
biomarkers then offer new possibilities for targeted treatment of patients and outcome 
prediction.  
 
6.4 Establishing DNA methylation patterns through         
cis-acting sequences and combinatorial transcription 
factor binding 
One of the main questions concerning CpG islands (CGIs) is why these sequences are 
protected from the wave of de novo methylation at the time of implantation when almost the 
entire genome undergoes de novo methylation, or likewise, why some CGIs become de novo 
methylated in cancer while others are protected from it. It was often assumed that this may 
be a function of local CpG ratio or the GC content. Some experiments however, in ES cells 
(Brandeis et al., 1994) and transgenic mice (Siegfried et al., 1999) indicated that CpG island 
methylation is controlled by specific local cis-acting sequences (Straussman et al., 2009) 
which can be bound by specific factors.  
The hypothesis that a transcription factor provides methylation protection dates back to the 
reports of two independent groups in 1994, showing that a Sp1-binding site plays a role in 
protecting the adenine phosphoribosyltransferase (APRT) gene from de novo methylation in 
humans and mice (Brandeis et al., 1994; Macleod et al., 1994). Since Sp1-deficient animals 
had no obvious ‘methylation defects’, the concept of methylation protection by transcription 
factors has been controversially discussed. Likewise, binding of the insulator protein CTCF 
has been shown to protect a linked transgene from heterochromatin-mediated extension and 
subsequent de novo DNA methylation (Feltus et al., 2006; Mutskov et al., 2002). Indeed, 
CTCF can act as chromatin barrier by preventing the spread of heterochromatin structures. 
Furthermore CTCF binding to a differentially methylated domain upstream of the H19 gene is 
required to maintain the unmethylated state and proper expression of the maternal H19 
allele.  
Anecdotal evidence clearly supports a role of additional specific DNA binding proteins in 
establishing and maintaining DNA methylation patterns. Boumber et al., for example, 
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described a polymorphism in the RIL (a candidate tumor suppressor gene) promoter that 
creates a Sp1/Sp3 binding site and therefore protects against methylation in cancer. Thereby 
it serves as direct proof that genetic polymorphisms can influence an epigenetic state 
(Boumber et al., 2008). Another study demonstrated that glucocorticoid hormones were 
found to induce stable DNA demethylation within a key enhancer of the rat liver-specific 
tyrosine aminotransferase (TAT) gene (Thomassin et al., 2001). Also other studies showed 
that regulation of local DNA methylation status by transcription factors could indeed provide a 
way to modulate gene expression during development (Han et al., 2001; Kress et al., 2006; 
Lin and Hsieh, 2001; Macleod et al., 1994; Tagoh et al., 2004). However, it is still unclear 
whether the reported observations represent isolated cases or whether methylation 
protection represents a general mechanism.  
Earlier computational studies identified specific nucleotide sequences that correlated with 
CGIs which are either prone or resistant to methylation in cancer samples. Feltus et al. 
identified a set of 13 sequence motifs derived from methylation-prone or 
methylation-resistant CGIs in multiple DNMT1 overexpressing clones using MEME and 
MAST algorithms. These sequence features were thought to act in cis to play a role in the 
local susceptibility of CGIs to aberrant DNA methylation (Feltus et al., 2006). Using an 
algorithm program, called HDFINDER, Das et al. was able to identify sequence motifs using 
data from normal human adult brain DNA which had similar sequence dependence on the 
epigenetic state of some selected CGIs as demonstrated in studies from Feltus et al. (Das et 
al., 2006). Studies from Keshet et al. showed a statistical enrichment of several short 
sequence motifs in hypermethylated promoter regions from Caco-2 and PC3 cells performing 
mDIP combined to microarray (containing approximately 10,000 promoter elements) 
analyses. Hypergeometric P values of the subsequent motif finding algorithm ranged from  
10-4 to 10-9 (Keshet et al., 2006). A paper from Bock et al. demonstrated that besides 
sequence patterns also repeat frequencies and predicted DNA structures are highly 
correlated with CpG island methylation (Bock et al., 2006). 
On the basis of the above computational analyses, it was postulated that most de novo 
methylation in cancer takes place in an instructive manner through interactions between 
cis-acting sequences on the DNA and trans-acting protein complexes capable of recruiting 
DNA methyltransferases. An example for this mechanism has been observed in 
promyelocytic leukemia: the PML-RAR fusion protein can induce gene hypermethylation and 
gene silencing at specific target promoters (Keshet et al., 2006).  
All studies described above were based on few CpG islands and none of them was able to 
identify defined consensus sequence motifs resembling consensus sites for known 
transcription factors (Straussman et al., 2009). Only one recent survey of methylation states 
at CpG islands in normal human tissues described the association of unmethylated CpG 
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islands with the consensus motif for the human zinc finger transcription factor specific protein 
(SP) 1 and for the signal transducer and activator of transcription (STAT) 1 transcription 
factor (Straussman et al., 2009). 
To address the question why some CGIs are resistant to CpG methylation in cancer cells 
while others are prone to methylation, we used the global methylation profiles generated by 
the newly developed and adapted MCIp-microarray (MCIp-on-chip) approach. Using a 
powerful de novo motif analysis (HOMER) it could be shown that a number of defined 
sequence motifs are strongly enriched in CpG islands that are generally resistant to de novo 
methylation in cancer. These sequence motifs were previously shown to represent the most 
conserved motifs in mammalian promoters such as NRF-1, NFY, Sp1 and GABP (Xie et al., 
2005a). However, the observed correlation is also evident at intergenic, promoter-distal CpG 
islands that are not directly associated with transcription.  
We also showed that the sole presence of a consensus motif for any of the general factors is 
not sufficient to confer ‘protection’ from de novo methylation. In fact, protection from de novo 
methylation requires the stable binding of these factors to their binding sites which, in turn, 
requires the presence of neighboring motifs that are co-bound by at least one other 
ubiquitous (or in some cases cell type-specific) transcription factor. The stable binding of 
these factors likely recruits co-factors that in turn create a protective chromatin environment, 
e.g. by introducing protective histone marks like H3K4 methylation. A schematic model 
describing the methylation protection hypothesis is shown in Figure 6-1.  
 
 
Figure 6-1 A model for DNA methylation protection by the combinatorial action of general transcription 
factors 
If two or more consensus sites for general transcription factors are located in close proximity, these sites are likely 
to be bound stably by the corresponding factors. The stable binding of these factors likely recruits co-factors that 
in turn create a protective chromatin environment, e.g. by introducing protective histone marks like H3K4 
methylation. These regions are only rarely methylated during neoplastic transformation or aging. A single, isolated 
motif is less likely to be bound by its corresponding factor and will have a less protective chromatin environment. 
These regions are more likely targeted by de novo methylation in cancer. 
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Most methylation-resistant CpG islands were bound by combinations of ubiquitous 
transcription factors and were also associated with attributes associated with basic cellular 
functions like cell survival and proliferation, whereas methylation-prone CpG islands 
generally associated with organismic development, differentiation and cell communication, 
which are frequently regulated by cell type-specific transcription factors. A schematic model 
which describes the different role of ubiquitous transcription factors compared to cell 
type-specific transcription factors with regard to protection from de novo methylation is 
shown in Figure 6-2. 
 
 
Figure 6-2 Transcription factors protect from de novo methylation 
Protective motifs are bound by general transcription factors (marked in blue) creating a chromatin environment 
that excludes DNA methylation. Therefore the probability of acquiring de novo methylation is permanently low. In 
contrast, cell type-specific transcription factors (marked in yellow) may only offer temporary protection (e.g. during 
embryonic development) and have an increased probability of acquiring de novo methylation over time. The loss 
of epigenetic boundaries (marked as stars) (e.g. CTCF) may further increase probability of acquiring de novo 
methylation.  
 
Interestingly, genes that are associated with CpG islands that were commonly methylated in 
normal and cancer cells were enriched for predicted targets of specific (mostly 
uncharacterized) miRNAs (Figure 5-40), however, the relevance of this observation is 
uncertain and requires functional validation.  
We also observed that methylation-prone regions are significantly enriched for certain repeat 
motifs (GAGA, CACA) implying that they may also act as cis-acting sequences and direct de 
novo DNA methylation. GAGA resembles the consensus motif for Drosophila GAGA-binding 
factor, a trithorax group member that has been implicated in preventing heterochromatin 
spreading (Nakayama et al., 2007), however, a mammalian homologue has not been 
described so far. CA-repeats may play a role in RNA splicing and are bound by the 
heterogeneous nuclear ribonucleoprotein (hnRNP) L in a repeat length dependent manner 
(Hui et al., 2003), but there is no known link to DNA methylation or chromatin structure. 
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With the exception of the Sp1/3 motif, none of the other motifs has previously been 
associated with the establishment or maintenance of DNA methylation (Boumber et al., 2008; 
Brandeis et al., 1994; Straussman et al., 2009) but all are known to recruit epigenetic 
modifiers to their binding sites. NFY (also known as CAAT-binding factor), a regulator of 
many cell cycle control genes, actively recruits co-activators (like p300) that induce histone 
acetylation at NFY-bound promoters (Faniello et al., 1999). Ubiquitously expressed NRF1 
and GABP (also called NRF2) are able to recruit co-activators (PCG1, p300/CBP) that create 
a chromatin environment favoring transcription (Izumi et al., 2003). YY1 has been shown to 
recruit Polycomb group proteins that control H3K27 methylation, a mark that is established 
on unmethylated CGI genes early in development and then maintained in differentiated cell 
types by the presence of an EZH2-containing Polycomb complex. In cancer cells, as 
opposed to normal cells, the presence of this complex brings about the recruitment of DNA 
methyltransferases, leading to de novo methylation and therefore to aberrant silencing during 
tumorigenesis (Schlesinger et al., 2007; Vire et al., 2006). However, a recent study by 
Lindroth et al. elegantly demonstrated that H3K27 methylation (recruited by YY1) and CpG 
DNA methylation at the murine Rasgrf1 locus are mutually exclusive, suggesting that both 
epigenetic marks are interdependent and antagonistic (Lindroth et al., 2008). This is also 
consistent with a recent study globally mapping key histone modifications and subunits of 
Polycomb-repressive complexes 1 and 2 (PRC1 and PRC2) in ES cells (Ku et al., 2008). 
PRC2 contains EZH2, which catalyzes H3K27me3. PCR1 components, in turn, contain 
proteins with affinity for H3K27me3. Genome-wide analysis of PRC1 and PRC2 occupancy 
identified a YY1-like motif enriched in CpG islands that were not targeted by PRC2. 
Additional motifs identified in this study (ETS, NFY, AP-1, MYC and NRF1) (Ku et al., 2008), 
partially overlapped with those observed in the present study. Motifs enriched in EZH2 
negative CGIs are recognized by several well-characterized classes of transcriptional 
activators that are highly enriched in ES cells. Some of the implicated factors have key 
functions in the ES cell regulatory network (e.g. NFY, Myc) while others are constitutive 
activators with general housekeeping functions (e.g. Ets1). In contrast, in PRC2-positive 
CGIs transcriptional activator motifs are depleted while repressor motifs are enriched. Thus, 
PCR2 appears to localize to CGIs that are transcriptional silent in ES cells because they lack 
activating DNA sequence motifs. These findings further corroborate the negative correlation 
of repressive epigenetic marks and cis-acting sequences conferring transcriptional activity. 
 
In line with several recent observations demonstrating that the DNA methylation status 
correlates with histone modifications (Brunner et al., 2009; Meissner et al., 2008; Schmidl et 
al., 2009), the factors binding the identified sequences likely share the ability to recruit RNA 
polymerase II and to create an ‘active’ chromatin environment that may prevent or at least 
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impede de novo CpG methylation at particular CpG islands (Figure 6-1). A recently 
published, analogous study demonstrated that the presence of RNA polymerase II, active or 
stalled, predicts the epigenetic fate of promoter CpG islands in cancer (Takeshima et al., 
2009). Through performing chromatin immunoprecipitation combined to microarray 
hybridization (ChIP-on-chip) analysis of RNA polymerase II (Pol II) and histone modifications 
it could be shown that even among the genes with low transcription, the presence of Pol II 
was associated with marked resistance to DNA methylation while H3K27me3 was associated 
with increased susceptibility (Takeshima et al., 2009). 
RNA polymerase II does not stably bind DNA on its own – its stable recruitment requires 
cis-acting factors of which Sp1 is one of the best studied so far (Lemon and Tjian, 2000). A 
high level of overlap between transcription factor and Pol II binding is expected and the 
association of Pol II with resistance to de novo methylation is likely a consequence of its 
interaction with combinations of transcription factors present at the promoter. However, our 
data also clearly shows that the correlation of motif occurrence or transcription factor binding 
and ‘methylation protection’ are found not only in promoter proximal but also in promoter 
distal sites, thus ruling out a direct link with the process of transcription or the presence of 
Pol II. Therefore the present thesis suggests that cis-acting factors may have a protective 
role independent of Pol II binding.  
 
In conclusion, these data provide strong experimental and computational evidence that 
specific sequence motifs are associated with the DNA methylation states of CpG islands in 
normal and malignant cells. Most of the identified sequence motifs are identical to consensus 
motifs for known, general transcription factors and our data strongly suggests that the 
combinatorial binding of these factors plays a dominant role in regulating the DNA 
methylation status at a large set of CpG islands. These findings also imply that the aberrant 
methylation patterns in cancer cells may at least in part result from a ‘loss of protection’. This 
would also imply a default tendency to methylate and repress DNA sequences during 
successive cell divisions that are not marked by activating transcription factors or histone 
modifications.  
 
6.5 Perspectives 
The results of the present thesis led to the identification of hundreds of hypermethylated 
genes of potential pathogenic relevance in cancer development. Comparing the methylation 
patterns of the different patients should highlight correlations between methylation of specific 
genes and clinical parameters such as subclasses or prognosis. The final aim of our studies 
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is the identification of specific marker genes that in the future may provide a novel basis for 
improved patient outcome prediction, prognostication, diagnosis, monitoring and treatment.  
However, additional studies will be necessary to find an optimal set of epigenetic biomarkers 
and evaluate the significance of these markers in a routine clinical setting before the clinical 
implementation will become accomplishable. A new method with this potential would be to 
screen patient samples by multiplexing (12-30 plex) of an optimal set consisting of 12-30 
biomarkers using QGE after MCIp enrichment. This quantitative and multiplexed methylation 
analyses should be much more sensitive than the methylation-specific PCR (MSP), which 
was used for the detection of tumor-related DNA methylation in serum/plasma, urine and 
other fluids. Thus, MCIp combined with QGE might be helpful to identify patient subgroups 
that are likely to benefit from demethylation therapy. Moreover, in future established 
methylation markers might be used to detect therapeutic success of demethylating agents 
during the course of treatment.  
DNA methylation is an early event that often precedes the appearance of a tumor. As the 
early stages of cancer development have the highest potential for therapeutic interventions, 
the inhibition or the withdrawal of these epigenetic modifications could open up new 
possibilities for cancer prevention in the future. Furthermore, as DNA methylation possibly 
also changes during the course of the disease, integrated approaches could be superior for 
outcome prediction. A combination of methylation and gene expression markers as well as 
known prognostic factors such as cytogenetics and molecular alterations could account for 
refining AML classification. 
Our global and locus-wide analyses of DNA methylation patterns strongly suggest that the 
combinatorial binding of cis-acting transcription factors plays a major role in shaping a cells’ 
methylome, both in health and disease. Proximal promoter regions that are often studied in 
the context of cancer may reflect only a small proportion of regulatory regions that are 
subject to alterations in cancer. In order to understand the relevance of alterations in 
transcription factor networks for the establishment of global DNA methylation patterns, we 
probably need to study not only CGIs, but basically all regions within the whole range of CpG 
densities, because many transcription factors (like C/EBPs, RUNX1, or PU.1) do not have 
preferences for CpG islands. One possibility to reduce the candidate sequences from the 
complete human genome to potentially regulatory relevant regions would be to define 
putative regulatory sites by mapping histone H3 lysine 4 mono-methylation (H3K4me1) as 
this histone mark is often associated with enhancers. Defining the methylation profiles of 
those regions could allow the identification of further cis-acting sequences and corresponding 
transcription factors associated with differentiation and disease states. 
Another future study could include the characterization of the exact mechanism establishing 
and maintaining the DNA methylation patterns during leukemogenesis. Using a knockdown 
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test sytem our hypothesis that transcription factors normally confer methylation protection 
could be corroborated. Since DNA methylation, in particular within CGIs, may be a 
consequence of the absence or inactivation of transcriptional activators, knockdown of 
transcription factors should then lead to methylation of the respective CGI. In a 
complementary approach, the epigenetic profile of stably introduced plasmids into THP-1 
cells containing CGIs of varying motif composition could be studied over time. These 
experiments could show whether certain motifs actually do confer methylation protection to 
the surrounding sequences. If the expected changes are reproducible, the exact timing of 
DNA methylation changes and other associated epigenetic events (like the recruitment of 
DNMTs, the loss of activating or the deposition of repressive histone marks) could be studied 
sequentially.
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7 Summary 
Aberrant DNA methylation of CpG islands (CGIs) is a common alteration during malignant 
transformation that leads to the abnormal silencing of tumor suppressor genes and plays a 
role in disease initiation and progression. The major aim of the present thesis was the 
implementation of methodologies to identify epigenetic marker genes that can be used for 
the diagnosis as well as for the targeted treatment of tumors. Furthermore, the molecular 
mechanisms controlling the methylation status of CpG islands in normal and malignant cells 
should be analyzed. To address these issues, a novel and robust technique, called 
methyl-CpG immunoprecipitation (MCIp) was developed that allows for the unbiased 
genome-wide profiling of CpG methylation in DNA samples where quantity is limited. This 
approach is based on a recombinant, antibody-like protein that efficiently binds native 
CpG-methylated DNA and enables the fractionation of DNA fragments depending on the 
particular methyl-CpG content. This application facilitates the monitoring of CpG island 
methylation either on single gene or on genome-wide levels. Initial genome-wide methylation 
profiling of myeloid leukemia cell lines using 12K CpG island microarrays identified over one 
hundred genes with aberrantly methylated CpG islands. Interestingly, the comparison with 
gene expression data revealed that more than half of the identified genes were not 
expressed in various healthy cell types, indicating that hypermethylation in cancer may be 
largely independent of the transcriptional status of the affected gene. The majority of 
individually tested genes were also hypermethylated in primary blast cells from AML patients.  
The MCIp approach was further optimized and adapted for a more suitable microarray 
platform (Agilent 244K CGI microarrays). The in-depth comparison of MCIp and 
MassARRAY for two established cell lines showed an excellent correlation over a set of 140 
genes (1,150 amplicons covering approximately 13,500 CpG dinucleotides). In order to 
identify potential marker genes, global comparative CpG island methylation profiles for more 
than 25 AML samples (of mostly normal karyotype) and ten patients with colorectal 
carcinoma using MCIp in combination with microarray were generated. Our comprehensive 
analysis identified a large array of CGIs that are previously unrecognized targets of 
hypermethylation in AML. For the identification of potential marker genes, approximately 400 
regions were selected based on the array results for screening a large set of 200 AML 
patients. The data are now ready to be subjected to computational analyses.  
In order to get insights into the process regulating the methylation status of CpG islands, 
factors should be identified that are responsible for maintaining or establishing methylated 
states of CGIs in health and disease as well as for de novo methylation in cancer. De novo 
motif discovery analysis revealed two repetitive sequence motifs (GAGA, CACA) that were 
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commonly enriched in CpG islands that were methylated in cancer. More strikingly, the 
global analysis demonstrated a highly significant association of unmethylated CpG islands 
with consensus sequences for GA binding protein (GABP), specific protein (Sp) 1 and 3, 
nuclear respiratory factor (NRF) 1, nuclear factor (NF) Y, yin-yang (YY) 1 and an unknown 
factor in all analyzed samples. Using ChIP-on-chip assays we also showed that most of the 
identified motifs for Sp1, NRF1 and YY1 were actually bound by the respective factors in 
normal cells and that these regions did not acquire de novo methylation in leukemia cells. In 
addition, the data provide global evidence that the stable binding of any of these transcription 
factors to their consensus motif depends on their co-occurrence with neighboring consensus 
motifs. Thus, the results of the present thesis suggest a major role for cooperative 
transcription factor binding in maintaining the unmethylated status of CpG islands in health 
and disease. The data also implies that the majority of de novo methylated CpG islands are 
characterized by the lack of sequence motif combinations and the absence of activating 
transcription factor binding. 
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8 Zusammenfassung 
Tumorzellen zeichnen sich häufig durch ein verändertes DNA-Methylierungsmuster aus. 
Fehlerhafte DNA-Methylierung von CpG-Inseln (CGIs) kann zur abnormen Repression von 
Tumorsuppressorgenen führen und Tumorwachstum fördern. Hauptziel der vorliegenden 
Arbeit war es, Methoden zu etablieren, um diagnostisch oder therapeutisch verwertbare 
epigenetische Biomarker zu identifizieren. Desweiteren sollten die molekularen 
Mechanismen analysiert werden, die den Methylierungsstatus von CGIs sowohl in gesunden 
als auch in entarteten Zellen regulieren. 
Für den unvoreingenommenen, globalen Nachweis von differentieller genomischer 
CpG-Methylierung wurde eine neuartige Methode, die sogenannte 
Methyl-CpG-Immunpräzipitation (MCIp), entwickelt und etabliert. Diese Technologie basiert 
auf einem rekombinanten Antikörper-ähnlichen Protein, das doppelsträngige, methylierte 
DNA binden kann und eine Fraktionierung der DNA-Fragmente hinsichtlich ihres 
Methylierungsgrades ermöglicht. Die Detektion methylierter DNA kann sowohl auf 
Einzelgenebene als auch genomweit durchgeführt werden. Die ersten genomweiten 
Methylierungsanalysen von myeloischen Leukämiezelllinien mit 12K CpG-Insel-Mikroarrays 
führten zur Identifizierung von über einhundert Genen, die in den Zelllinien im Vergleich zu 
normalen Blutmonozyten von Hypermethylierung betroffen waren. Ein Vergleich mit 
Expressionsdaten zeigte, dass ein Großteil der methylierten Gene weder in normalen 
myeloischen Zellen noch in den untersuchten Tumorzellen exprimiert war. Dies könnte 
darauf hindeuten, dass die tumorspezifische Hypermethylierung unabhängig vom 
transkriptionellen Status eines Gens ist. Die meisten der getesteten Genfragmente waren 
auch in primären AML-Blasten hypermethyliert.  
Die MCIp-Technik wurde weiter optimiert und auf eine neue und besser geeignete 
Mikroarray-Plattform angepasst (Agilent 244K CpG-Insel Mikroarrays). Die Validierung der 
Mikroarraydaten mittels MassARRAY-Technologie (1150 Amplikons aus 140 Genen, welche 
13500 CpG Dinukleotide abdeckten) zeigte eine sehr gute Korrelation beider Methoden. Zur 
Identifizierung von potentiellen Biomarkern wurden globale DNA-Methylierungsprofile 
einerseits von Blasten aus 25 AML-Patienten mit primär normalem Karyotyp, aber auch von 
zehn Patienten mit kolorektalem Karzinom erstellt. Unsere Analysen identifizierten eine 
Reihe von Genen von denen bislang nicht bekannt war, dass sie von Hypermethylierung 
betroffen sein können. Um relevante Markergene zu identifizieren, wurden ca. 400 Regionen 
anhand der Arrayergebnisse ausgewählt und in einem größeren Patientenkollektiv (200 AML 
Proben) mithilfe der MassARRAY-Technologie validiert. Die entsprechenden Daten werden 
aktuell noch bioinformatischen Analysen unterzogen. 
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Um Einblick in den Mechanismus zu gewinnen, wie die Methylierung von CpG-Inseln 
reguliert wird, sollten Faktoren identifiziert werden, welche einen entscheidenden Einfluss bei 
der Entstehung und Aufrechterhaltung von Methylierungsmustern sowohl in gesunden als 
auch in Tumorzellen haben. Mittels de novo-Motivanalysen konnte gezeigt werden, dass 
zwei repetitive Sequenzmotive (GAGA, CACA) häufig in CGIs angereichert waren, welche in 
Tumorzellen methyliert wurden. Darüber hinaus stellten wir mittels globaler Analysen eine 
hochsignifikante Assoziation von unmethylierten CGIs mit Konsensussequenzen für GABP 
(GA binding protein), Sp1 (Specific protein 1), NRF1 (nuclear respiratory factor 1), NFY 
(nuclear factor Y), YY1 (ying-yang 1) und einem unbekannten Faktor in allen untersuchten 
Proben fest. 
Mittels ChIP-on-Chip Analysen konnte außerdem gezeigt werden, dass die meisten der 
identifizierten Motive für Sp1, NRF1 und YY1 tatsächlich von dem betreffenden Faktor in 
normalen Zellen gebunden wurden, und dass diese Regionen in Leukämiezellen nicht von 
einer de novo-Methylierung betroffen waren. Desweiteren verdeutlichten die Ergebnisse, 
dass die stabile Bindung eines dieser Transkriptionsfaktoren an seine Konsensussequenz 
vom gleichzeitigen Vorkommen benachbarter Konsensusmotive abhängig ist. Folglich führen 
die Ergebnisse dieser Dissertation zu der Annahme, dass die kooperative Bindung von 
Transkriptionsfaktoren eine entscheidende Rolle für die Aufrechterhaltung des 
unmethylierten Status von CGIs in gesunden wie auch in kranken Zellen spielt. Die Daten 
implizieren auch, dass die Mehrheit der de novo methylierten CGIs durch das Fehlen von 
Kombinationen bestimmter Sequenzmotive und der daraus resultierenden Abwesenheit 
aktivierender Transkriptionsfaktoren charakterisiert ist. 
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10 Abbreviations 
AML     Acute myeloid leukemia 
AS     Antisense 
5mC     5-methylcytosine 
bp     Base pair 
BS     Bisulfite 
BSA     Bovine serum albumin 
°C     Degree Celsius 
cDNA     Complementary DNA 
CGI     CpG island 
ChIP     Chromatin immunoprecipitation 
CIAP     Calf intestinal alkaline phosphatase 
CpG     Cytosine-guanine dinucleotide 
dd     Double distilled 
DEPC     Diethyl pyrocarbonate 
DMEM     Dulbecco’s Modified Eagle Medium 
DMR     Differential methylated region 
DMSO     Dimethyl sulfoyde 
DNMT     DNA methyltransferase 
dNTP     Deoxiribonucleotide triphosphate 
ECL     Enhanced chemiluminescence 
EDTA     Ethylenediaminetetraacetic acid 
ES cell     Embryonic stem cell 
EtOH     Ethanol 
FACS     Fluorescence activated cell sorting 
FCS     Fetal Calf Serum 
gDNA     Genomic DNA 
GO     Gene ontology 
H     Hour 
HELP     Hpa II tiny fragment Enrichment by LM-PCR 
HSC     Hematopoietic stem cell 
H3K4me1    Histone 3 lysine 4 monomethylation 
H3K4me2    Histone 3 lysine 4 dimethylation 
H3K4me3    Histone 3 lysine 4 trimethylation 
HAT     Histone acetyltransferase 
HDAC     Histone deacetylase 
HMT     Histone methyltransferase 
IP     Immunoprecipitation 
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LM-PCR    Ligation-mediated polymerase chain reaction 
MALDI-TOF MS Matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry 
MBD     Methyl-CpG binding domain 
MCIp     Methyl-CpG immunoprecipitation 
MeCP2     Methyl-CpG binding Protein 2 
MeDIP     Methylated DNA immunoprecipitation 
Min     Minute 
MO     Monocyte 
MOPS     3-(N-Morpholino) propanesulfonic acid 
mRNA     Messenger RNA 
MSP     Methyl-specific PCR 
MvA     Signal log ratio vs. average log intensity 
NaOAc     Sodium acetate 
NK cell     Natural killer cell 
NP-40     Nonidet P-40 
O/N     Overnight 
PB-MNCs    Peripheral blood mononuclear cells 
PBS     Phosphate buffered saline 
PEG     Polyethyleneglycol 
PCR     Polymerase chain reaction 
qPCR     Quantitative PCR 
RLGS     Restriction landmark genomic scanning 
rpm     Rounds per minute 
RT     Room temperature 
RT-qPCR    Quantitative reverse transcription PCR 
s     Second 
S     Sense 
SAM     S-adenosylmethionine 
SAP     Shrimp alkaline phosphatase 
SD     Standard deviation 
SDS     Sodium dodecyl sulfate 
SNP     Single nucleotide polymorphism 
TAE     Tris acetate /EDTA electrophoresis buffer 
TE     Tris-EDTA 
TEMED    N,N,N’,N’,-Tetramethylenediamine 
TSS     Transcription start site 
UCSC     University of California, Santa Cruz 
X-gal     5-Bromo-4-chloro-3-indoyl-β-D-galactopyranosid 
 Publications 
 - 167 -    
11 Publications 
Rapid and sensitive detection of CpG-methylation using methyl-binding (MB)-PCR 
Gebhard C, Schwarzfischer L, Pham TH, Andreesen R, Mackensen A, Rehli M. 
Nucleic Acids Res. 2006 Jul 5;34(11):e82. 
 
 
Genome-wide profiling of CpG methylation identifies novel targets of aberrant 
hypermethylation in myeloid leukemia 
Gebhard C, Schwarzfischer L, Pham TH, Schilling E, Klug M, Andreesen R, Rehli M 
Cancer Res. 2006 Jun 15;66(12):6118-28 
 
 
General Transcription factor binding at CpG islands in normal cells correlates with 
resistance to de novo DNA methylation in cancer 
Gebhard C, Benner C, Ehrich M, Schwarzfischer L, Schilling E, Klug M, Dietmaier W, Thiede 
C, Holler E, Andreesen R, Rehli M 
Cancer Res. 2010 Feb 70(4)  
 
 
Active DNA demethylation in human postmitotic cells correlates with activating 
histone modifications, but not transcription levels 
Klug M, Heinz S, Gebhard C, Schwarzfischer L, Krause S, Andreesen R, Rehli M 
(submitted) 
 
Eidesstattliche Erklärung 
- 168 - 
12 Eidesstattliche Erklärung 
Ich erkläre hiermit an Eides statt, dass ich die vorliegende Arbeit ohne unzulässige Hilfe 
Dritter und ohne Benutzung anderer als der angegebenen Hilfsmittel angefertigt habe. Die 
aus anderen Quellen direkt oder indirekt übernommenen Daten und Konzepte sind unter 
Angabe des Literaturzitats gekennzeichnet. 
 
Weitere Personen waren an der inhaltlich-materiellen Herstellung der vorliegenden Arbeit 
nicht beteiligt. Insbesondere habe ich hierfür nicht die entgeltliche Hilfe eines 
Promotionsberaters oder anderer Personen in Anspruch genommen. Niemand hat von mir 
weder unmittelbar noch mittelbar geldwerte Leistungen für Arbeiten erhalten, die in 
Zusammenhang mit dem Inhalt der vorgelegten Dissertation stehen. 
 
Die Arbeit wurde bisher weder im In- noch Ausland in gleicher oder ähnlicher Form einer 
anderen Prüfungsbehörde vorgelegt. 
 
 
 
 
 
 
 
----------------------------------------------    ---------------------------------------------- 
                (Claudia Gebhard) 
 
 
 
 Acknowledgement 
 - 169 -    
13 Acknowledgement 
Für die Ermöglichung dieser Doktorarbeit und seine großzügige Unterstützung während dieser Zeit 
möchte ich mich sehr herzlich bei Prof. Dr. Reinhard Andreesen bedanken. 
 
Bei Prof. Dr. Stephan Schneuwly bedanke ich mich sehr für die Betreuung und Begutachtung dieser 
Arbeit. 
 
Mein besonderer Dank gilt Prof. Dr. Michael Rehli für die ausgezeichnete Betreuung während all der 
Jahre, sein großes Interesse und seine endlose Geduld. Seine Tür stand immer offen für 
Diskussionen, Anregungen und Fragen. Danke für den San Diego-Aufenthalt und die Teilnahme an 
vielen Kongressen.  
 
Maja, was hätte ich ohne dich gemachtugut, dass du zu uns nach Regensburg gekommen bist. 
Danke für die lustige Zeit, sowohl im Labor, als auch außerhalb (VGTsu). Für deine Hilfsbereitschaft 
und Unterstützung zu jeder Zeit, die ganzen Aktionen, die wir zusammen durchgezogen haben, und 
dass du mir geholfen hast, ständig die Schokoschubladen zu leeren ☺  
 
Vielen Dank Lucia, für deine tatkräftige Unterstützung zu jeder Zeit. Auf jede Frage hattest du eine 
passende Antwort. Und ohne deine Ordnung hätten wir so manche Plasmide oder Sequenzierprimer 
nicht mehr gefunden ☺ 
 
Ein besonderer Dank gilt Dagmar für ihren Einsatz und ihre Unterstützung, v.a. mit dem 
Massenspektrometer (du hast auch in nervenaufreibenden Situationen Ruhe bewahrt ☺). 
 
Vielen Dank an meine beiden Schatzis Moni und Carol! Schade, dass ihr nicht mehr in unserer 
Arbeitsgruppe seid! Vielen Dank, dass ihr in jeder Lebenslage für mich da seid. Moni, ohne dich wäre 
Krankengymnastik nur halb so lustig gewesen (v.a. um 7 Uhr morgens). 
 
Ein herzliches Dankeschön an alle anderen Laborkollegen für die angenehme Atmosphäre, die stete 
Hilfsbereitschaft, die gute Laune, die schöne gemeinsame Zeit im Labor und auch die lustigen 
Abende. Danke also an Hang, Chris, Eddy, Ireen, Julia, und die Carreras-Crew mit Prof. Dr. Marina 
Kreutz, Kaste, Katrin, Eva, Alice, Gabi, Monika W., sowie Ute, Sandra und Martina. 
 
Auch bei meinen früheren Laborkollegen Sabine, Tobi, Mike, Monika E. und Alex möchte ich mich 
recht herzlich bedanken. Vielen, vielen Dank, Mike, für deine Hilfe und Geduld bei meinen 
Computerproblemen. 
 
Herzlichen Dank auch an Kristina und Julia für den Seelenbeistand und die Abende außerhalb des 
Labors and Altug für seine lustige und beruhigende Art, sowie Dagi und Nico für die lustigen 
Gespräche, die Gummibärchen und die in letzter Zeit stark nachlassenden McFit Besuche!  
 
I thank Dr. Mathias Ehrich, Dr. Dirk van den Boom and Dr. Karsten Schmidt at Sequenom, Inc. San 
Diego for giving me the fantastic opportunity to get practical experience with the MassARRAY system 
and for the great time in San Diego. In particular, I would like to thank Mathias for the advice given to 
me at all stages of this study and Tricia Zwiefelhofer for her support, help and the training on the 
MassCleave technology. I would also like to thank all lab members from Sequenom for the great time 
and funny evenings outside the lab. I will never forget it! 
 
Herzlichen Dank an alle im Forschungsbau H1 und allen Forschern drumherum, die ich nicht alle 
aufzählen kann, für den schönen Laboralltag. 
 
Nicht zuletzt geht mein Dank an all meine Freunde, die immer für mich da waren. Danke an Flo, für 
alles (v.a. deine Geduld und Unterstützung)! Eoin, thanks so much for your help with the corrections! 
 
Zum Schluss möchte ich mich noch bei meiner Familie bedanken, die immer für mich da ist. 
Insbesondere geht mein Dank an meine Eltern, die mir durch ihre Unterstützung und den seelischen 
Beistand mein Studium und diese Arbeit erst ermöglicht haben.  
